1. Search Result
Search Result
Results for "

A novel pai 1 Inhibitors

" in MCE Product Catalog:

9852

Inhibitors & Agonists

47

Screening Libraries

23

Dye Reagents

23

Biochemical Assay Reagents

371

Peptides

7

MCE Kits

8

Inhibitory Antibodies

1607

Natural
Products

711

Recombinant Proteins

259

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-122098
    Diaplasinin

    pai-749

    PAI-1 Cardiovascular Disease
    Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 295 nm. Antithrombotic efficacy.
  • HY-15253
    Tiplaxtinin

    pai-039; Tiplasinin

    PAI-1 Apoptosis Metabolic Disease Cancer
    Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM.
  • HY-100447
    TM5275 sodium

    PAI-1 Cancer Cardiovascular Disease
    TM5275 sodium is a plasminogen activator inhibitor (PAI-1) with an IC50 of 6.95 μM.
  • HY-N0518
    Toddalolactone

    PAI-1 Cardiovascular Disease
    Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM.
  • HY-N1504
    Loureirin B

    PAI-1 Potassium Channel ERK JNK Metabolic Disease
    Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
  • HY-101761
    TM5441

    PAI-1 Apoptosis Cancer
    TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC50 values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence.
  • HY-U00439
    Protein kinase inhibitors 1

    DYRK Cancer
    Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
  • HY-13053
    Ro-0335

    Reverse Transcriptase Cancer
    RO-0335 is a novel and potent diphenylether nonnucleoside reverse transcriptase inhibitor(NNRTI). RO-0335 inhibits Wt HIV-1 with an IC50 of 1.1 nM and retained activity (IC50< 100 nM) against 92% of a large number of NNRTI-resistant clinical isolates.
  • HY-19422
    PNU-248686A

    MMP Cancer
    PNU-248686A is a novel matrix metalloproteinase (MMP) inhibitor.
  • HY-125957
    A-3 hydrochloride

    PKA Casein Kinase CaMK PKC Others
    A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively.
  • HY-115292
    Simvastatin hydroxy acid sodium

    Tenivastatin sodium; Simvastatin Impurity A sodium

    HMG-CoA Reductase (HMGCR) Cancer
    Simvastatin hydroxy acid sodium (Tenivastatin sodium; Simvastatin Impurity A sodium) is an active hydrolytic metabolite of Simvastatin (HY-17502). Simvastatin shows a inhibition of HMG-CoA reductase with a Ki value of 0.12 nM.
  • HY-100368A
    MELK-8a hydrochloride

    MELK Cancer
    MELK-8a hydrochloride is a novel maternal embryonic leucine zipper kinase (MELK) inhibitor with an IC50 of 2 nM.
  • HY-10614
    A-966492

    PARP Cancer
    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.
  • HY-14200
    (S)-Rasagiline

    TVP1022; S-pai

    Monoamine Oxidase Neurological Disease
    (S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
  • HY-14200A
    (S)-Rasagiline mesylate

    TVP1022 mesylate; S-pai mesylate

    Monoamine Oxidase Neurological Disease
    (S)-Rasagiline (TVP1022) mesylate is the relatively inactive S-enantiomer form of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
  • HY-16670
    Dafadine-A

    Cytochrome P450 Others
    Dafadine-A, an analog of dafadine, is a novel inhibitor of DAF-9 cytochrome P450 in the nematode Caenorhabditis elegans; also inhibits the mammalian ortholog of DAF-9(CYP27A1).
  • HY-100454
    CGP 25454A

    Dopamine Receptor Neurological Disease
    CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.
  • HY-15613
    Maritoclax

    Marinopyrrole A

    Bcl-2 Family Cancer
    Maritoclax (Marinopyrrole A) is a novel and specific Mcl-1 inhibitor with an IC50 value of 10.1 μM, and shows >8 fold selectivity than BCL-xl (IC50 > 80 μM).
  • HY-U00439A
    Protein kinase inhibitors 1 hydrochloride

    (E)-5-((2-Oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione hydrochloride

    DYRK Cancer
    Protein kinase inhibitors 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2.
  • HY-14454
    TPh A

    Triphenyl Compound A

    Others Cancer
    TPh A (Triphenyl Compound A) is a potent inhibitor of the nuclear protein pirin and binds specifically to pirin with a Ki of 0.6 uM. TPh A disrupts the formation of the bcl3–pirin complex. TPh A can be used as a novel small molecule tool to regulate pirin in cells.
  • HY-117604
    THPP-1

    Phosphodiesterase (PDE) Neurological Disease
    THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.
  • HY-131005
    Eph inhibitor 2

    Ephrin Receptor Cancer
    Eph inhibitor 2 (Example 35) is a Eph family tyrosine kinase inhibitor.
  • HY-15858
    AP-III-a4

    ENOblock

    Enolase Cancer
    ENOblock(AP-III-a4) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.
  • HY-15858A
    AP-III-a4 hydrochloride

    ENOblock hydrochloride

    Enolase Cancer
    AP-III-a4 hydrochloride (ENOblock hydrochloride) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.
  • HY-112152
    GSK726701A

    Prostaglandin Receptor Inflammation/Immunology Neurological Disease Endocrinology
    GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC50 of 7.4.
  • HY-U00235
    SR121566A

    Integrin Inflammation/Immunology
    SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
  • HY-80012
    SJB3-019A

    Deubiquitinase Cancer
    SJB3-019A is a potent and novel USP1 inhibitor, 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells with IC50 of 0.0781 μM.
  • HY-13960
    GSK1324726A

    I-BET726

    Epigenetic Reader Domain Apoptosis Cancer
    GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC50=41 nM), BRD3 (IC50=31 nM), and BRD4 (IC50=22 nM).
  • HY-101809
    CNS-5161 hydrochloride

    CNS 5161A

    iGluR Cardiovascular Disease
    CNS-5161 hydrochloride is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
  • HY-121879
    SHP836

    Phosphatase Cancer
    SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2.
  • HY-N2238
    Dipsanoside A

    Others Metabolic Disease
    Dipsanoside A is a novel tetrairidoid glucoside from Dipsacus asper. Dipsacus asper Wall., a perennial plant widespread in China, has been used in traditional Chinese medicine for hundreds of years as a tonic for refreshment, as a fissiparism promoter of the osseous cells, and as an embryo security agent, etc.
  • HY-106410A
    Zabofloxacin hydrochloride

    DW-224a

    Bacterial Topoisomerase Infection
    Zabofloxacin hydrochloride (DW-224a) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin hydrochloride has excellent activity against gram-positive pathogens including Steptococcus aureusStreptococcus pyogenes and S.pneumonia. Zabofloxacin hydrochloride is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP).
  • HY-12100
    Umeclidinium bromide

    GSK573719A

    mAChR Inflammation/Immunology
    Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
  • HY-14111
    GSK189254A

    GSK189254

    Histamine Receptor Neurological Disease Endocrinology
    GSK189254A (GSK189254) is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.
  • HY-11054
    TH-237A

    meso-GS 164

    Others Neurological Disease
    TH-237A(meso-GS 164) is a novel neuroprotective agent exhibiting favorable permeation across the blood brain barrier.
  • HY-106410
    Zabofloxacin

    DW-224a Free base

    Bacterial Topoisomerase Infection
    Zabofloxacin (DW-224a Free base) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin has excellent activity against gram-positive pathogens including Steptococcus aureusStreptococcus pyogenes and S.pneumonia. Zabofloxacin is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP).
  • HY-19373
    RWJ-445167

    3DP-10017

    Thrombin Factor Xa Cardiovascular Disease
    RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
  • HY-19519A
    Ladarixin sodium

    DF 2156A

    CXCR Infection Inflammation/Immunology
    Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
  • HY-N9521
    3-O-β-D-Glucopyranosyl(1→2)-[a-Lrhamnopyranosyl(1→3)]-β-D-glucopyranosyl 28-O-β-D-glucuronopyranoside

    Others
    3-O-β-D-Glucopyranosyl(1→2)-[a-Lrhamnopyranosyl(1→3)]-β-D-glucopyranosyl 28-O-β-D-glucuronopyranoside, a saponin, is isolated from Polaskia chichipe Backbg. 3-O-β-D-Glucopyranosyl(1→2)-[a-Lrhamnopyranosyl(1→3)]-β-D-glucopyranosyl 28-O-β-D-glucuronopyranoside shows ability to inhibit melanin biosynthesis by B16 melanoma cell with inhibitory activity 84.2% at 100μM.
  • HY-19819
    NSC117079

    Others Inflammation/Immunology
    NSC117079 is a novel PHLPP inhibitor.
  • HY-15759A
    Napsagatran hydrate

    Ro 46-6240 hydrate; Ro 46-6240/010 hydrate

    Thrombin Cardiovascular Disease
    Napsagatran hydrate is a novel and specific thrombin inhibitor.
  • HY-W012037
    8-Hydroxyquinoline hemisulfate

    8-Quinolinol hemisulfate

    Bacterial Antibiotic Infection
    8-Hydroxyquinoline hemisulfate (8-Quinolinol hemisulfate) is a monoprotic bidentate chelating agent, exhibits antiseptic, disinfectant, and pesticide properties, functioning as a transcription inhibitor.
  • HY-50730
    Asparagusic acid

    Parasite Infection
    Asparagusic acid is a sulfur-containing flavor component produced by asparagus plants, with anti-parasitic effect. Asparagusic acid is a plant growth inhibitor.
  • HY-19519
    Ladarixin

    DF 2156A free base

    CXCR Cancer Inflammation/Immunology
    Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.
  • HY-111285
    HAMNO

    NSC111847

    Others Cancer
    HAMNO is a novel protein interaction inhibitor of replication protein A (RPA).
  • HY-111485
    INCB-057643

    Epigenetic Reader Domain Apoptosis Cancer
    INCB-057643 is a novel, orally bioavailable BET inhibitor.
  • HY-19626
    NSC23925

    P-glycoprotein Cancer
    NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor.
  • HY-105661
    IMD-0560

    IKK Cancer
    IMD-0560 is a novel IκB kinase β inhibitor.
  • HY-101791
    P-gp inhibitor 1

    P-glycoprotein Cancer
    P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.
  • HY-16706
    Remodelin

    Histone Acetyltransferase Cancer
    Remodelin is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.
  • HY-16009
    (+)-Phenserine

    AChE Endocrinology Neurological Disease
    (+)-Phenserine is a novel selective cholinesterase noncompetitive inhibitor with an IC50 of 45.3 μM.
  • HY-12663
    AS2521780

    PKC Inflammation/Immunology
    AS2521780 is a novel PKCθ selective inhibitor with an IC50 of 0.48 nM.
  • HY-16742
    Gepotidacin

    GSK2140944

    Bacterial Topoisomerase Infection
    Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.
  • HY-101873S
    Atorvastatin lactone D5

    HMG-CoA Reductase (HMGCR) Metabolic Disease Inflammation/Immunology
    Atorvastatin lactone D5 is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a prodrug form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
  • HY-112543
    S119-8

    Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV).
  • HY-135813
    LtaS-IN-1

    Bacterial Infection
    LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.
  • HY-112914
    mTOR inhibitor-1

    mTOR Autophagy Cancer
    mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy.
  • HY-14672
    Soblidotin

    Auristatin PE; TZT-1027

    Microtubule/Tubulin Cancer
    Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization.
  • HY-13465
    VCH-916

    HCV Infection
    VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
  • HY-16738A
    Eleclazine hydrochloride

    GS 6615 hydrochloride

    Sodium Channel Others
    Eleclazine hydrochloride is a novel late Na+ current inhibitor with IC50 value of 0.7 uM.
  • HY-17631A
    Edonerpic maleate

    T-817 maleate; T-817MA

    Amyloid-β Neurological Disease
    Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides ().
  • HY-15374
    Frentizole

    Amyloid-β Inflammation/Immunology
    Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.
  • HY-70003
    Carboxypeptidase G2 (CPG2) Inhibitor

    CPG2 Inhibitor

    Carboxypeptidase Cancer
    Carboxypeptidase G2 (CPG2) Inhibitor is a novel Carboxypeptidase G2 (CPG2) Inhibitor, Antitumor agents.
  • HY-15774A
    CBB1003 hydrochloride

    Histone Demethylase Cancer
    CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
  • HY-15868
    HS-173

    PI3K Apoptosis Cancer
    HS-173 is a novel PI3K inhibitor, that is used for cancer treatment.
  • HY-15665
    XMD17-109

    ERK Cancer
    XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC50 of 162 nM.
  • HY-15774
    CBB1003

    Histone Demethylase Cancer
    CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
  • HY-19350
    BML-210

    HDAC Apoptosis Cancer
    BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized.
  • HY-10990
    Abexinostat

    CRA 024781; PCI-24781

    HDAC Cancer
    Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM.
  • HY-100020
    BAY-1436032

    Isocitrate Dehydrogenase (IDH) Cancer
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
  • HY-100615
    Revizinone

    R80122

    Phosphodiesterase (PDE) Cardiovascular Disease
    Revizinone is a novel selective phosphodiesterase (PDE) inhibitor with IC50 values on this enzyme to 0.036 microM.
  • HY-101918
    DS-1040 Tosylate

    Others Cardiovascular Disease
    DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.
  • HY-B1287
    Citalopram hydrobromide

    (±)-Citalopram hydrobromide; Lu 10-171

    Serotonin Transporter Autophagy Neurological Disease Cancer
    Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect.
  • HY-15588
    L189

    DNA/RNA Synthesis Cancer
    L189 is a novel human DNA ligase inhibitor, inhibits hLigI/III/IV with IC50 of 5/9/5 μM.
  • HY-18928
    FAK inhibitor 5

    FAK Cancer
    FAK inhibitor 5 (compound 2) is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.
  • HY-16787
    ICA-121431

    Sodium Channel Cardiovascular Disease
    ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 µM).
  • HY-100693
    SYP-5

    HIF/HIF Prolyl-Hydroxylase Cancer
    SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis.
  • HY-13055A
    Telotristat ethyl

    LX1032; LX1606

    Tryptophan Hydroxylase Cancer Neurological Disease
    Telotristat ethyl (LX1032) is a novel, orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production.
  • HY-12974
    PRT-060318

    PRT318

    Syk Cancer
    PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase Syk with an IC50 of 4 nM.
  • HY-18685
    CPDA

    Phosphatase Metabolic Disease
    CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.
  • HY-16902
    RO9021

    Syk Inflammation/Immunology
    RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.
  • HY-16207
    FGH10019

    Fatty Acid Synthase (FASN) Metabolic Disease
    FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM.
  • HY-15465B
    KN-93 phosphate

    CaMK Autophagy Cancer
    KN-93 phosphate is a novel membrane-permeant synthetic inhibitor of purified neuronal CaMK-II, with Ki of 370 nM.
  • HY-102045
    T-3764518

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    T-3764518 is a novel and potent stearoyl coenzyme A desaturase (SCD) inhibitor with an IC50 of 4.7 nM.
  • HY-18728
    STF-31

    GLUT Autophagy Cancer
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1μM[1][2].
  • HY-N6677
    β-​Apo-​8'-​carotenal

    Apocarotenal

    Cytochrome P450 Cancer
    β-Apo-8'-carotenal (Apocarotenal), a provitamin A carotenoid, is an inducer of CYPlA1 and CYPlA2 in rat. β-Apo-8'-carotenal is present in many fruits and vegetables.
  • HY-15956
    CPI-169 racemate

    Epigenetic Reader Domain Cancer
    CPI-169 racemate is the racemate of CPI-169. CPI-169 is a novel and potent EZH2 inhibitor.
  • HY-76212
    ATB107

    Others Infection
    ATB107 is a novel and potent inhibitor of indole-3-glycerol phosphate synthase (IGPS) with a KD of 3 μM.
  • HY-13019
    BI605906

    IKK Others
    BI605906 is a novel IKKβ inhibitor with an IC50 value of 380 nM when assayed at 0.1 mM ATP.
  • HY-13064A
    Cobimetinib hemifumarate

    GDC-0973 hemifumarate; XL-518 hemifumarate

    MEK Apoptosis Cancer
    Cobimetinib hemifumarate is a novel selective MEK1 inhibitor, and the IC50 value against MEK1 is 4.2 nM.
  • HY-13537A
    BPR1J-097 Hydrochloride

    FLT3 Cancer
    BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11 nM.
  • HY-13055
    Telotristat etiprate

    LX1606 Hippurate

    Tryptophan Hydroxylase Neurological Disease Cancer
    Telotristat etiprate (LX1606 Hippurate) is a novel, orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production.
  • HY-106992
    S 3304

    MMP Cancer
    S 3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.
  • HY-13537
    BPR1J-097

    FLT3 Cancer
    BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM.
  • HY-12289
    Defactinib

    VS-6063; PF-04554878

    FAK Cancer
    Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.
  • HY-15958
    VBY-825

    Cathepsin Cancer
    VBY-825 is a novel, reversible cathepsin inhibitor with high potency against cathepsins B, L, S and V.
  • HY-19720
    Emixustat

    ACU-4429

    Others Metabolic Disease
    Emixustat, a novel visual cycle modulator, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro.
  • HY-B1558A
    Bifemelane hydrochloride

    MCI-2016

    Monoamine Oxidase Neurological Disease
    Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.
  • HY-15586
    L67

    DNA Ligase Inhibitor

    DNA/RNA Synthesis Cancer
    L67 is a novel, competitive human DNA ligase inhibitor, inhibits DNA ligases I and III with IC50 of 10 μM and 10 μM.
  • HY-15343
    CEP-33779

    JAK Cancer
    CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
  • HY-106087
    IX 207-887

    Interleukin Related Inflammation/Immunology
    IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1).
  • HY-122524
    7-Methylguanosine

    Nucleoside Antimetabolite/Analog Endogenous Metabolite Inflammation/Immunology
    7-Methylguanosine is a novel cNIIIB nucleotidase inhibitor with IC50 value of 87.8 ± 7.5 µM.
  • HY-13075
    c-Fms-IN-3

    c-Fms Inflammation/Immunology
    c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.
  • HY-108248
    KU-32

    HSP Metabolic Disease Neurological Disease Cardiovascular Disease
    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
  • HY-141834
    Carboxylesterase-IN-1

    Others
    Carboxylesterase-IN-1, a novel pesticide, exhibits inhibitory action on carboxylesterase at 50 μg/mL similar to the known inhibitor triphenyl phosphate.
  • HY-132937
    PRMT5-IN-9

    Histone Methyltransferase
    PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC50 of 0.01 μM.
  • HY-19969
    YM-90709

    Interleukin Related Inflammation/Immunology
    YM-90709 is a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor.
  • HY-50703
    MK-2461

    c-Met/HGFR Cancer
    MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.
  • HY-N7089
    Benzoyleneurea

    Bacterial Infection
    Benzoyleneurea possesses anti-bacterial activity. Benzoyleneurea scaffold can be used in the synthesis of novel protein geranylgeranyltransferase-I (PGGTase-I) inhibitors.
  • HY-100735
    C 87

    TNF Receptor Inflammation/Immunology
    C 87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM.
  • HY-15679
    PI4KIII beta inhibitor 3

    PI4K Cancer
    PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC50 of 5.7 nM.
  • HY-136717
    FBPase-1 inhibitor-1

    Others Metabolic Disease
    FBPase-1 inhibitor-1 (compound 1) is a novel allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1).
  • HY-112180
    Rilematovir

    JNJ-678; JNJ-53718678

    RSV Infection
    Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) treatment.
  • HY-G0023
    Niraparib metabolite M1

    Niraparib carboxylic acid metabolite M1; M1 metabolite of niraparib

    Drug Metabolite Others
    Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.
  • HY-101520
    Dot1L-IN-1

    Histone Methyltransferase Cancer
    Dot1L-IN-1 is a highly potent, selective and structurally novel Dot1L inhibitor with a Ki of 2 pM.
  • HY-13577A
    Oclacitinib maleate

    PF-03394197 maleate

    JAK Inflammation/Immunology
    Oclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM).
  • HY-12289A
    Defactinib hydrochloride

    VS-6063 hydrochloride; PF 04554878 hydrochloride

    FAK Cancer
    Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
  • HY-12479A
    Epetraborole hydrochloride

    GSK2251052 hydrochloride

    Bacterial Infection
    Epetraborole hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding "to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase".
  • HY-B1040
    Ftaxilide

    Bacterial Infection
    Ftaxilide is a novel antituberculosis agent.
  • HY-U00071
    Dobupride

    Others Metabolic Disease
    Dobupride is a novel gastroprokinetic drug.
  • HY-100180
    Delpazolid

    LCB01-0371

    Bacterial Antibiotic Infection
    Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC90 of 2 μg/mL for both of them.
  • HY-12796A
    Raxatrigine hydrochloride

    GSK-1014802 hydrochloride; CNV1014802 hydrochloride

    Sodium Channel Neurological Disease
    Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
  • HY-12965
    S49076

    FGFR c-Met/HGFR Cancer
    S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
  • HY-12796
    Raxatrigine

    GSK-1014802; CNV1014802

    Sodium Channel Neurological Disease
    Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
  • HY-U00438
    LP117

    Lipoxygenase Inflammation/Immunology
    LP117 is a novel and potent inhibitor of 5-Lipoxygenase (5-LO) product synthesis with an IC50 of 1.1 μM.
  • HY-13562A
    Banoxantrone dihydrochloride

    AQ4N dihydrochloride

    Topoisomerase Cancer
    Banoxantrone dihydrochloride is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
  • HY-135042
    CAY10614

    Toll-like Receptor (TLR) Neurological Disease
    CAY10614 is a potent TLR4 antagonist. CAY10614 inhibits the lipid A-induced activation of TLR4, with an IC50 of 1.675 μM. CAY10614 can improve survival of mice in lethal endotoxin shock model.
  • HY-15583
    Auristatin F

    Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin F is a potent cytotoxin. Auristatin F, a potent microtubule inhibitor and vascular damaging agent (VDA), can be used in antibody-drug conjugates (ADC).
  • HY-132595
    Teprasiran

    QPI-1002

    MDM-2/p53 Cancer
    Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI).
  • HY-15736
    Sodium Channel inhibitor 1

    Sodium Channel Neurological Disease
    Sodium Channel inhibitor1, one of 3-Oxoisoindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.
  • HY-108413
    Talazoparib tosylate

    BMN 673ts

    PARP Cancer
    Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
  • HY-18606
    K-Ras G12C-IN-3

    Ras Cancer
    K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.
  • HY-13991
    CCG-1423

    Ras Cancer
    CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.
  • HY-15192
    GSK 650394

    SGK Influenza Virus Cancer Infection
    GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
  • HY-15719
    NU 7026

    LY293646

    DNA-PK Apoptosis Cancer
    NU 7026 (LY293646) is a novel specific DNA-PK inhibitor with IC50 of 0.23 μM, also inhibits PI3K with IC50 of 13 μM.
  • HY-12054A
    Hesperadin hydrochloride

    Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC50 of 250 nM.
  • HY-112273A
    CD532 hydrochloride

    Aurora Kinase Cancer
    CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer.
  • HY-112273
    CD532

    Aurora Kinase Cancer
    CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer.
  • HY-122470
    Stampidine

    Reverse Transcriptase HIV Infection
    Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively.
  • HY-B0579
    Cyclosporin A

    Cyclosporine A; Ciclosporin A; CsA

    Phosphatase Complement System Antibiotic Inflammation/Immunology Cancer
    Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM. Cyclosporin A also inhibits CD11a/CD18 adhesion.
  • HY-P1290
    PKA Inhibitor Fragment (6-22) amide

    PKI-(6-22)-amide

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice.
  • HY-12054
    Hesperadin

    Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral.
  • HY-P1290A
    PKA Inhibitor Fragment (6-22) amide TFA

    PKI-(6-22)-amide TFA

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse low-level morphine antinociceptive tolerance in mice.
  • HY-15720B
    Glycyl H-1152 hydrochloride

    ROCK Aurora Kinase CaMK Neurological Disease
    Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and PKG, with IC50s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride.
  • HY-18643
    TZ9

    E1/E2/E3 Enzyme Cancer
    TZ9 is a novel inhibitor of Rad6 ubiquitin conjugating enzyme(E2 enzyme); inhibits MDA-MB-231 cell proliferation with IC50 of ~6 uM.
  • HY-15716
    Kobe0065

    Ras Apoptosis Cancer
    Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46±13 μM.
  • HY-111387
    IDF-11774

    HIF/HIF Prolyl-Hydroxylase Cancer
    IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65 μM.
  • HY-13535
    ATN-161

    Integrin Cancer
    ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
  • HY-139585
    Tigulixostat

    Xanthine Oxidase Metabolic Disease
    Tigulixostat is a novel (indolyl)heteroarylcarboxylate derivatives effective as non-purine selective xanthine oxidase inhibitor, which lowers the production of uric acid.
  • HY-15707
    NS6180

    Potassium Channel Inflammation/Immunology
    NS6180 is a novel potent and selective KCa3.1 channel inhibitor(IC50= 9 nM) prevents T-cell activation and inflammation.
  • HY-111108
    LDH-IN-1

    Lactate Dehydrogenase Cancer
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
  • HY-13535A
    ATN-161 trifluoroacetate salt

    ATN-161 TFA salt

    Integrin Cancer
    ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
  • HY-141838
    LpxA-IN-1

    Others
    LpxA-IN-1 is a novel UDP-N-acetylglucosamine acyltransferase (LpxA) inhibitor (IC50 2 nM) with activity against Pseudomonas aeruginosa (MIC 8 μg/mL).
  • HY-B0099
    Edaravone

    MCI-186

    MMP Apoptosis Neurological Disease
    Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
  • HY-B0396
    Tebipenem pivoxil

    L084

    Bacterial Antibiotic Infection
    Tebipenem Pivoxil is a novel oral carbapenem antibiotic.
  • HY-107385
    Epristeride

    ONO-9302; SKF105657

    5 alpha Reductase Cancer
    Epristeride is a novel 5α-reductase inhibor.
  • HY-U00274
    Ropitoin

    TR 2985

    Others Cardiovascular Disease
    Ropitoin (TR 2985) is a novel antiarrhythmic drug.
  • HY-100194
    FKK

    Others Inflammation/Immunology Cardiovascular Disease
    FKK is an indazole derivative and also a novel bronchodilator.
  • HY-N0693
    Schisandrin A

    Schizandrin-A; Wuweizisu-A; Deoxyschizandrin

    Cytochrome P450 Autophagy Virus Protease Inflammation/Immunology Cancer
    Schisandrin A inhibits CYP3A activity with an IC50 of 6.60 μM and Ki of 5.83 μM, respectively.
  • HY-131976
    BVDV-IN-1

    DNA/RNA Synthesis Infection
    BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV), with an EC50 of 1.8 μM. BVDV-IN-1 directly binds to a hydrophobic pocket of the BVDV RdRp. BVDV-IN-1 has antiviral activity against BVDV resistant to NNI thiosemicarbazone (TSC).
  • HY-14908
    Vidofludimus

    4sc-101; SC12267

    Dihydroorotate Dehydrogenase DNA/RNA Synthesis Interleukin Related Inflammation/Immunology
    Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
  • HY-14711
    Reversine

    Aurora Kinase Autophagy Cancer
    Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC50s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.
  • HY-16665
    iCRT 14

    Wnt Cancer
    iCRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT), with IC50 of 40.3 nM against Wnt responsive STF16 luciferase.
  • HY-18337
    IOWH-032

    CFTR Autophagy Metabolic Disease
    IOWH-032 is a novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays.
  • HY-15440
    Temsavir

    BMS-626529

    HIV Infection
    Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
  • HY-100654
    10-DEBC hydrochloride

    Akt Bacterial Infection Inflammation/Immunology
    10-DEBC hydrochloride is a selective Akt inhibitor, with an IC50 of 1.28 μM. 10-DEBC hydrochloride is a novel anti-TB compound.
  • HY-103001
    HMN-154

    Others Cancer
    HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
  • HY-100863
    BRCA1-IN-1

    PARP Cancer
    BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively.
  • HY-13503
    Epothilone A

    Epo A

    Microtubule/Tubulin Apoptosis Cancer
    Epothilone A is a competitive inhibitor of the binding of [ 3H] paclitaxel to tubulin polymers, with a Ki of 0.6-1.4 μM.
  • HY-11007
    GNF-2

    Bcr-Abl SARS-CoV Cancer
    GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM [1].
  • HY-10038
    A 922500

    DGAT-1 Inhibitor 4a

    Acyltransferase Metabolic Disease
    A 922500 (DGAT-1 Inhibitor 4a) is a potent, selective, and orally bioavailable diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC50s of 9 and 22 nM against human and mouse DGAT-1, respectively.
  • HY-116872
    MAC13772

    Bacterial Infection
    MAC13772 is a potent inhibitor of the enzyme BioA (IC50=250 nM), the antepenultimate step in biotin biosynthesis. MAC13772 is a novel antibacterial compound.
  • HY-U00416
    ARS-1323

    Ras Cancer
    ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
  • HY-19612B
    DDP-38003 trihydrochloride

    Histone Demethylase Cancer
    DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM.
  • HY-19612A
    DDP-38003 dihydrochloride

    Histone Demethylase Cancer
    DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM.
  • HY-18957
    Lifirafenib

    BGB-283

    EGFR Raf Cancer
    Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRaf V600E and EGFR, respectively.
  • HY-100249
    XEN723

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.
  • HY-111421
    ODM-204

    Androgen Receptor Cytochrome P450 Cancer
    ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively.
  • HY-15846
    CPI-203

    Epigenetic Reader Domain Apoptosis Cancer
    CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (BRD4 α-screen assay).
  • HY-13271
    Tubastatin A Hydrochloride

    Tubastatin A HCl; TSA HCl

    HDAC Autophagy Apoptosis Cancer
    Tubastatin A (Hydrochloride) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).
  • HY-101217
    BI 689648

    Cytochrome P450 Endocrinology
    BI 689648 is a novel, highly selective aldosterone synthase inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively.
  • HY-15515
    SEA0400

    Na+/Ca2+ Exchanger Cardiovascular Disease
    SEA0400 is a novel and selective inhibitor of the Na +-Ca 2+ exchanger (NCX), inhibiting Na +-dependent Ca 2+ uptake in cultured neurons, astrocytes, and microglia with IC50s of from 5 to 33 nM.
  • HY-138294
    RAS/RAS-RAF-IN-1

    Ras Raf Cancer
    RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.
  • HY-107426
    Verrucarin A

    Muconomycin A

    Apoptosis Reactive Oxygen Species Cancer
    Verrucarin A (Muconomycin A), a Type D macrocyclic mycotoxin derived from the pathogen fungus Myrothecium verrucaria, is an inhibitor of protein synthesis. Verrucarin A inhibits growth of leukemia cell lines and activates caspases and apoptosis and inflammatory signaling in macrophages. Verrucarin A effectively increased the phosphorylation of p38 MAPK and diminished the phosphorylation of ERK/Akt. Verrucarin A caused cell cycle deregulation through the induction of p21 and p53.
  • HY-N6628
    6,2'-Dihydroxyflavone

    GABA Receptor Neurological Disease
    6,2'-Dihydroxyflavone is a novel antagonist of GABAA receptor.
  • HY-103668A
    SSD114 hydrochloride

    GABA Receptor Neurological Disease
    SSD114 hydrochloride is a novel GABAB receptor positive allosteric modulator.
  • HY-14864
    Mapracorat

    ZK-245186; BOL-303242X

    Glucocorticoid Receptor Endocrinology
    Mapracorat is a novel non-steroidal selective glucocorticoid receptor agonist.
  • HY-100592
    Nicaraven

    Others Cancer
    Nicaraven is a novel chemically synthesized hydroxyl radical-specific scavenger.
  • HY-18595
    BI 224436

    HIV HIV Integrase Infection
    BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC50 values of less than 15 nM against different HIV-1 laboratory strains.
  • HY-17645
    Tenalisib

    RP6530

    PI3K Cancer
    Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and PI3Kγ inhibitor with IC50 values of 25 and 33 nM, respectively.
  • HY-12873
    RBC8

    Ras Cancer
    RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell.
  • HY-100791
    NSC23005 sodium

    Others Cancer
    NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
  • HY-13299A
    MK-8033 hydrochloride

    c-Met/HGFR Cancer
    MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
  • HY-N2221
    Ganoderal A

    Others Metabolic Disease
    Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor.
  • HY-12743A
    K-7174 dihydrochloride

    Others Inflammation/Immunology
    K-7174 dihydrochloride is a novel cell adhesion inhibitor; inhibits the expression of vascular cell adhesion molecule-1 (VCAM-1) induced by either IL-1β or TNF-α.
  • HY-12743
    K-7174

    Others Inflammation/Immunology
    K-7174 is a novel cell adhesion inhibitor; inhibits the expression of vascular cell adhesion molecule-1 (VCAM-1) induced by either IL-1β or TNF-α.
  • HY-N0897
    Corylifol A

    Corylifol-A; Corylinin

    STAT Others
    Corylifol A inhibits IL-6-induced STAT3 activation and phosphorylation, with an IC50 of 0.81 μM.
  • HY-N1447
    Ganoderic acid A

    Apoptosis Autophagy Endogenous Metabolite Cancer
    Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS.
  • HY-18983
    Calyculin A

    (-)-Calyculin A

    Phosphatase Cancer
    Calyculin A ((-)-Calyculin A) is a potent and cell-permeable protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) inhibitor with IC50s of 2 nM and 0.5-1 nM, respectively.
  • HY-N0060
    Ferulic acid

    Coniferic acid

    FGFR Endogenous Metabolite Cancer
    Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
  • HY-15841
    CEP-37440

    ALK FAK Cancer
    CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
  • HY-N2523
    Gigantol

    Wnt Cancer
    Gigantol is a bibenzyl compound derived from several medicinal orchids. Giganto shows promising therapeutic potential against cancer cells. Gigantol is a novel inhibitor of the Wnt/β-catenin pathway.
  • HY-N0060A
    Ferulic acid sodium

    Coniferic acid sodium

    FGFR Endogenous Metabolite Reactive Oxygen Species Cardiovascular Disease Cancer
    Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
  • HY-13299
    MK-8033

    c-Met/HGFR Cancer
    MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
  • HY-U00417
    ARS-1630

    Ras Cancer
    ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
  • HY-N0694
    Schisantherin A

    Gomisin-C; Schizantherin-A; Wuweizi ester-A

    NF-κB Inflammation/Immunology
    Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation.
  • HY-101184
    T807

    AV-1451

    Others Neurological Disease
    T807 a novel tau positron emission tomography (PET) tracer.
  • HY-B2136
    Tannic acid

    Potassium Channel Cancer Inflammation/Immunology
    Tannic acid is a novel hERG channel blocker with IC50 of 3.4 μM.
  • HY-14909
    Bardoxolone

    CDDO; RTA 401

    Keap1-Nrf2 Cancer
    Bardoxolone is a novel nuclear regulator factor (Nrf-2) activator.
  • HY-101632
    Irindalone

    Lu 21-​098

    5-HT Receptor Neurological Disease
    Irindalone is a novel serotonin 5-HT2 antagonist.
  • HY-14798
    Palifosfamide

    Isophosphoramide mustard; IPM; ZIO-201

    DNA Alkylator/Crosslinker Drug Metabolite Cancer
    Palifosfamide is a novel DNA alkylator and the active metabolite of ifosfamide, with antitumor activity.
  • HY-131907
    LpxC-IN-5

    Bacterial Infection
    LpxC-IN-5 is a potent non-hydroxamate LpxC (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor with an IC50 of 20 nM. LpxC-IN-5 shows antibacterial activity against E. coli ATCC25922, P. aeruginosa ATCC27853, K. pneumoniae ATCC13883 and P. aeruginosa 5567 with MIC of 16, 4, 64, and 4 μg/mL, respectively.
  • HY-N0505
    Rosiridin

    Monoamine Oxidase Neurological Disease
    Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC50=5.38).
  • HY-12960
    SKLB4771

    FLT3-​IN-​1

    FLT3 Cancer
    SKLB4771 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.
  • HY-N2150
    Psammaplin A

    HDAC DNA Methyltransferase DNA/RNA Synthesis Bacterial Cancer Infection
    Psammaplin A, a marine metabolite, is a potent inhibitor of HDAC and DNA methyltransferases. Psammaplin A ia a highly potent and selective DAC1 inhibitor with an IC50 of 0.9 nM. Psammaplin A possess the antimicrobial effect on the Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Antitumor Activity.
  • HY-U00459
    GSK2850163

    IRE1 Cancer
    GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively.
  • HY-U00459B
    GSK2850163 hydrochloride

    IRE1 Cancer
    GSK2850163 hydrochloride is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively.
  • HY-108486
    Herbimycin A

    Bacterial Antibiotic Infection
    Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 v-src and p210 BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.
  • HY-136194
    TL13-22

    ALK Cancer
    TL13-22 is a negative control for TL13-12 (HY-122582) and a potent ALK inhibitor with an IC50 of 0.54 nM. TL13-22 does not degrade ALK in cells.
  • HY-B0505
    Moguisteine

    BBR-2173

    Others Neurological Disease Cancer
    Moguisteine(BBR-2173) is a novel peripheral non-narcotic antitussive drug.
  • HY-109168
    Bersacapavir

    JNJ-6379; JNJ-56136379

    HBV Infection
    Bersacapavir is a novel Hepatitis B Virus capsid assembly modulator.
  • HY-N0553
    Gypenoside XVII

    Gynosaponin S

    Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.
  • HY-101738A
    Peliglitazar racemate

    BMS 426707-01 racemate

    PPAR Metabolic Disease
    Peliglitazar racemate is the racemate of Peliglitazar. Peliglitazar is a novel dual α/γ PPAR activator.
  • HY-U00233
    FG8119

    NNC13-8119

    GABA Receptor Neurological Disease
    FG8119 is a novel benzodiazepine agonist extracted from patent US 4745112 A.
  • HY-124330
    Tripolin A

    (E)-Tripolin A

    Aurora Kinase Others
    Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive Aurora A kinase inhibitor, with IC50 values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively.
  • HY-15681
    Senexin A

    CDK Cancer
    Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.
  • HY-N2065
    Withaferin A

    NF-κB Ferroptosis Cancer Inflammation/Immunology
    Withaferin A is a steroidal lactone isolated from Withania somnifera, inhibits NF-kB activation and targets vimentin, with potent antiinflammatory and anticancer activities. Withaferin A is an inhibitor of endothelial protein C receptor (EPCR) shedding.
  • HY-N8120
    Bisabolone oxide A

    Glucosidase Metabolic Disease
    Bisabolone oxide A is an α-glucosidase inhibitor.
  • HY-12654
    Molidustat

    BAY 85-3934

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with mean IC50 values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3.
  • HY-18604
    K-Ras G12C-IN-1

    Ras Cancer
    K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.
  • HY-B2175
    Aspirin Aluminum

    Aluminum diacetylsalicylate

    Others Inflammation/Immunology
    Aspirin Aluminum is a novel intermolecular compound which can inhibit gastrointestinal mucosal disorders induced by NSAIDs (non-steroidal anti-inflammatory agents) extracted from patent WO 2010064441 A1.
  • HY-13781
    Pemetrexed disodium hemipenta hydrate

    LY231514 disodium hemipenta hydrate

    Antifolate Autophagy Apoptosis Cancer
    Pemetrexed disodium hemipenta hydrate is a novel antifolate, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively.
  • HY-16929
    Latrunculin A

    LAT-A

    Arp2/3 Complex Others
    Latrunculin A (LAT-A) is a toxin isolated from the red sea sponge Latrunculia magnifica, binds to actin monomers, inhibits polymerization of actin, with Kds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively.
  • HY-136072
    QPX7728-OH disodium

    Bacterial Infection
    QPX7728-OH disodium (compound 13) is a boronic acid β-lactamase inhibitor, exacted from WO2018005662A1, compound 13. QPX7728-OH disodium inhibits cleavage of Nitrocefin (HY-108913) by purified class A, C and D enzymes, with Kis less than 0.1 µΜ.
  • HY-125916
    Pseurotin A

    Others Cancer
    Pseurotin A, a secondary metabolite of Aspergillus and other fungi, is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50=3.6 μM). Antitumor activity.
  • HY-15595A
    360A iodide

    360 A iodide

    G-quadruplex Telomerase Cancer
    360A iodide is a selective stabilizer of G-quadruplex, and also inhibits telomerase activity with an IC50 of 300 nM for telomerase in TRAP-G4 assay.
  • HY-107531
    A 1070722

    GSK-3 Cancer
    A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain.
  • HY-130841
    Apcin-A

    APC Ligand for Target Protein for PROTAC Cancer
    Apcin-A, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V (HY-130257).
  • HY-101493
    SUN11602

    FGFR Neurological Disease
    SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.
  • HY-18003
    Oleanolic acid derivative 2

    Others Inflammation/Immunology
    Oleanolic acid derivative 2 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.
  • HY-14734B
    Anamorelin Fumarate

    ONO-7643 Fumarate; RC1291 Fumarate

    GHSR Cancer Endocrinology
    Anamorelin Fumarate is a novel ghrelin receptor agonist with EC50 value of 0.74 nM in the FLIPR assay.
  • HY-18219
    Walrycin B

    Bacterial Antibiotic Infection
    Walrycin B is a novel antibacterial compound specifically targeting the essential WalR response regulator.
  • HY-U00178
    Idoxifene

    CB7432

    Estrogen Receptor/ERR Cancer
    Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM).
  • HY-U00026
    Semotiadil recemate fumarate

    Calcium Channel Cardiovascular Disease
    Semotiadil recemate fumarate is the recemate of Semotiadil fumarate. Semotiadil fumarate is a novel vasoselective Ca 2+ channel antagonist.
  • HY-18002
    Oleanolic acid derivative 1

    Others Inflammation/Immunology
    Oleanolic acid derivative 1 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.
  • HY-13254A
    A-674563 hydrochloride

    Akt Cancer
    A-674563 hydrochloride is a potent and selective Akt1 inhibitor with Ki of 11 nM.
  • HY-136071
    QPX7728 methoxy acetoxy methy ester

    Bacterial Infection
    QPX7728 methoxy acetoxy methy ester is a boronic acid β-lactamase inhibitor, exacted from WO2018005662A1, compound 43.
  • HY-136070
    QPX7728 bis-acetoxy methyl ester

    Bacterial Infection
    QPX7728 bis-acetoxy methyl ester is a boronic acid β-lactamase inhibitor, exacted from WO2018005662A1, compound 42.
  • HY-116090
    Conoidin A

    Parasite Infection Neurological Disease Cardiovascular Disease
    Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 µM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease.
  • HY-N6687
    Calcimycin

    A-23187; Antibiotic A-23187

    Bacterial Fungal Apoptosis Autophagy Antibiotic Cancer Infection
    Calcimycin (A-23187) is an antibiotic and a unique divalent cation ionophore (like calcium and magnesium). Calcimycin induces Ca 2+-dependent cell death by increasing intracellular calcium concentration. Calcimycin inhibits the growth of Gram-positive bacteria and some fungi. Calcimycin also inhibits the activity of ATPase and uncouples oxidative phosphorylation (OXPHOS) of mammalian cells. Calcimycin induces apoptosis.
  • HY-127002A
    Squarunkin A hydrochloride

    Src Cancer
    Squarunkin A hydrochloride is a potent and selective UNC119-cargo interaction inhibitor (IC50 of 10 nM for inhibiting the UNC119A-myristoylated Src N-terminal peptide interaction). Squarunkin A hydrochloride interferes with the activation of Src kinase in cells.
  • HY-118773
    MreB Perturbing Compound A22 hydrochloride

    A22 hydrochloride

    Bacterial Inflammation/Immunology
    MreB Perturbing Compound A22 hydrochloride is a benzylisothiourea compound that interacts with the ATP binding site of MreB rapidly and reversibly. MreB Perturbing Compound A22 hydrochloride blocks normal rod shape formation and inhibits chromosome partitioning in E. coli, inhibiting growth (MIC=3.1 µg/ml).
  • HY-13271A
    Tubastatin A

    HDAC Autophagy Apoptosis Cancer
    Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).
  • HY-11011
    A-770041

    Src Inflammation/Immunology
    A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.
  • HY-13254
    A-674563

    Akt Cancer
    A-674563 is an orally active and selective Akt1 inhibitor with a Ki of 11 nM.
  • HY-N2498
    Glomeratose A

    Lactate Dehydrogenase Others
    Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia.
  • HY-15764
    A 419259

    RK-20449

    Src Cancer
    A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family with IC50 of 9 nM, <3 nM and <3 nM for Src, Lck and Lyn, respectively.
  • HY-18360
    TMP269

    HDAC Cancer
    TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC50s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
  • HY-N6796
    Manumycin A

    Farnesyl Transferase Ras Apoptosis Phospholipase Cancer Infection
    Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (Ki =1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling. Manumycin A is a nSMase inhibitor (EC50=0.25 μM).
  • HY-129337
    Reveromycin A

    Antibiotic Fungal Apoptosis Cancer Infection
    Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity.
  • HY-N0466
    Rebaudioside A

    Endogenous Metabolite Glucosidase Others
    Rebaudioside A is a steviol glycoside, α-glucosidase inhibitor with IC50 of 35.01 μg/ml.
  • HY-13261
    A66

    PI3K Cancer
    A66 is a highly specific and selective p110α inhibitor with an IC50 of 32 nM.
  • HY-17387
    (-)-Huperzine A

    Huperzine A

    AChE Apoptosis iGluR Neurological Disease
    (-)-Huperzine A (Huperzine A) is an alkaloid isolated from a Chinese club moss, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease.
  • HY-N6773
    Cytochalasin A

    HIV Protease Fungal Infection
    Cytochalasin A is a cell-permeable fungal toxin that is an oxidized derivative of cytochalasin B. Cytochalasin A is an inhibitor of HIV-1 protease (IC50=3 μM) and inhibits actin polymerization and interferes with microtubule assembly by reacting with sulfhydryl groups. Antibiotic and fungicidal activitives.
  • HY-110195
    Smurf1-IN-A01

    A01

    Others Others
    Smurf1-IN-A01 (A01) is an ubiquitin ligase Smad ubiquitination regulatory factor-1 (Smurf1) inhibitor with a kd of 3.664 nM, which increases BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation.
  • HY-N3417
    Kongensin A

    HSP RIP kinase Apoptosis Cancer Inflammation/Immunology
    Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent HSP90 inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications.
  • HY-19563
    A-893

    Histone Methyltransferase Cancer
    A-893 is a cell-active inhibitor of Methyltransferase SMYD2, with an IC50 of 2.8 nM.
  • HY-16699
    Nexturastat A

    HDAC Cancer
    Nexturastat A is a potent and selective HDAC6 inhibitor with IC50 of 5 nM; no inhibition on other HDAC forms.
  • HY-19376
    NAMI-A

    FAK Cancer
    NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.
  • HY-19741
    A-1331852

    Bcl-2 Family Cancer
    A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.
  • HY-N1505
    Loureirin A

    Akt Cardiovascular Disease
    Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
  • HY-17634
    Glecaprevir

    ABT-493

    HCV HCV Protease SARS-CoV Infection
    Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 4.09 μM.
  • HY-18675
    IQ-R

    Others Others
    IQ-R is a novel hypoxia-sensitive fluorescent probe, consisting of an indolequinone unit and a rhodol fluorophore.
  • HY-14423
    Velneperit

    S2367

    Neuropeptide Y Receptor Metabolic Disease Endocrinology
    Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist.
  • HY-N1378
    (E)-Cardamonin

    (E)-Cardamomin; (E)-Alpinetin chalcone

    TRP Channel Apoptosis Neurological Disease Cancer
    (E)-Cardamonin ((E)-Cardamomin) is a novel antagonist of hTRPA1 cation channel with an IC50 of 454 nM.
  • HY-U00030
    Rispenzepine

    mAChR Neurological Disease
    Rispenzepine is a novel antimuscarinic compound with a preferential action at M1, and M3 receptor subtypes.
  • HY-A0122
    Plicamycin

    Mithramycin A

    DNA/RNA Synthesis Bacterial Antibiotic Cancer Infection
    Plicamycin is a selective specificity protein 1 (Sp1) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein.
  • HY-103397
    Nanaomycin A

    DNA Methyltransferase Parasite Cancer Infection
    Nanaomycin A is the first selective DNMT3B inhibitor with an IC50 of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells. Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM.
  • HY-15771
    Tirabrutinib

    ONO-4059; GS-4059

    Btk Cancer
    Tirabrutinib (ONO-4059) is a selective and novel inhibitor of BTK with IC50 2.2 nM, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
  • HY-16191
    ELR510444

    Microtubule/Tubulin Apoptosis Cancer
    ELR510444 is a novel microtubule disruptor; inhibits MDA-MB-231 cell proliferation with IC50 of 30.9 nM; not a substrate for the P-glycoprotein drug transporter and retains activity in βIII-tubulin-overexpressing cell lines.
  • HY-12872A
    Nazartinib mesylate

    EGF816 mesylate

    EGFR Cancer
    Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min −1 on EGFR(L858R/790M) mutant, respectively.
  • HY-16478
    Trifluridine/tipiracil hydrochloride mixture

    TAS-102

    Nucleoside Antimetabolite/Analog Thymidylate Synthase Cancer
    Trifluridine-tipiracil hydrochloride mixture (TAS-102) is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent thymidine phosphorylase inhibitor, tipiracil, in a 1:0.5 molar ratio.
  • HY-15771A
    Tirabrutinib hydrochloride

    ONO-4059 hydrochloride; GS-4059 hydrochloride

    Btk Cancer
    Tirabrutinib (ONO-4059) hydrochloride is a selective and novel inhibitor of BTK with IC50 2.2 nM, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
  • HY-13231
    CDK9-IN-1

    CDK HIV Infection
    CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
  • HY-110096
    A-484954

    CaMK Autophagy Cancer
    A-484954 is a highly selective eukaryotic elongationfactor-2 (eEF2) inhibitor, with an IC50 of 280 nM.
  • HY-126406
    Tirandamycin A

    Bacterial DNA/RNA Synthesis Parasite Antibiotic Infection
    Tirandamycin A, an antibiotic, is a bacterial RNA polymerase inhibitor. Tirandamycin A has antiamoebic and antibacterial properties.
  • HY-N3389
    Licoisoflavone A

    Others Metabolic Disease
    Licoisoflavone A is an isoflavone. Licoisoflavone A inhibits lipid peroxidation with an IC50 of 7.2 μM.
  • HY-107433
    U18666A

    HCV Infection Neurological Disease
    U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus.
  • HY-N7452
    Coumermycin A1

    JAK Bacterial Metabolic Disease
    Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.
  • HY-12458
    Pyrindamycin A

    DNA/RNA Synthesis Cancer Infection
    Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC50 of 3.9 μg/ml.
  • HY-19725
    A-1155463

    Bcl-2 Family Cancer
    A-1155463 is a highly potent and selective BCL-XL inhibitor with an EC50 of 70 nM in Molt-4 cell.
  • HY-N6584
    Saikogenin A

    Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    Saikogenin A, extracted from a Chinese herbal plant called Tsai-Fu, is a dipeptidyl peptidase-IV (DPP-IV) inhibitor.
  • HY-137473
    Methyl pyropheophorbide-a

    Pyropheophorbide-a methyl ester

    Apoptosis Cancer
    Methyl pyropheophorbide-a (Pyropheophorbide-a methyl ester), a chlorophyll-a derivative, is a potent photosensitizer that can be used in photodynamic therapy (PDT) of cancer. Methyl pyropheophorbide-a has photodynamic activity and can induce apoptosis and inhibit tumor growth.
  • HY-B0856
    Validamycin A

    Fungal Tyrosinase Antibiotic Infection
    Validamycin A, a fungicidal, is an agricultural antibiotic. Validamycin A is originally isolated from Streptomyces hygroscopicus var. limoneus. Validamycin A inhibits the growth of A. flavus, with a MIC of 1μg/mL. Validamycin A shows potent inhibitory activity against trehalase of Rhizoctonia solani, with an IC50 of 72 μM. Validamycin A is a reversible tyrosinase inhibitor, with a Ki of 5.893 mM.
  • HY-15480
    NSC 42834

    JAK2 Inhibitor V; Z3

    JAK Cancer
    NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.
  • HY-N2392
    Kukoamine A

    Parasite Infection Cardiovascular Disease
    Kukoamine A is a natural occurring spermine derivative, acts as a potent inhibitor of trypanothione reductase (Ki, 1.8 μM), with antihypertensive activity.
  • HY-113957
    MPI_5a

    HDAC Cancer
    MPI_5a is a potent and selective HDAC6 inhibitor (IC50=36 nM). MPI_5a weakly inhibits other HDAC isoforms. MPI_5a inhibits acyl-tubulin accumulation in cells with an IC50 value of 210 nM.
  • HY-114200
    Imrecoxib

    BAP-909

    COX Inflammation/Immunology
    Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect.
  • HY-15391
    Lucitanib

    E-3810

    VEGFR FGFR Cancer
    Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
  • HY-15405
    Teriflunomide

    A77 1726

    Others Inflammation/Immunology
    Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation.
  • HY-122723
    GOT1 inhibitor-1

    Others Cancer
    GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC).
  • HY-15595
    360A

    G-quadruplex Telomerase Cancer
    360A is a selective stabilizer of G-quadruplex, and also inhibits telomerase activity with an IC50 of 300 nM for telomerase in TRAP-G4 assay.
  • HY-16014
    A-385358

    Bcl-2 Family Cancer
    A-385358 is a selective inhibitor of Bcl-XL with Kis of 0.80 and 67 nM for Bcl-XL and Bcl-2, respectively.
  • HY-14682
    GSK319347A

    IKK Inflammation/Immunology
    GSK319347A is a dual inhibitor of TBK1 and IKKε with IC50s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC50 of 790 nM.
  • HY-136195
    TL13-110

    ALK Cancer
    TL13-110 is a negative control for TL13-112 (HY-123919) and a potent ALK inhibitor with an IC50 of 0.34 nM. TL13-110 does not degrade ALK in cells.
  • HY-13020
    GSK1838705A

    ALK IGF-1R Insulin Receptor Cancer Endocrinology
    GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC50s of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC50 of 0.5 nM.
  • HY-13562S
    Banoxantrone (D12)

    AQ4N D12

    Topoisomerase Cancer
    Banoxantrone D12 (AQ4N D12) is the deuterium labeled banoxantrone. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
  • HY-12839
    p38 MAPK-IN-1

    p38 MAPK Autophagy Inflammation/Immunology
    p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.
  • HY-109586
    BRL-50481

    Phosphodiesterase (PDE) Neurological Disease
    BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15, 12.1, 62 and 490 μM for PDE7A, PDE7B, PDE4 and PDE3, respectively.
  • HY-119974
    Caracemide

    NSC-253272

    DNA/RNA Synthesis Bacterial Cancer Infection
    Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity.
  • HY-13562AS
    Banoxantrone D12 dihydrochloride

    AQ4N D12 dihydrochloride

    Topoisomerase Cancer
    Banoxantrone D12 dihydrochloride (AQ4N D12 dihydrochloride) is the deuterium labeled banoxantrone dihydrochloride. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
  • HY-19529
    Ro 46-2005

    Endothelin Receptor Cardiovascular Disease Endocrinology
    Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.
  • HY-N0842
    Bevirimat

    PA-457; MPC-4326; YK FH312

    HIV Infection
    Bevirimat (PA-457; MPC-4326; YK FH312) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.
  • HY-N6793
    Phomopsin A

    Microtubule/Tubulin Cancer
    Phomopsin A is a cyclic hexapeptide mycotoxin isolated from the fungus Phomopsis leptostomiformis. Phomopsin A is a noncompetitive inhibitor of the binding of radiolabeled vincristine to tubulin.
  • HY-126421
    Kansuinine A

    Interleukin Related Cancer Infection
    Kansuinine A inhibits IL-6-induced Stat3 activation. Kansuinine A possesses antiviral and anticancer activity.
  • HY-P0171
    Motixafortide

    BKT140 (4-fluorobenzoyl); BL-8040; TF14016

    CXCR Cancer Endocrinology
    Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ~1 nM.
  • HY-18102A
    GLPG0492 (R enantiomer)

    Androgen Receptor Neurological Disease
    GLPG0492 R enantiomer is the R enantiomer of GLPG-0492, which is a novel selective androgen receptor modulator.
  • HY-B0023
    Azelnidipine

    CS 905

    Calcium Channel Cardiovascular Disease
    Azelnidipine(CS 905; Calblock) is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive.
  • HY-N0805A
    Alisol B

    Others Metabolic Disease
    Alisol B is a potentially novel therapeutic compound for bone disorders by targeting the differentiation of osteoclasts as well as their functions.
  • HY-14855B
    Tedizolid phosphate

    TR-701FA

    Bacterial Antibiotic Infection
    Tedizolid phosphate (TR-701FA) is a novel oxazolidinone with activity against Gram-positive pathogens.
  • HY-13742
    Ropidoxuridine

    IPdR

    Others Cancer
    Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.
  • HY-19721
    ABT-639

    Calcium Channel Neurological Disease
    ABT-639 is a novel, peripherally acting, selective T-type Ca 2+ channel blocker.
  • HY-101616
    ABT-639 hydrochloride

    Calcium Channel Neurological Disease
    ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca 2+ channel blocker.
  • HY-101835
    Decoyinine

    Angustmycin A

    Others Cancer
    Decoyinine is a selective inhibitor of GMP synthetase (GMPS).
  • HY-100201
    A-196

    Histone Methyltransferase Cancer
    A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC50 values of 25 nM and 144 nM, respectively. A-196 inhibits SUV4-20 biochemically in a substrate-competitive manner. A-196 represents a first-in-class chemical probe of SUV4-20 to investigate the role of histone methyltransferases in genomic integrity.
  • HY-N2300
    Kuwanon A

    NO Synthase Metabolic Disease Inflammation/Immunology
    Kuwanon A is a flavone derivative isolated from the root barks of the mulberry tree (Morus alba L.); inhibits nitric oxide production with an IC50 of 10.5 μM.
  • HY-N2360
    Hinokiflavone

    E1/E2/E3 Enzyme Cancer
    Hinokiflavone is a novel modulator of pre-mRNA splicing activity in vitro and in cellulo. Hinokiflavone blocks splicing of pre-mRNA substrates by inhibiting spliceosome assembly, specifically preventing B complex formation. Hinokiflavone is a SUMO protease inhibitor, inhibiting sentrin-specific protease 1 (SENP1) activity.
  • HY-105755
    Antimycin A3

    Mitochondrial Metabolism Apoptosis Cancer Infection
    Antimycin A3, an antibiotic isolated from a number of Streptomyces species, shows antifungal activities. Antimycin A3 is a potent inhibitor of respiration. Antimycin A3 inhibits the electron transfer activity of ubiquinol-cytochrome c oxidoreductase. Antimycin A3 inhibits ATP-citrate lyase with a Ki value of 60.1 µM.
  • HY-N2344
    Procyanidin A1

    Proanthocyanidin A1

    PKC Inflammation/Immunology
    Procyanidin A1 (Proanthocyanidin A1) is a procyanidin dimer, which inhibits degranulation downstream of protein kinase C activation or Ca 2+ influx from an internal store in RBL-213 cells. Procyanidin A1 has antiallergic effects.
  • HY-15764A
    A 419259 trihydrochloride

    RK 20449 trihydrochloride

    Src Cancer
    A 419259 trihydrochloride is a Src family kinases inhibitor with IC50s of 9 nM, 3 nM and 3 nM for Src, Lck and Lyn, respectively.
  • HY-W040129
    Chromomycin A3

    Bacterial Fungal Antibiotic Cancer Infection
    Chromomycin A3 is an aureolic acid-type antitumor antibiotic. Chromomycin A3 forms dimeric complexes with divalent cations, such as Mg 2+, which strongly binds to the GC rich sequence of DNA to inhibit DNA replication and transcription. Chromomycin A3 has a variety of utilities as a staining agent for human sperm chromatin, autophagy inducing agent, and apoptosis inhibitor.
  • HY-14164
    Zileuton

    A 64077; Abbott 64077

    Lipoxygenase Ferroptosis Inflammation/Immunology Cancer
    Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
  • HY-103266
    TC-A 2317 hydrochloride

    Aurora Kinase Cancer
    TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity.
  • HY-117025A
    Manzamine A hydrochloride

    GSK-3 CDK Parasite HIV Proton Pump Autophagy Cancer Infection Neurological Disease
    Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 and 1.5μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1.
  • HY-50709
    A939572

    Stearoyl-CoA Desaturase (SCD) Cancer
    A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.
  • HY-107833
    A40926

    Bacterial Infection
    A40926, the precursor of Dalbavancin, is a second-generation glycopeptide antibiotic. A40926 inhibits gram-positive bacteria, and is very active against Neisseria gonorrhoeae.
  • HY-N6862
    Lucideric acid A

    MMP Cancer
    Lucideric acid A is a natural compound isolated from Ganoderma lucidum, inhibits PMA-induced MMP-9 activity, with anti-invasive effect on hepatoma cells.
  • HY-50880
    Elacridar hydrochloride

    GF120918A

    P-glycoprotein Cancer
    Elacridar hydrochloride (GF120918A) is a potent P-glycoprotein (Pgp) and BCRP inhibitor.
  • HY-112205
    RR-11a

    Others Cancer
    RR-11a is a synthetic enzyme inhibitor of Legumain.
  • HY-B1856
    Haloxyfop

    Acetyl-CoA Carboxylase Metabolic Disease
    Haloxyfop is an aryloxyphenoxypropionic acid herbicide and is widely used in grass weeds in broad-leaf crops. Haloxyfop inhibits the acetyl coenzyme A carboxylase (EC 6.4.1.2) from corn seedling chloroplasts with an IC50 of 0.5 μM, but has no effect on this enzyme in pea.
  • HY-N6781
    Ophiobolin A

    Phosphodiesterase (PDE) Cancer Infection
    Ophiobolin A, a fungal metabolite and a phytotoxin, is a potent and irreversibly inhibitor of calmodulin-activated cyclic nucleotide phosphodiesterase, with an IC50 value of 9 μM. Ophiobolin A antimicrobial and anticancer activity.
  • HY-N0754
    Eupalinolide A

    HSP Inflammation/Immunology
    Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of HSF1 by inhibiting the interaction between HSF1 and HSP90.
  • HY-N6702
    Enniatin A

    Acyltransferase Infection Cardiovascular Disease
    Enniatin A is a Fusarium mycotoxin. Enniatin A inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 22 μM in an enzyme assay using rat liver microsomes.
  • HY-15440A
    Fostemsavir

    BMS-663068

    HIV Infection
    Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
  • HY-100558
    Bafilomycin A1

    Proton Pump Autophagy Antibiotic Bacterial Apoptosis Cancer Infection
    Bafilomycin A1 is a specific and reversible inhibitor of vacuolar H +-ATPase (V-ATPase) with IC50 values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis.
  • HY-12842
    UC-112

    IAP Apoptosis Cancer
    UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).
  • HY-11000
    GSK429286A

    ROCK Cancer
    GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM.
  • HY-N5012
    Eurycomanone

    Pasakbumin A

    Others Endocrinology
    Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.
  • HY-101744
    Ipsalazide

    Autophagy Inflammation/Immunology
    Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.
  • HY-76772B
    (-)-Cevimeline hydrochloride hemihydrate

    (-)-SNI-2011; (-)-AF102B hydrochloride hemihydrate

    mAChR Neurological Disease
    (-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
  • HY-19356
    Rocaglamide

    Roc-A

    NF-κB HSP Eukaryotic Initiation Factor (eIF) Cancer
    Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
  • HY-14164A
    Zileuton sodium

    A 64077 sodium; Abbott 64077 sodium

    Lipoxygenase Inflammation/Immunology
    Zileuton sodium (A 64077 sodium) is a potent and selective inhibitor of 5-lipoxygenase, exhibiting inflammatory activities.
  • HY-107406
    Antimycin A1

    Mitochondrial Metabolism Cancer
    Antimycin A1 is a specific electron transfer inhibitor of ubiquinol-cytochrome c oxidoreductase. Antimycin A1 inhibits angiogenesis through decrease in VEGF production caused by inhibition of HIF-1α activation.
  • HY-15897
    LDN-212854

    TGF-β Receptor Cancer
    LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC50=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors.
  • HY-13671
    LW6

    HIF-1α inhibitor; LW8

    HIF/HIF Prolyl-Hydroxylase Apoptosis Cancer
    LW6 (HIF-1α inhibitor) is a novel HIF-1 inhibitor with an IC50 of 4.4 μM. LW6 decreases HIF-1α protein expression without affecting HIF-1β expression.
  • HY-17388
    (±)-Huperzine A

    AChE Neurological Disease
    (±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).
  • HY-N4185
    Licoflavone A

    Phosphatase Neurological Disease
    Licoflavone A is a flavonoid isolated from the roots of Glycyrrhiza uralensis, inhibits protein tyrosine phosphatase-1B (PTP1B), with an IC50 of 54.5 μM.
  • HY-10425
    A-443654

    Akt Cancer
    A-443654 is a pan-Akt inhibitor and has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
  • HY-12507
    GSK-7975A

    Calcium Channel Inflammation/Immunology
    GSK-7975A is a potent and orally available CRAC channel inhibitor.
  • HY-120944
    BAY-7598

    MMP Inflammation/Immunology
    BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC50s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively.
  • HY-100599
    Urolithin A

    Drug Metabolite Reactive Oxygen Species DNA/RNA Synthesis Autophagy Apoptosis Endogenous Metabolite Cancer
    Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis.
  • HY-N2998
    Ganoderenic acid A

    Others Metabolic Disease
    Ganoderenic acid A is a lanostane-type triterpene. Ganoderenic acid A is a potent inhibitor of β-glucuronidase. Ganoderenic acid A has a potent hepatoprotective effect against CCl4-induced liver injury.
  • HY-N6017
    Bakkenolide A

    Others Cancer
    Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
  • HY-N0365
    Sennoside A

    HIV Infection
    Sennoside A is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia). Sennoside A is a HIV-1 inhibitor effective on HIV-1 replication.
  • HY-N4096
    Tsugaric acid A

    Others Inflammation/Immunology
    Tsugaric acid A can significantly inhibit superoxide anion formation. Tsugaric acid A also protects human keratinocytes against damage induced by ultraviolet B (UV B) light. Tsugaric acid A can protect keratinocytes from photodamage.
  • HY-N3925
    Ganoderol A

    Bacterial Infection Metabolic Disease Inflammation/Immunology
    Ganoderol A is a terpenoid extracted from Ganoderma lucidum with antimicrobial activities. Ganoderol A inhibits cholesterol synthesis pathway and has significant anti-inflammatory activity and protection against ultraviolet A (UVA) damage.
  • HY-101945
    A-69412

    Lipoxygenase Inflammation/Immunology
    A-69412 is a reversible, specific inhibitor of the 5-lipoxygenase (5-LO). A-69412 has the potential to treat asthma and ulcerative colitis, and possibly other inflammatory and allergic conditions.
  • HY-18990
    GSK180736A

    ROCK Cardiovascular Disease
    GSK180736A is potent Rho-associated coiled-coil kinase 1 (ROCK1) inhibitor with an IC50 of 100 nM. GSK180736A is also a selective and ATP-competitive G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM.
  • HY-100431
    IMR-1

    Notch Cancer
    IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with an IC50 of 26 μM. IMR-1 prevents the recruitment of Mastermind-like 1 (Maml1) to the Notch Ternary Complex (NTC) on chromatin, inhibits Notch target gene transcription and dramatically inhibits tumor growth.
  • HY-101930
    BMS-816336

    Others Metabolic Disease
    BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC50 of 3.0 nM.
  • HY-112707
    AM9405

    Cannabinoid Receptor 5-HT Receptor Neurological Disease
    AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC50s of 45.71 and 0.076 nM, respectively.
  • HY-12009
    Pazopanib Hydrochloride

    GW786034 (Hydrochloride)

    PDGFR VEGFR FGFR c-Kit c-Fms Autophagy Cancer
    Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-B0099S
    Edaravone D5

    MCI-186 D5

    MMP Apoptosis Neurological Disease
    Edaravone D5 is a deuterium labeled Edaravone. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
  • HY-122135
    A-317567

    Sodium Channel Neurological Disease
    A-317567 is a potent acid-sensing ion channel 3 (ASIC-3) inhibitor with an IC50 of 1.025 μM. A-317567 has antidepressant and antinociception effects.
  • HY-N2575
    Hypocrellin A

    PKC Bacterial Parasite Cancer Infection
    Hypocrellin A, a naturally occurring PKC inhibitor, has many biological and pharmacological properties, such as antitumour, antiviral, antibacterial, and antileishmanial activities. Hypocrellin A is a promising photosensitizer for anticancer photodynamic therapy (PDT).
  • HY-N1483
    Guanfu base A

    Potassium Channel Cardiovascular Disease
    Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes. Guanfu base A also inhibits HERG channel current.
  • HY-P0018
    Pepstatin

    Pepstatin A

    Proteasome HIV Protease Autophagy Infection Cancer
    Pepstatin (Pepstatin A) is a specific aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
  • HY-136532
    ZT-1a

    Others Neurological Disease
    ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. ZT-1a inhibits SPAK activity with IC50s of 44.3, 35.0, 46.7 μM at ATP concentrations of 0.01, 0.1 and 1 mM, respectively.
  • HY-P0018A
    Pepstatin Trifluoroacetate

    Pepstatin A Trifluoroacetate

    Proteasome HIV Protease Infection
    Pepstatin Trifluoroacetate (Pepstatin A Trifluoroacetate) is a specific aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
  • HY-16232
    GLUFOSFAMIDE

    D 19575; Glucosylifosfamide mustard

    Others Cancer
    Glufosfamide is a novel alkylating agent in which the active metabolite of isophosphoramide mustard is glycosidically linked to β-D-glucose.
  • HY-15430A
    Encenicline hydrochloride

    EVP-6124 hydrochloride

    nAChR Neurological Disease
    Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).
  • HY-15430
    Encenicline

    EVP-6124

    nAChR Neurological Disease
    Encenicline (EVP-6124) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).
  • HY-100882
    ONO-7300243

    LPL Receptor Cardiovascular Disease
    ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
  • HY-11013
    ZSET1446

    ST-101

    Calcium Channel nAChR Neurological Disease
    ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.
  • HY-N2318
    Podocarpic acid

    TRP Channel Neurological Disease
    Podocarpic acid is a natural product, which has the best all-round positive effect and acts as a novel TRPA1 activator.
  • HY-15257A
    Mavoglurant racemate

    AFQ-056 racemate

    mGluR Neurological Disease
    Mavoglurant racemate (AFQ-056 racemate) is the racemate of Mavoglurant. Mavoglurant is a novel, non-competitive mGlu5 receptor antagonist.
  • HY-P1687
    Siomycin A

    Bacterial Apoptosis Cancer
    Siomycin A is a thiopeptide antibiotic and is a Forkhead box M1(FOXM1) selective inhibitor without affecting other members of the Forkhead box family. Siomycin A has anti-tumor and promotes apoptosis.
  • HY-114305
    A1874

    PROTACs Epigenetic Reader Domain Cancer
    A1874 is a nutlin-based (MDM2 ligand) and BRD4-degrading PROTAC with a DC50 of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation.
  • HY-N2306A
    Aclacinomycin A hydrochloride

    Aclarubicin hydrochloride

    Proteasome Topoisomerase Cancer
    Aclacinomycin A hydrochloride (Aclarubicin hydrochloride), a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II. An effective anthracycline chemotherapeutic agent for hematologic cancers and solid tumors.
  • HY-121993
    Combretastatin A-1

    Microtubule/Tubulin Cancer
    Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects.
  • HY-111417
    GSK2973980A

    Acyltransferase Metabolic Disease
    GSK2973980A is a potent and selective Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 3 nM.
  • HY-111458
    GSK2643943A

    Deubiquitinase Cancer
    GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor, with an IC50 of 160 nM for USP20/Ub-Rho.
  • HY-100522
    FMK 9a

    Autophagy Cancer
    FMK 9a is an autophagin-1 inhibitor with IC50 values of 80 and 73 μM in FRET and LRA assay.
  • HY-107455
    A-485

    Epigenetic Reader Domain Histone Acetyltransferase Cancer
    A-485 is a potent and selective catalytic inhibitor of p300/CBP with IC50s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.
  • HY-N6744
    Chaetoglobosin A

    Apoptosis Cancer Infection
    Chaetoglobosin A, the active principle within the extract of Penicillium aquamarinium, is a member of the cytochalasan family. Chaetoglobosin A preferentially induces apoptosis. Chaetoglobosin A targets filamentous actin in CLL cells and thereby induces cell-cycle arrest and inhibits membrane ruffling and cell migration.
  • HY-101512
    A-395

    Histone Methyltransferase Cancer
    A-395 is an antagonist of polycomb repressive complex 2 (PRC2) protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC50 of 18 nM.
  • HY-N6936
    Sennidin A

    HCV Akt GLUT Infection
    Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation.
  • HY-12855A
    Lys05

    Lys01 trihydrochloride

    Autophagy Cancer
    Lys05 (Lys01 trihydrochloride) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
  • HY-15956A
    CPI-169

    CPI 169 R-enantiomer

    Histone Methyltransferase Cancer
    CPI-169 (CPI 169 R-enantiomer) is a novel and potent EZH2 inhibitor, with IC50s of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
  • HY-18009
    LFM-A13

    Btk Polo-like Kinase (PLK) JAK Cancer
    LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
  • HY-114038
    SB-747651A

    p38 MAPK Inflammation/Immunology
    SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research.
  • HY-110313
    SB-747651A dihydrochloride

    p38 MAPK Inflammation/Immunology
    SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research.
  • HY-101143
    PGMI-004A

    Phosphatase Cancer
    PGMI-004A is a potent phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 13.1 μM.
  • HY-N6073
    Soyasapogenol A

    Apoptosis Inflammation/Immunology
    Soyasapogenol A, a triterpene compound, isolated from the roots of Abrus cantoniensis. Soyasapogenol A directly prevents apoptosis of hepatocytes, and secondly, inhibits the elevation of plasma TNF-α, which consequently results in the prevention of liver damage in the Concanavalin A-induced hepatitis model.
  • HY-15144
    Trichostatin A

    TSA

    HDAC Cancer
    Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC.
  • HY-P1975
    Aureobasidin A

    Basifungin

    Fungal Infection Inflammation/Immunology
    Aureobasidin A (Basifungin), a cyclic depsipetide, is an antifungal antibiotic. Aureobasidin A (Basifungin) A is an inhibitor of the inositolphosphorylceramide synthase AUR1.
  • HY-117832
    Pyripyropene A

    Acyltransferase Infection Inflammation/Immunology Cardiovascular Disease
    Pyripyropene A is a potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.
  • HY-12468
    A-1210477

    Bcl-2 Family Apoptosis Cancer
    A-1210477 is a potent and selective inhibitor of MCL-1 with a Ki of 0.45 nM. A-1210477 specifically binds MCL-1 and promotes apoptosis of cancer cells in an MCL-1-dependent manner.
  • HY-131059
    CBS1117

    Influenza Virus Infection
    CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process.
  • HY-100226
    A-205804

    Integrin Inflammation/Immunology
    A-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC50 of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.
  • HY-N6795
    Leptomycin A

    CRM1 HIV Infection
    Leptomycin A, a Streptomyces metabolite, is an inhibitor of CRM1 (exportin 1) that blocks CRM1 interaction with nuclear export signals, preventing the nuclear export of a broad range of proteins. Leptomycin A suppresses HIV-1 replication. Less potent than Leptomycin B.
  • HY-100681
    GSK2837808A

    Lactate Dehydrogenase Cancer
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 1.9 and 14 nM for LDHA and LDHB, respectively.
  • HY-137563
    A2793

    Potassium Channel Neurological Disease
    A2793 is an efficient dual TWIK-related acid-sensitive K + channel (TASK)-1/TRESK inhibitor, with an IC50 of 6.8 μM for mTRESK. A2764 is more selective for TRESK, and it only moderately influences TREK-1 and TALK-1.
  • HY-12339
    NVS-CRF38

    CRFR Endocrinology
    NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.
  • HY-16993
    OICR-9429

    Histone Methyltransferase Cancer
    OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction with IC50 of 5 uM.
  • HY-10194A
    Sepantronium hydrochloride

    YM-155 hydrochloride

    Survivin Autophagy Cancer
    Sepantronium hydrochloride (YM-155 hydrochloride) is a novel survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.
  • HY-101950
    KIN1148

    Influenza Virus Infection
    KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.
  • HY-17013
    Dofequidar

    P-glycoprotein Cancer
    Dofequidar(MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR.
  • HY-16674
    10-Oxo Docetaxel

    Docetaxel Impurity 1

    Microtubule/Tubulin Cancer
    10-Oxo Docetaxel (Docetaxel Impurity 1) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.
  • HY-13640
    Rabacfosadine

    GS-9219; VDC-1101

    Others Cancer
    Rabacfosadine (GS-9219), a novel prodrug of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
  • HY-U00004
    OSIP-486823

    OSIP 486823; OSIP486823; CP248

    Microtubule/Tubulin Cancer
    OSIP-486823 is a novel microtubule-interfering agent with distinct biological effects on both protein kinase G (PKG) and microtubules.
  • HY-123955
    Casein Kinase inhibitor A86

    Casein Kinase CDK Apoptosis Cancer
    Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities.
  • HY-12583
    A-366

    Histone Methyltransferase Epigenetic Reader Domain Cancer
    A-366 is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC50=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (Ki=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families.
  • HY-10208
    Pazopanib

    GW786034

    VEGFR c-Kit PDGFR Autophagy FGFR Cancer
    Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-114395
    NVS-ZP7-4

    Others Inflammation/Immunology
    NVS-ZP7-4 is a Zinc transporter SLC39A7 (ZIP7) inhibitor that is also the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.
  • HY-N2112
    Glaucocalyxin A

    PI3K Akt Apoptosis Cancer
    Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect.
  • HY-128553
    Antineoplaston A10

    Ras Apoptosis Endogenous Metabolite Cancer
    Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
  • HY-107587
    A-286982

    Integrin Inflammation/Immunology
    A-286982 is a potent and allosteric LFA-1/ICAM-1 interaction inhibitor with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding and LFA-1-mediated cellular adhesion assay, respectively.
  • HY-N2638
    Ilexsaponin A

    Others Cardiovascular Disease
    Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes.
  • HY-N6687B
    Calcimycin hemimagnesium

    A-23187 hemimagnesium; Antibiotic A-23187 hemimagnesium

    Bacterial Fungal Apoptosis Autophagy Cancer Infection
    Calcimycin (A-23187) hemimagnesium is an antibiotic and a unique divalent cation ionophore (like calcium and magnesium). Calcimycin hemimagnesium induces Ca 2+-dependent cell death by increasing intracellular calcium concentration. Calcimycin hemimagnesium inhibits the growth of Gram-positive bacteria and some fungi. Calcimycin hemimagnesium also inhibits the activity of ATPase and uncouples oxidative phosphorylation (OXPHOS) of mammalian cells. Calcimycin hemimagnesium induces apoptosis.
  • HY-N6687A
    Calcimycin hemicalcium salt

    A-23187 hemicalcium salt; Antibiotic A-23187 hemicalcium salt

    Bacterial Fungal Apoptosis Autophagy Antibiotic Cancer Infection
    Calcimycin hemicalcium salt (A-23187 hemicalcium salt) is an antibiotic and a unique divalent cation ionophore (like calcium and magnesium). Calcimycin hemicalcium salt induces Ca 2+-dependent cell death by increasing intracellular calcium concentration. Calcimycin hemicalcium salt inhibits the growth of Gram-positive bacteria and some fungi. Calcimycin hemicalcium salt also inhibits the activity of ATPase and uncouples oxidative phosphorylation (OXPHOS) of mammalian cells. Calcimycin hemicalcium salt induces apoptosis.
  • HY-N7043
    Isosilybin A

    Apoptosis Cancer
    Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis.
  • HY-N2298
    Camellianin A

    Apoptosis Cancer
    Camellianin A, the main flavonoid in A. nitida leaves, displays anticancer activity and angiotensin converting enzyme (ACE)-inhibitory activity. Camellianin A inhibits the proliferation of the human Hep G2 and MCF-7 cell lines and induces the significant increase of the G0/G1 cell population.
  • HY-13746B
    Sardomozide dihydrochloride

    CGP 48664A

    Others Cancer
    Sardomozide dihydrochloride is an S-adenosylmethionine decarboxylase (SAMDC) inhibitor with an IC50 of 5 nM.
  • HY-18303
    AMG-47a

    Src VEGFR p38 MAPK JAK Inflammation/Immunology
    AMG-47a is a potent and orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, with an IC50 of 0.2 nM. AMG-47a also inhibits VEGF2, p38α, Jak3 and MLR and IL-2 with IC50s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively. AMG-47a has anti-inflammatory activity.
  • HY-100611
    CaCCinh-A01

    Chloride Channel Cancer Inflammation/Immunology
    CaCCinh-A01 is an inhibitor of both TMEM16A and calcium-activated chloride channel (CaCC) with IC50s of 2.1 and 10 μM, respectively.
  • HY-108706
    KDM2A/7A-IN-1

    Histone Demethylase Cancer
    KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC50 of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases.
  • HY-A0150
    Alclometasone

    7a-​Chloro-​16a-​methyl prednisolone

    Glucocorticoid Receptor Inflammation/Immunology
    Alclometasone (7a-Chloro-16a-methyl prednisolone) is a glucocorticoid and inhibits the release of pro-inflammatory mediators from leukocytes. Alclometasone can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis, eczema, psoriasis and allergic dermatitis.
  • HY-100228A
    SKF89976A hydrochloride

    d,l-SKF89976A hydrochloride

    GABA Receptor Neurological Disease
    SKF89976A hydrochloride is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHO cells, respectively.
  • HY-14347
    EBE-A22

    Others Cancer
    EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
  • HY-100118
    BW-A 78U

    Phosphodiesterase (PDE) Inflammation/Immunology
    BW-A 78U is a PDE4 inhibitor with an IC50 of 3 μM.
  • HY-108254
    Bisindolylmaleimide IV

    Arcyriarubin A

    PKC CMV Infection
    Bisindolylmaleimide IV (Arcyriarubin A) is a potent protein kinase C (PKC) inhibitor, with IC50s ranging from 0.1 to 0.55 μM. Bisindolylmaleimide IV also inhibits PKA (IC50=3.1-11.8μM). Bisindolylmaleimide IV is a potent, selective inhibitor of human cytomegalovirus (HCMV) replication in cell culture with an IC50 of 0.2 μM.
  • HY-16576A
    (Z)-SMI-4a

    Pim Cancer
    (Z)-SMI-4a is a poten, selective, cell-permeable and ATP-competitive Pim-1 inhibitor with an IC50 of 24 μM and a Ki of 0.6 µM. (Z)-SMI-4a also inhibits Pim-2 (IC50 of 100 μM), and does not significantly inhibit the other serine/threonine- or tyrosine-kinases. (Z)-SMI-4a has anticancer activity.
  • HY-15827
    NSC 405020

    MMP Cancer
    NSC 405020 is a novel small molecule inhibitor of MT1-MMP that specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2.
  • HY-N5025
    Bullatine A

    P2X Receptor Apoptosis Cancer Inflammation/Immunology
    Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed.
  • HY-14855A
    (S)-Tedizolid

    (S)-TR 700; (S)-DA 7157

    Bacterial Antibiotic Infection
    (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
  • HY-100160
    RP 54275

    2-Octadecyl-1H-indole-5-carboxylic acid

    Others Cardiovascular Disease
    RP 54275 (2-Octadecyl-1H-indole-5-carboxylic acid) is a novel hypocholesterolaemic drug.
  • HY-17522
    Meptyldinocap

    2,4-DNOPC

    Bacterial Infection
    Meptyldinocap (2,4-DNOPC) is a novel powdery mildew (Erysiphe necator) fungicide which shows protectant and post-infective activities.
  • HY-12279
    Umbralisib

    TGR-1202; RP5264

    PI3K Cancer
    Umbralisib (TGR-1202) is a novel PI3Kδ inhibitor, with IC50 and EC50 of 22.2 nM and 24.3 nM, respectively; Umbralisib (TGR-1202) is also active against CK1ε, with an EC50 value of 6.0 μM.
  • HY-19929
    Tanimilast

    CHF-6001

    Phosphodiesterase (PDE) Inflammation/Immunology
    Tanimilast (CHF-6001) is a novel highly potent and selective phosphodiesterase 4 inhibitor(IC50=0.026 ± 0.006 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration.Tanimilast is used for the research of obstructive lung diseases.
  • HY-15440B
    Fostemsavir Tris

    BMS-663068 Tris

    HIV Infection
    Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
  • HY-12279C
    Umbralisib hydrochloride

    TGR-1202 hydrochloride; RP5264 hydrochloride

    PI3K Cancer
    Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel PI3Kδ inhibitor, with IC50 and EC50 of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against CK1ε, with an EC50 value of 6.0 μM.
  • HY-114936
    Piericidin A

    AR-054

    Bacterial ADC Cytotoxin Antibiotic Mitochondrial Metabolism Cancer Infection Neurological Disease
    Piericidin A (AR-054) is a natural mitochondrial NADH-ubiquinone oxidoreductase (complex I) inhibitor. Piericidin A is a potent neurotoxin and inhibits mitochondrial respiration by disrupting the electron transport system through its action on NADH-ubiquinone reductase. Piericidin A is also a potential quorum-sensing inhibitor that suppresses the expression of the virulence genes of Erwinia carotovora subsp. atroseptica (Eca). Piericidin A is an ADC cytotoxin and has anti-bacterial, anticancer, insecticidal activity.
  • HY-15005C
    Sofosbuvir impurity A

    HCV Infection
    Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-78349
    A 77-01

    TGF-β Receptor Cancer
    A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM.
  • HY-106080A
    Furegrelate sodium

    U-63557A

    Others Cardiovascular Disease
    Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent.
  • HY-100528
    Nanchangmycin

    Nanchangmycin A

    Bacterial Antibiotic Infection
    Nanchangmycin, a polyether antibiotic produced by Streptomyces nanchangensis NS3226, inhibits gram-positive bacteria. Nanchangmycin is a broad spectrum antiviral active against Zika virus.
  • HY-123954
    Casein Kinase inhibitor A51

    Casein Kinase CDK Apoptosis Cancer
    Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities.
  • HY-15790
    Elobixibat

    A 3309; AZD 7806

    Others Metabolic Disease
    Elobixibat is a potent ileal bile acid transporter (IBAT) inhibitor with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT.
  • HY-114267
    Cbz-B3A

    mTOR Others
    Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).
  • HY-10442
    3-Deazaneplanocin A

    DZNep; 3-Deazaneplanocin

    Histone Methyltransferase Cancer
    3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor.
  • HY-16592
    Brefeldin A

    BFA; Cyanein; Decumbin

    Autophagy CRISPR/Cas9 Mitophagy HSV Antibiotic Cancer Infection
    Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus. Brefeldin A is also an autophagy and mitophagy inhibitor. Brefeldin A is a CRISPR/Cas9 activator. Brefeldin A inhibits HSV-1 and has anti-cancer activity.
  • HY-13237
    GSK2578215A

    LRRK2 Autophagy Mitophagy Neurological Disease
    GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC50s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.
  • HY-100183
    GSK2239633A

    CCR Inflammation/Immunology Endocrinology
    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [ 125I]-TARC to human CCR4 with a pIC50 of 7.96 ± 0.11.
  • HY-112726
    PXS-4728A

    Monoamine Oxidase Inflammation/Immunology
    PXS-4728A is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO). PXS-4728A ameliorates chronic obstructive pulmonary disease in mice.
  • HY-B0422
    Nateglinide

    A4166; Senaglinide

    Potassium Channel Dipeptidyl Peptidase Metabolic Disease
    Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K + channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.
  • HY-B1202A
    Alrestatin sodium

    AY-22284A

    Aldose Reductase Endocrinology
    Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
  • HY-13339
    Brofaromine

    CGP 11305A

    Monoamine Oxidase Neurological Disease
    Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC50 of 0.2 μM for MAO-A.
  • HY-B0093A
    Benazepril hydrochloride

    CGS14824A

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Benazepril hydrochloride, an angiotensin converting enzyme inhibitor, which is a medication used to treat high blood pressure.
  • HY-108516
    TC-E 5001

    PARP Cancer
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively.
  • HY-135642
    SMS1-IN-1

    Others Inflammation/Immunology
    SMS1-IN-1, compound SAPA 1j, is a novel and the most potent sphingomyelin synthase 1 (SMS1) inhibitor with an IC50 value of 2.1 μM. SMS1-IN-1 has the potential for the treatment of atherosclerosis.
  • HY-112416
    AZD4320

    Bcl-2 Family Cancer
    AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.
  • HY-110398
    5,6,7-Trimethoxyflavone

    Baicalein trimethyl ether

    p38 MAPK Inflammation/Immunology Cancer
    5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera.
  • HY-115555
    K-Ras-PDEδ-IN-1

    Phosphodiesterase (PDE) Cancer
    K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM.
  • HY-129589
    Thailanstatin A

    ADC Cytotoxin Cancer
    Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC50s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC.
  • HY-N7454
    Anhydroerythromycin A

    Infection
    Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
  • HY-138794
    XL177A

    Deubiquitinase Cancer
    XL177A is a highly potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. XL177A elicits cancer cell killing through a p53-dependent mechanism.
  • HY-112468
    PNU112455A hydrochloride

    CDK Cancer
    PNU112455A hydrochloride is an ATP-competitive CDK2 and CDK5 inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively.
  • HY-12521
    GSK-5498A

    CRAC Channel Inflammation/Immunology
    GSK-5498A is a selective small molecule blocker of CARC (IC50, 1 μM); inhibits mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety of species.
  • HY-111359
    GPR40 agonist 1

    GPR40 Metabolic Disease
    GPR40 agonist 1 is a potent and novel GPR40 full agonist with an EC50 of 2 nM and 17 nM for hGPR40 and rGPR40, respectively.
  • HY-109002
    Apararenone

    MT-3995

    Mineralocorticoid Receptor Metabolic Disease Cardiovascular Disease
    Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.
  • HY-18668
    Integrin Antagonists 27

    Integrin Cancer
    Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.
  • HY-16753
    Ridinilazole

    SMT19969

    Bacterial Infection
    Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25 µg/mL (MIC90=8 µg/mL) against C. difficile.
  • HY-N6601
    Pomolic acid

    Randialic acid A

    Apoptosis Cancer
    Randialic acid A (Pomolic acid) is a pentacyclic triterpene isolated from Euscaphis japonica (Tunb.). Randialic acid A (Pomolic acid) inhibits tumor cells growth and induces cell apoptosis. Randialic acid A (Pomolic acid) has a potential for the treatment of prostate cancer (PC).
  • HY-N2959
    Brevilin A

    JAK STAT Apoptosis Autophagy Cancer
    Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of JAK-STAT signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC50 = 10.6 µM) in Cancer Cells. Brevilin A induces apoptosis and autophagy via mitochondrial pathway and PI3K/AKT/mTOR inactivation in colon adenocarcinoma cell CT26.
  • HY-N0931
    Santacruzamate A

    CAY-10683

    HDAC Cancer
    Santacruzamate A (CAY-10683) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM.
  • HY-13036A
    IBT6A

    Btk Cancer
    IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
  • HY-19794
    MP-A08

    SphK Cancer
    MP-A08 is a highly selective ATP competitive sphingosine kinase (SPHK1) inhibitor that targets both SphK1 and SphK2 with Ki values of 6.9 ± 0.8 μM and 27 ± 3 μM, respectively.
  • HY-13036B
    IBT6A hydrochloride

    Btk Cancer
    IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
  • HY-N0619
    Mulberroside A

    TNF Receptor Interleukin Related Tyrosinase Inflammation/Immunology
    Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC50 of 53.6 μM.
  • HY-18299
    Purvalanol B

    NG 95

    CDK Parasite Cancer Infection
    Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC50s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC50>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum.
  • HY-16576
    TCS-PIM-1-4a

    SMI-4a

    Pim Apoptosis Cancer
    TCS-PIM-1-4a (SMI-4a) is a pan-Pim kinases inhibitor that blocks mTORC1 activity via activation of AMPK. TCS-PIM-1-4a kills a wide range of both myeloid and lymphoid cell lines (IC50 values ranging from 0.8 μM to 40 μM).
  • HY-104064
    1A-116

    Ras Cancer
    1A-116 is a Rac1 inhibitor, with antitumoral and antimetastatic effects in several types of cancer, such as breast cancer. 1A-116 prevents Rac1-regulated processes involved in the primary tumorigenesis and metastastic processes [1] .
  • HY-B0597
    Fondaparinux sodium

    Fondaparin sodium; SR-90107A

    Factor Xa Cardiovascular Disease
    Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
  • HY-17474A
    Parecoxib Sodium

    SC 69124A

    COX Inflammation/Immunology Cancer
    Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
  • HY-17647
    Zoliflodacin

    ETX0914; AZD0914

    DNA/RNA Synthesis Bacterial Infection
    Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC90 of 0.25 μg/mL.
  • HY-136063
    Mefentrifluconazole

    Fungal Cytochrome P450 Infection
    Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM).
  • HY-18299A
    Purvalanol A

    NG-60

    CDK Autophagy Apoptosis Cancer
    Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
  • HY-14595
    Biochanin A

    4-Methylgenistein; Olmelin

    FAAH Autophagy Neurological Disease Cancer
    Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
  • HY-124129
    10074-A4

    c-Myc Cancer
    10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects.
  • HY-120994B
    Sp-8-CPT-cAMPS

    PKA Inflammation/Immunology Neurological Disease
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold.
  • HY-120994A
    Rp-8-CPT-cAMPS

    PKA Inflammation/Immunology Neurological Disease
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
  • HY-N0035
    Arctigenin

    (-)-Arctigenin

    MMP Influenza Virus Autophagy Apoptosis Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
  • HY-118135
    4-Methylumbelliferyl-α-D-galactopyranoside

    4MU-α-Gal

    Others Others
    4-Methylumbelliferyl-α-D-galactopyranoside (4MU-α-Gal), a substrate for α-galactosidase A (GLA), is a blue pro-fluorogenic substrate. 4-Methylumbelliferyl-α-D-galactopyranoside forms two products, galactose and fluorescent 4MU, upon cleavage by GLA.
  • HY-120994
    Rp-8-CPT-cAMPS sodium

    PKA Inflammation/Immunology Neurological Disease
    Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
  • HY-16312
    MDL-29951

    iGluR Neurological Disease
    MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [ 3H]glycine binding in vitro and in vivo.
  • HY-N1476
    Heterophyllin B

    PI3K Cancer
    Heterophyllin B is an active cyclic peptide isolated from Pseudostellaria heterophylla. Heterophyllin B provides a novel strategy for the treatment of esophageal cancer.
  • HY-15748
    JNJ-40411813

    ADX-71149

    mGluR Neurological Disease
    JNJ-40411813 (ADX-71149) is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.
  • HY-111556
    BSJ-03-123

    PROTACs CDK Cancer
    BSJ-03-123 is a PROTAC connected by ligands for Cereblon and CDK as a potent and novel CDK6-selective small-molecule degrader.
  • HY-14342
    MK-5046

    Bombesin Receptor Others
    MK-5046 is a novel BRS-3 agonist, binds to BRS-3 with high affinity (mouse Ki = 1.6 nM, human Ki = 25 nM).
  • HY-12366
    Ubrogepant

    MK-1602

    CGRP Receptor Neurological Disease Cardiovascular Disease
    Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine.
  • HY-14792
    Inolitazone

    Efatutazone; CS-7017; RS5444

    PPAR Cancer
    Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
  • HY-N0913
    Manninotriose

    Others Others
    Manninotriose is a novel and important player in the RFO(Raffinose family oligosaccharides) metabolism of red dead deadnettle; potential to improve the side effects of MTX for ALL treatment.
  • HY-N0892
    AKBA

    Acetyl-11-keto-β-boswellic acid

    HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Endogenous Metabolite Cancer
    AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.
  • HY-135809
    A2764 dihydrochloride

    Potassium Channel Neurological Disease
    A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K + channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC50=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception.
  • HY-12530
    Velpatasvir

    GS-5816

    HCV SARS-CoV Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM.
  • HY-117233
    UU-T02

    β-catenin Wnt Cancer Metabolic Disease
    UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM. UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells.
  • HY-134673A
    UZH1a

    Apoptosis Cancer
    UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1a can be used for epitranscriptomic modulation of cellular processes. UZH1a has antitumor activity. UZH1a also can be used as a chemical probe for studying METTL3.
  • HY-N7613
    6''-O-Acetylsaikosaponin A

    Others Others
    6''-O-Acetylsaikosaponin A, an acetyl saikosaponin isolated from the roots of Bupleurum chinense, shows some osteoclast-inhibiting activities.
  • HY-10432A
    A 83-01 sodium salt

    TGF-β Receptor ALK Cancer
    A 83-01 sodium salt is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-P1184
    HNGF6A

    Reactive Oxygen Species Metabolic Disease Neurological Disease Cardiovascular Disease
    HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.
  • HY-109120
    Odevixibat

    A4250

    Others Metabolic Disease
    Odevixibat (A4250) is a potent, selective and orally active inhibitor of the ileal bile acid transporter (IBAT). Odevixibat (A4250)decreases cholestatic liver and bile duct injury in mice model. Odevixibat (A4250) has the potential for the treatment of primary biliary cirrhosis.
  • HY-100540
    Golgicide A

    GCA

    Enterovirus Cancer Infection
    Golgicide A (GCA) is a potent, highly specific, and reversible inhibitor of the cis-Golgi ADP-ribosylation factor guanine nucleotide exchange factors (ArfGEF) GBF1. Golgicide A drastically reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus species.
  • HY-100790
    Ciliobrevin A

    HPI-4

    Hedgehog Cancer
    Ciliobrevin A (HPI-4) is a hedgehog (Hh) signaling pathway inhibitor with median inhibitory concentration (IC50) less than 10 μM.
  • HY-109592
    Imidaprilate

    6366A; Imidaprilat

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease.
  • HY-14929A
    Migalastat hydrochloride

    GR181413A

    Others Others
    Migalastat hydrochloride (GR181413A) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.
  • HY-131182
    DS-1971a

    Sodium Channel Neurological Disease
    DS-1971a is a potent, selective, and orally active NaV1.7 inhibitor, with IC50s of 22.8 and 59.4 nM for hNaV1.7 and mNaV1.7, respectively. DS-1971a exerts analgesic effects.
  • HY-100431A
    IMR-1A

    Notch Drug Metabolite Cancer
    IMR-1A, a acid metabolite of IMR-1, is a Notch inhibitor with an IC50 of 0.5 μM. IMR-1A has a 50-fold increase in potency with respect to IMR-1. IMR-1 can metabolize in vivo to IMR-1A.
  • HY-B0220E
    Erythromycin A dihydrate

    Bacterial Antibiotic Infection
    Erythromycin dihyrate dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin dihyrate acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid.
  • HY-109785A
    (R)-Gyramide A hydrochloride

    Infection
    (R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that disrupts supercoiling activity with an IC50 value of 3.3 µM. (R)-Gyramide A hydrochloride demonstrates antibacterial activity against E. coli, P. aeruginosa, and S. enterica (MICs of 10-80 µM). (R)-Gyramide A hydrochloride does not affect the closely related enzyme topoisomerase IV.
  • HY-128553A
    (Rac)-Antineoplaston A10

    Ras Apoptosis Cancer
    (rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
  • HY-14792B
    Inolitazone dihydrochloride

    Efatutazone dihydrochloride; CS-7017 dihydrochloride; RS5444 dihydrochloride

    PPAR Cancer
    Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
  • HY-17460A
    Garenoxacin Mesylate hydrate

    BMS284756 Mesylate hydrate

    Bacterial Infection
    Garenoxacin Mesylate hydrate (BMS284756 Mesylate hydrate) is a novel oral des-fluoro(6) quinolone with potent antimicrobial activity, against common respiratory pathogens, including resistant strains.
  • HY-U00151
    Dopropidil

    Calcium Channel Cardiovascular Disease
    Dopropidil is a novel anti-anginal calcium ion modulating agent, possessing intracellular calcium antagonist activity and anti-ischemic effects in several predictive animal models.
  • HY-16704
    ESI-09

    Virus Protease Cancer
    ESI-09 is a novel noncyclic nucleotide EPAC antagonist with IC50 values of 3.2 and 1.4 μM for EPAC1 and EPAC2, respectively.
  • HY-106101
    Echinomycin

    Quinomycin A; NSC-13502

    HIF/HIF Prolyl-Hydroxylase Antibiotic Cancer
    Echinomycin (Quinomycin A) is potent small-molecule and cell-permeable inhibitor of hypoxia-inducible factor-1 (HIF-1) DNA-binding activity. Echinomycin selectively inhibits the cancer stem cells (CSCs) with an IC50 of 29.4 pM.
  • HY-10432
    A 83-01

    ALK TGF-β Receptor Cancer
    A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-130242
    PXS-5120A

    Monoamine Oxidase Inflammation/Immunology
    PXS-5120A is a potent, irreversible fluoroallylamine inhibitor of Lysyl Oxidase-like 2/3 (LOXL2/3) with anti-fibrotic activity. PXS-5120A is >300-fold selective for LOXL2 (Ki of 83 nM; pIC50 of 8.4) over LOXL (pIC50 of 5.8).
  • HY-16677A
    Mofegiline hydrochloride

    MDL72974A

    Monoamine Oxidase Neurological Disease
    Mofegiline hydrochloride (MDL72974A) is a potent and selective enzyme-activated irreversible inhibitor of MAO-B; shows marked selectivity for the B form (IC50 = 680 and 3.6 nM for MAO-A and MAO-B).
  • HY-N0134
    Tanshinone I

    Tanshinone A

    Phospholipase Cardiovascular Disease Cancer
    Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM).
  • HY-N7715
    Ferulic acid acyl-β-D-glucoside

    Ferulic acid glucoside

    Drug Metabolite Others
    Ferulic acid acyl-β-D-glucoside is a metabolite of Ferulic Acid (HY-N0060). Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
  • HY-12949A
    ML204 hydrochloride

    TRP Channel Neurological Disease
    ML204 hydrochloride is a novel, potent, selective TRPC4/TRPC5 channel inhibitor, with at least 19-fold selectivity against TRPC6 and no appreciable effect on all other TRP channels, nor on voltage-gated sodium, potassium, or Ca 2+ channels.
  • HY-111388A
    SEL120-34A monohydrochloride

    CDK Cancer
    SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726. Has anti-tumor activity.
  • HY-B0958
    Mupirocin

    BRL-4910A; Pseudomonic acid

    Bacterial Antibiotic Infection
    Mupirocin (BRL-4910A) is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin (BRL-4910A) apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.
  • HY-N2278
    Kushenol A

    Leachianone E

    Tyrosinase Glucosidase Cancer
    Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively. Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase. Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging.
  • HY-10029
    Nutlin-3a

    Rebemadlin

    MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis Cancer
    Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas.
  • HY-111174
    Diprotin A

    Ile-Pro-Ile

    Dipeptidyl Peptidase Metabolic Disease
    Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).
  • HY-103000
    HSF1A

    HSP Cancer Cardiovascular Disease
    HSF1A is a cell-permeable activator of heat shock transcription factor 1 (HSF1). HSF1A also acts as a specific inhibitor of TRiC/CCT. Chaperonin TCP-1 ring complex (TRiC)/chaperonin containing TCP-1 (CCT) plays a pivotal role in toxin translocation and/or refolding.
  • HY-N6704
    Enniatin A1

    ERK Apoptosis Cancer
    Enniatin A1 isolated from Fusarium mycotoxins is a cyclic hexadepsipeptide consisting of alternating D-α-hydroxyisovaleric acids and N-methyl-L-amino acids. Enniatin A1 possesses anticarcinogenic properties by induction of apoptosis and disruption of ERK signalling pathway. Enniatin A1 inhibits ACAT with an IC50 of 49 μM in rat liver microsomes.
  • HY-12843
    Bohemine

    CDK ERK Cancer
    Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities.
  • HY-P0018B
    Pepstatin Ammonium

    Pepstatin A Ammonium

    Proteasome HIV Protease Cancer Infection
    Pepstatin Ammonium is a specific aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
  • HY-114286
    PXS-5153A

    Monoamine Oxidase Inflammation/Immunology
    PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC50 of <40 nM for LOXL2 across all mammalian species and an IC50 of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis.
  • HY-117833
    PXS-4681A

    Monoamine Oxidase Inflammation/Immunology
    PXS-4681A is a potent, selective, irreversible and orally active semicarbazide-sensitive amine oxidase (SSAO; VAP-1) inhibitor with a Ki of 37 nM. PXS-4681A shows highly selectivity over related amine oxidases, ion channels, and seven-transmembrane domain receptors. PXS-4681A has anti-inflammatory effects.
  • HY-112569
    MAT2A inhibitor 2

    Others Cancer
    MAT2A inhibitor 2 is a methionine adenosyltransferase 2A (MAT2A) inhibitor.
  • HY-103128
    inS3-54A18

    STAT Cancer
    inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties.
  • HY-100612
    T16Ainh-A01

    Chloride Channel Others
    T16Ainh-A01, an aminophenylthiazole, is a potent transmembrane protein 16A (TMEM16A) inhibitor, inhibiting TMEM16A-mediated chloride currents with an IC50 value of ~1 µM. TMEM16A (ANO1) functions as a calcium-activated chloride channel (CaCC).
  • HY-14137
    Rimonabant Hydrochloride

    SR 141716A Hydrochloride

    Cannabinoid Receptor Bacterial Cancer Infection Metabolic Disease
    Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
  • HY-U00387
    CCK-A receptor inhibitor 1

    Cholecystokinin Receptor Metabolic Disease Endocrinology
    CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) receptor inhibitor with a binging IC50 of 340 nM.
  • HY-10794
    MF498

    Prostaglandin Receptor Metabolic Disease Endocrinology
    MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, displayed strong binding affinity for the EP4 receptor with Ki of 0.7 nM.
  • HY-19371
    Lorediplon

    GABA Receptor Neurological Disease
    Lorediplon is a novel non-benzodiazepine, hypnotic drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit, associated with promoting sleep.
  • HY-12343
    ML277

    CID-53347902

    Potassium Channel Cardiovascular Disease
    ML277(CID53347902) is a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator with EC50 of 270 nM.
  • HY-15985
    CTX-0294885

    Others Others
    CTX-0294885 is a a novel bisanilino pyrimidine; exhibits inhibitory activity against a broad range of kinases in vitro, and further developed it into a Sepharose-supported kinase capture reagent.
  • HY-U00072
    RS-601

    Leukotriene Receptor Prostaglandin Receptor Inflammation/Immunology Endocrinology
    RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.
  • HY-P3278
    Caloxin 2A1

    Proton Pump Metabolic Disease
    Caloxin 2A1 is an extracellular plasma membrane Ca 2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg 2+-ATPase or Na +-K +-ATPase.
  • HY-N8395
    Tunicamycin V

    Tunicamycin A

    Bacterial Infection
    Tunicamycin V (Tunicamycin A) is a nucleoside natural product that inhibits bacterial phospho-N-acetylmuramyl-pentapeptide transferase (MraY) with an IC50 of 0.35 μM. Tunicamycin V has antibacterial activties.
  • HY-19921
    JTK-853

    HCV Infection
    JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.
  • HY-139536
    MAT2A inhibitor 4

    Others Cancer
    MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2 (MAT2A). MAT2A inhibitor 4 can be used for the research of cancer.
  • HY-W011518
    2′-Deoxy-2′-fluoroguanosine

    Influenza Virus Infection
    2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation.
  • HY-131179
    Influenza A virus-IN-1

    Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA.
  • HY-50877
    GSK461364

    GSK461364A

    Polo-like Kinase (PLK) Cancer
    GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM.
  • HY-10524
    GSK1904529A

    IGF-1R Insulin Receptor Apoptosis Cancer Endocrinology
    GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity.
  • HY-10985
    Marizomib

    Salinosporamide A; NPI-0052

    Proteasome Cancer
    Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC50=3.5, 28, and 430 nM, respectively).
  • HY-N7394A
    (-)-Zuonin A

    D-Epigalbacin

    JNK Cancer
    (-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively.
  • HY-122909
    GSK2593074A

    GSK'074

    RIP kinase Inflammation/Immunology
    GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3.
  • HY-13470
    GSK126

    GSK2816126A

    Histone Methyltransferase Cancer
    GSK126 (GSK2816126A) is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC50 of 9.9 nM.
  • HY-139296
    PP2A Cancerous-IN-1

    Akt Cancer
    PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities.
  • HY-N7119
    Cimicifugoside

    Others Inflammation/Immunology
    Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function.
  • HY-14880A
    Bavisant dihydrochloride

    Histamine Receptor Neurological Disease Endocrinology
    Bavisant Hcl (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.
  • HY-15708
    LY2795050

    Opioid Receptor Neurological Disease
    LY2795050 is a novel selective κ-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo.
  • HY-15228
    RX-3117

    TV-1360; fluorocyclopentenylcytosine

    Nucleoside Antimetabolite/Analog Cancer
    RX-3117(TV-1360; Fluorocyclopentenylcytosine) is novel a cytidine analog; shows anticancer activity in several cancer cell lines, including gemcitabine-resistant variants.
  • HY-14880B
    Bavisant dihydrochloride hydrate

    JNJ31001074AAC

    Histamine Receptor Neurological Disease Endocrinology
    Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.
  • HY-N7067
    Revaprazan hydrochloride

    Bacterial COX Infection
    Revaprazan hydrochloride is a novel acid pump antagonist (APA). Revaprazan hydrochloride reduces COX-2 expression and has significant anti-inflammatory actions activities in H. pylori infection.
  • HY-14880
    Bavisant

    JNJ-31001074

    Histamine Receptor Neurological Disease Endocrinology
    Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.
  • HY-12195
    ABT-239

    Histamine Receptor TRP Channel Neurological Disease Endocrinology
    ABT-239 is a novel, highly efficacious, non-imidazole class of H3R antagonist and a transient receptor potential vanilloid type 1 (TRPV1) antagonist. 
  • HY-N8041
    Mogroside III A2

    HSV Infection
    Mogroside III A2 is a cucurbitane glycoside. Mogroside III A2 can inhibit Epstein-Barr virus early antigen (EBV-EA) activation. Mogroside III A2 shows weak inhibitory effects on activation of NOR 1.
  • HY-112205A
    RR-11a analog

    Parasite Infection
    RR-11a analog is a potent and selective inhibitors of asparaginyl endopeptidases (AE) (Legumain), with IC50 values of 4.5 nM, 4.5 nM and 31 nM for AE1 in Trichomonas Vaginalis, AE in Ixodes ricinus and AE in Schistosoma mansoni, respectively.
  • HY-110106
    I-BET151 dihydrochloride

    GSK1210151A dihydrochloride

    Epigenetic Reader Domain Cancer
    I-BET151 dihydrochloride (GSK1210151A dihydrochloride) is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively.
  • HY-13235
    I-BET151

    GSK1210151A

    Epigenetic Reader Domain Cancer
    I-BET151 (GSK1210151A) is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively.
  • HY-139139
    MAT2A inhibitor 3

    Others Cancer
    MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC50 of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers.
  • HY-W002585
    O6-Benzylguanine

    DNA/RNA Synthesis Apoptosis Cancer
    O6-Benzylguanine, a guanine analog, is the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (MGMT/AGT) inhibitor. O6-Benzylguanine acts as an AGT substrate, which transfers its benzyl group to the AGT cysteine residue, thereby irreversibly inactivating AGT and preventing DNA repair. O6-Benzylguanine induces tumor cell apoptosis. Antineoplastic activity.
  • HY-N0853
    Alisol A

    Alisol-A

    Autophagy Others
    Alisol A is a natural product.
  • HY-13954
    A 839977

    P2X Receptor Neurological Disease Inflammation/Immunology
    A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta.
  • HY-N3557
    Cauloside A

    Leontoside A

    Fungal Infection
    Cauloside A (Leontoside A) is a saponin isolated from Dipsacus asper roots. Cauloside A has potent antifungal activity.
  • HY-N2252
    Licarin A

    (+)-Licarin A

    TNF Receptor Prostaglandin Receptor COX Metabolic Disease Inflammation/Immunology Neurological Disease
    Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC50=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression.
  • HY-N0372
    Licochalcone A

    Licochalcone-A

    Autophagy Cancer
    Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs). Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .
  • HY-N0873
    Sagittatoside A

    Icariin-A

    Others Others
    Sagittatoside A is a natural compound isolated from traditional Chinese herb Yinyanghuo (Herba Epimdii).
  • HY-P0216
    A 779

    Angiotensin Receptor Cardiovascular Disease Endocrinology
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.
  • HY-15488
    A 438079

    P2X Receptor Neurological Disease
    A 438079 is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
  • HY-N1924
    Crassicauline A

    Crassicaulin A

    Others Neurological Disease
    Crassicauline A (Crassicaulin A) is a bioactive alkaloid found in roots of Aconitum carmichaeli. Crassicauline A (Crassicaulin A) possesses feeding deterrent activity against T. castaneum adults with an EC50 of 1134.5 ppm.
  • HY-107633
    A 1120

    Others Metabolic Disease
    A 1120 is a high-affinity nonretinoid retinol-binding protein 4 (RBP4) antagonist with a Ki value of 8.3 nM. A 1120 disrupts the interaction between RBP4 and its binding partner transthyretin.
  • HY-15488A
    A 438079 hydrochloride

    P2X Receptor Neurological Disease
    A 438079 (hydrochloride) is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
  • HY-78727
    Ibrutinib deacryloylpiperidine

    IBT4A

    Btk Cancer
    Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
  • HY-111388
    SEL120-34A

    CDK Cancer
    SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-111388B
    SEL120-34A HCl

    CDK Cancer
    SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
  • HY-18963
    Lavendustin A

    RG-14355

    EGFR Cancer
    Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of tyrosine kinase, with an IC50 of 11 ng/mL for EGFR-associated tyrosine kinase. It suppresses VEGF-induced angiogenesis and blocks the induction of LTPGABA-A.
  • HY-112131
    MAT2A inhibitor 1

    Others Cancer
    MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (MATA2) inhibitor with an IC50 less than l00 nM.
  • HY-13646A
    Encequidar mesylate

    HM30181 mesylate; HM30181A mesylate

    P-glycoprotein Cancer
    Encequidar mesylate (HM30181 mesylate; HM30181A mesylate) is a competitive and potent P-glycoprotein inhibitor.
  • HY-13646
    Encequidar

    HM30181; HM30181A

    P-glycoprotein Metabolic Disease
    Encequidar (HM30181; HM30181A) is a potent and selective inhibitor of P-glycoprotein.
  • HY-13863
    Hydroxy-Dynasore

    Dyngo-4a

    Dynamin Neurological Disease
    Hydroxy Dynasore (Dyngo-4a), a structural analog of Dynasore (HY-15304), is an potency improved, low cytotoxicity and non‐specific binding dynamin inhibitor with IC50 values of 0.38 μM and 2.3 μM for brain dynamin I and recombinant rat dynamin II, respectively. Hydroxy Dynasore inhibits dynamin‐dependent endocytosis of transferrin with an IC50 of 5.7 μM in vitro.
  • HY-13036C
    (Rac)-IBT6A hydrochloride

    Btk Cancer
    (Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
  • HY-13036
    (Rac)-IBT6A

    Btk Cancer
    (Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
  • HY-141716
    SW2_110A

    Histone Methyltransferase Cancer
    SW2_110A is a selective chromobox 8 chromodomain (CBX8 ChD) inhibitor with a Kd of 800 nM. SW2_110A shows minimal 5-fold selectivity for CBX8 ChD over all other CBX paralogs in vitro.
  • HY-125033
    EIDD-1931

    β-D-N4-hydroxycytidine; NHC

    SARS-CoV Enterovirus HCV Topoisomerase Infection
    EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent anti-virus agent. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV).
  • HY-10294
    Relacatib

    SB-462795

    Cathepsin Cancer Metabolic Disease
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo.
  • HY-14399
    Itanapraced

    CHF5074; CSP-1103

    γ-secretase Neurological Disease
    Itanapraced (CHF5074) is a novel γ-secretase modulator, reduces Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM, respectively.
  • HY-A0002
    Solifenacin Succinate

    YM905

    mAChR Neurological Disease
    Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
  • HY-19705B
    Adriforant hydrochloride

    PF-3893787 hydrochloride

    Histamine Receptor Inflammation/Immunology Endocrinology
    Adriforant hydrochloride (PF-3893787 hydrochloride) is a novel histamine H4 receptor antagonist binding affinity (Ki=2.4 nM) and is also a functional (Ki=1.56 nM) antagonist.
  • HY-15606
    Tanaproget

    NSP-989

    Progesterone Receptor Endocrinology
    Tanaproget (NSP-989) is a novel nonsteroidal progesterone receptor agonist which can bind to the PR from various species with a higher relative affinity than reference steroidal progestins.
  • HY-107018
    AR-A 2

    AR-A 000002

    5-HT Receptor Neurological Disease
    AR-A 2 is a selective 5-HT1B receptor antagonist, with high affinity to guinea pig cortex 5HT1B/1D and recombinant guinea pig 5-HT1B receptors (Ki=0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig 5-HT1D receptor (Ki, 5 nM), and shows an EC50 of 4.5 nM for the guinea pig 5-HT1B receptor; AR-A 2 can be used in the research of depression and anxiety.
  • HY-108542
    Tautomycetin

    Phosphatase Inflammation/Immunology
    Tautomycetin is a potent and specifical PP1 inhibitor with the potential apoptosis-inducing activity. Tautomycetin inhibits purified PP1 and PP2A enzymes with IC50s of 1.6 nM and 62 nM, respectively. Tautomycetin is an antifungal antibiotic and has immunosuppressive effects in vivo. Tautomycetin can be used as a novel powerful tool to elucidate the physiological roles of PP1 in various biological events.
  • HY-B0381B
    Levobetaxolol hydrochloride

    (S)-Betaxolol hydrochloride; AL-1577A

    Adrenergic Receptor Neurological Disease Endocrinology
    Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.
  • HY-129180
    XY028-133

    PROTACs CDK Cancer
    XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK.
  • HY-15881
    TCS JNK 5a

    JNK Inhibitor IX

    JNK Apoptosis Cancer
    TCS JNK 5a is a potent JNK3 inhibitor with a pIC50 of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC50 of 6.5.
  • HY-70044
    GSK-1070916

    GSK-1070916A

    Aurora Kinase Apoptosis Cancer
    GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
  • HY-15891A
    GW311616 hydrochloride

    GW311616A

    Elastase Inflammation/Immunology
    GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM.
  • HY-100540C
    Golgicide A-1

    GCA-1

    Others Infection
    Golgicide A-1 (GCA-1) is a less active cis-diastereomer of Golgicide A (GCA). Golgicide A-1 weakly inhibits mosquito reproduction.
  • HY-19828
    Herboxidiene

    GEX1A

    DNA/RNA Synthesis Cancer
    Herboxidiene (GEX1A) is a potent phytotoxic polyketide from Streptomyces sp. A7847 with a diverse range of activities, including herbicidal, anti-cholesterol, anti-tumor effects. Herboxidiene inhibits the pre-mRNA splicing process by binding to spliceosome-associated protein (SAP) 155, a subunit of SF3b, in the splicesome.
  • HY-P1184A
    HNGF6A TFA

    Reactive Oxygen Species Metabolic Disease Neurological Disease Cardiovascular Disease
    HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
  • HY-113509
    Lipoxin A4

    LXA4

    Interleukin Related Inflammation/Immunology
    Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM.
  • HY-12143
    Vofopitant dihydrochloride

    GR 205171A

    Neurokinin Receptor Cancer Neurological Disease Endocrinology
    Vofopitant dihydrochloride (GR 205171A) is a potent, selective and orally available tachykinin neurokinin 1(NK1) receptor antagonist, inhibits [ 3H]SP binding to the NK1 receptor with pKi values of 9.5 and 10.6 in rat and human membranes respectively, acts as a potential broad-spectrum anti-emetic agent.
  • HY-N6732
    K-252a

    SF2370; Antibiotic K 252a; Antibiotic SF 2370

    PKC PKA CaMK Trk Receptor Autophagy Antibiotic Infection Inflammation/Immunology
    K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca 2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively. K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene.
  • HY-12993
    RSV604

    A-60444

    RSV Infection
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM).
  • HY-A0034
    Solifenacin

    YM905 free base

    mAChR Neurological Disease
    Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
  • HY-139206
    IL-17A inhibitor 1

    Interleukin Related Inflammation/Immunology
    IL-17A inhibitor 1 (example 24) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells.
  • HY-117391
    AZ-Dyrk1B-33

    DYRK Cancer Metabolic Disease
    AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC50 of 7 nM.
  • HY-114286A
    PXS-5153A monohydrochloride

    Monoamine Oxidase Inflammation/Immunology
    PXS-5153A monohydrochloride is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC50 of <40 nM for LOXL2 across all mammalian species and an IC50 of 63 nM for human LOXL3. PXS-5153A monohydrochloride could reduce crosslinks and ameliorates fibrosis.
  • HY-15403
    Atrasentan

    ABT-627; (+)-A 127722; A-147627

    Endothelin Receptor Cancer Endocrinology Cardiovascular Disease
    Atrasentan (ABT-627) is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA.
  • HY-15403A
    Atrasentan hydrochloride

    ABT-627 hydrochloride; (+)-A 127722 hydrochloride; A-147627 hydrochloride

    Endothelin Receptor Cancer Endocrinology Cardiovascular Disease
    Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC50 of 0.0551 nM for ETA.
  • HY-12445
    CDKI-73

    LS-007

    CDK Apoptosis Cancer Inflammation/Immunology
    CDKI-73 (LS-007) is an orally active and highly efficacious CDK9 inhibitor, with Ki values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. CDKI-73 down-regulates the RNAPII phosphorylation. CDKI-73 is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion.
  • HY-P3278A
    Caloxin 2A1 TFA

    Proton Pump Metabolic Disease
    Caloxin 2A1 TFA is an extracellular plasma membrane Ca 2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg 2+-ATPase or Na +-K +-ATPase.
  • HY-P3204
    POT-4

    AL-78898A

    Complement System Metabolic Disease
    POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
  • HY-125741
    GW768505A free base

    VEGFR Cancer
    GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2, with a pIC50 of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity。
  • HY-B0492A
    Paroxetine hydrochloride hemihydrate

    BRL29060 hydrochloride hemihydrate; BRL29060A hemihydrate

    Serotonin Transporter Autophagy Neurological Disease
    Paroxetine hydrochloride hemihydrate is a potent selective serotonin-reuptake inhibitor, commonly prescribed as an antidepressant and has GRK2 inhibitory ability with IC50 of 14 μM.
  • HY-17448
    Varespladib methyl

    A-002; LY333013

    Phospholipase Inflammation/Immunology
    Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (PLA2).
  • HY-N0204
    Pulchinenoside A

    Anemoside A3

    Others Others
    Pulchinenoside A is a natural triterpenoid saponin that enhances synaptic plasticity in the adult mouse hippocampus and facilitates spatial memory in adult mice.
  • HY-N0476
    Wilforlide A

    Regelide; Abruslactone A

    Others Inflammation/Immunology
    Wilforlide A is a bioactive triterpene isolated from Tripterygium wilfordii Hook f. Wilforlide A has anti-inflammatory and immune suppressive effects.
  • HY-N0123
    Aloin

    Aloin-A; Barbaloin-A

    Others Cancer
    Aloin(Aloin-A; Barbaloin-A) is a natural antitumor anthraquinone glycoside with iron chelating and non-atherogenic activities.
  • HY-N2995
    Poricoic acid A

    Poricoic acid A(F)

    Others Cancer
    Poricoic acid A, isolated from Poria cocos, possesses anti-tumor activity. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis.
  • HY-104051
    Monacolin J

    Antibiotic MB 530A; Lovastatin diol lactone

    HMG-CoA Reductase (HMGCR) Autophagy Metabolic Disease
    Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase.
  • HY-14855
    Tedizolid

    TR 700; Torezolid; DA-7157

    Bacterial Antibiotic Infection
    Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
  • HY-16734A
    Amiselimod hydrochloride

    MT-1303 hydrochloride

    LPL Receptor Cancer
    Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
  • HY-139581
    Ropanicant

    SUVN-911 free base

    nAChR Neurological Disease
    Ropanicant (SUVN-911 free base) is a novel, potent, selective, and orally active neuronal nicotinic acetylcholine α4β2 receptor antagonist for the research of depression.
  • HY-19937
    Saroglitazar

    PPAR Metabolic Disease
    Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
  • HY-16617
    Auglurant

    VU0424238

    mGluR Neurological Disease
    Auglurant (VU0424238) is a novel and selective mGlu5 antagonist with an IC50 value of 11 nM (rat) and an IC50 value of 14 nM (human). Auglurant (VU0424238) has an acceptable CNS penetration.
  • HY-133246
    Monodes(N-carboxymethyl)valine Daclatasvir

    Daclatasvir Impurity A

    HCV Infection
    Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.
  • HY-101938
    Sinefungin

    Adenosyl-Ornithine; A-9145; Antibiotic 32232RP

    Histone Methyltransferase Fungal Antibiotic Infection Inflammation/Immunology
    Sinefungin is a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication. Sinefungin, a SET7/9 inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation.
  • HY-131447
    KY19382

    A3051

    GSK-3 Wnt β-catenin Metabolic Disease
    KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases.
  • HY-B0069
    Fludarabine

    F-ara-A; NSC 118218

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis STAT Apoptosis Cancer
    Fludarabine (NSC 118218) is a DNA synthesis inhibitor, which also inhibits phosphorylation of STAT1. Fludarabine, a pro-drug, is converted metabolically by dephosphorylation to the antimetabolite, F-ara-A.
  • HY-14247
    Fadrozole hydrochloride

    CGS 16949A; (Rac)-FAD286 hydrochloride

    Aromatase Cancer
    Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
  • HY-113965
    CUR61414

    Hedgehog Smo Apoptosis Inflammation/Immunology
    CUR61414 is a novel, potent and cell permeable Hedgehog signaling pathway inhibitor (IC50 =100-200 nM). CUR61414 is a small-molecule aminoproline class compound and selectively binds to smoothened (Smo) with a Ki  value of 44 nM. CUR-61414 can induce apoptosis in cancer cells without affecting neighboring non-tumor cells.
  • HY-114395A
    (R)-NVS-ZP7-4

    Others Inflammation/Immunology
    (R)-NVS-ZP7-4 is the R-isomer of NVS-ZP7-4. NVS-ZP7-4 is a Zinc transporter SLC39A7 (ZIP7) inhibitor that is also the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.
  • HY-13547
    ADPM06

    Apoptosis Cancer
    ADPM06, a lead candidate azadipyrromethene, is a novel nonporphyrin photodynamic therapeutic (PDT) agent. ADPM06 exhibits IC50 values in the micro-molar range in human tumor cells and induces apoptosis.
  • HY-111308
    RTI-118

    Neuropeptide Y Receptor Neurological Disease
    RTI-118 is a novel small-molecule neuropeptide S receptor (NPSR) antagonist. RTI-118 can relieve drug addiction including selectively decrease cocaine self-administration.
  • HY-13270
    ABT-751

    E7010

    Microtubule/Tubulin Autophagy Cancer
    ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.
  • HY-19937A
    Saroglitazar Magnesium

    PPAR Metabolic Disease
    Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
  • HY-12461
    WS6

    Others Inflammation/Immunology
    WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).
  • HY-N0853A
    Alisol A 24-acetate

    Alisol A 24-monoacetate; Alisol A monoacetate

    Others Others
    Alisol A 24-acetate (Alisol A 24-monoacetate) is a natural product.
  • HY-14660
    Dabrafenib

    GSK2118436A; GSK2118436

    Raf Cancer
    Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-Raf V600E, respectively.
  • HY-12186
    3-Deazaneplanocin A hydrochloride

    DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride

    Histone Methyltransferase Cancer
    3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor.
  • HY-136466
    A2ti-2

    Virus Protease Infection
    A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection.
  • HY-136465
    A2ti-1

    Virus Protease Infection
    A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection.
  • HY-16589
    Oligomycin A

    MCH 32

    ATP Synthase Fungal Antibiotic Cancer Infection
    Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial F0F1-ATPase inhibitor, with a Ki of 1 μM; Oligomycin A shows anti-fungal activity.
  • HY-19487A
    Ribocil B

    Ribocil S enantiomer; ent-Ribocil A

    Bacterial Infection
    Ribocil-B is the active S-isomer of ribocil which can inhibit flavin mononucleotide (FMN) with a KD of 6.6 nM.
  • HY-111174A
    Diprotin A TFA

    Ile-Pro-Ile TFA

    Dipeptidyl Peptidase Metabolic Disease
    Diprotin A TFA (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).
  • HY-101785
    eIF4A3-IN-2

    Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM.
  • HY-12151
    NS 1738

    NSC 213859

    nAChR Neurological Disease
    NS 1738 (NSC 213859) is a novel positive allosteric modulator of the α7 nAChR, with respect to positive modulation of α7 nAChR (EC50=3.4 μM in oocyte experiments).
  • HY-15781
    Morinidazole

    Bacterial Infection
    Morinidazole is a novel 5-nitroimidazole antimicrobial drug that undergoes extensive metabolism in humans via N+-glucuronidation and sulfation, for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria.
  • HY-N6013
    Aloin(mixture of A&B)

    MMP Bacterial Fungal Cancer Infection Inflammation/Immunology
    Aloin (mixture of A&B) is anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) has diverse biological activities such as anti-inflammatory, immunity, antidiabetic, antioxidant, antibacterial, antifungal, and antitumor activities. Aloin (mixture of A&B) also an effective inhibitor of stimulated granulocyte matrix metalloproteinases (MMPs).
  • HY-100501
    M2698

    MSC2363318A

    Ribosomal S6 Kinase (RSK) Akt Cancer
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.
  • HY-100540A
    (Rac)-Golgicide A

    (Rac)-GCA

    Enterovirus Infection
    (Rac)-Golgicide A ((Rac)-GCA) is a racemate of Golgicide A. Golgicide A (GCA) is a potent, highly specific, and reversible inhibitor of the cis-Golgi ADP-ribosylation factor guanine nucleotide exchange factors (ArfGEF) GBF1.Golgicide A drastically reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus species.
  • HY-13746
    Sardomozide

    CGP 48664; SAM-486A

    Others Cancer
    Sardomozide is an S-adenosylmethionine decarboxylase (SAMDC) inhibitor with an IC50 of 5 nM.
  • HY-B1311
    Proadifen hydrochloride

    SKF-525A; U-5446; RP-5171

    Cytochrome P450 Others
    Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).
  • HY-B0492
    Paroxetine hydrochloride

    BRL29060 hydrochloride; BRL29060A

    Serotonin Transporter Autophagy Neurological Disease Cancer
    Paroxetine hydrochloride is a potent selective serotonin-reuptake inhibitor, commonly prescribed as an and has GRK2 inhibitory ability with IC50 of 14 μM. Paroxetine hydrochloride can be used for the research of depressive disorder.
  • HY-P2265
    SAH-SOS1A

    Ras Cancer
    SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.
  • HY-17590
    Radafaxine hydrochloride

    GW-353162A; BW-306U

    Monoamine Transporter Neurological Disease
    Radafaxine hydrochloride (GW-353162A) is a DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, and nAChR family modulator.
  • HY-102026
    Formycin A

    NSC 102811

    HIV Nucleoside Antimetabolite/Analog Antibiotic Cancer Infection
    Formycin A (NSC 102811), a purine nucleoside antibiotic, is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an EC50 of 10 μM. Formycin A shows antitumor and antiviral activities.
  • HY-117319
    Indolmycin

    TAK-083; PA-155A

    Antibiotic Bacterial Infection Inflammation/Immunology
    Indolmycin (TAK-083), an antibiotic, is a competitive inhibitor of prokaryotic tryptophanyl-tRNA ligase (TrpS). Indolmycin (TAK-083) possesses both anti-viral and anti-bacterial activity.
  • HY-N0875
    IKarisoside A

    Icarisoside-A; Baohuoside II

    Others Inflammation/Immunology
    IKarisoside A (Icarisoside-A) is a natural flavonol glycoside and has anti-inflammatory properties.
  • HY-U00185
    A-437203

    Lu201640; A37203

    Dopamine Receptor Neurological Disease
    A-437203 is a selective D3 receptor antagonist with Ki of 71, 1.6, and 6220 nM for D2, D3, and D4 receptors, respectively.
  • HY-N5120
    Dihydrowithaferin A

    2,3-Dihydrowithaferin A

    AChE Cancer
    Dihydrowithaferin A (2, 3-dihydrowithaferin A) is a withanolide isolated from Withania somnifera. Dihydrowithaferin A is active against acetylcholinesterase (AChE).
  • HY-N0567
    Hydroxysafflor yellow A

    Safflomin A; HSYA

    Others Cancer
    Hydroxysafflor yellow A is a flavonoid derived and isolated from traditional Chinese medicine Carthamus tinctorius L.
  • HY-130320
    Monophosphoryl lipid A

    Glucopyranosyl lipid A

    Toll-like Receptor (TLR) Cancer Inflammation/Immunology
    Monophosphoryl lipid A (Glucopyranosyl lipid A) is a toll-like receptor 4 agonist. Monophosphoryl lipid A is derived from the cell wall of nonpathogenic Salmonella. Monophosphoryl lipid A can be used for the research of immunization and vaccine.
  • HY-117970
    MMPI-1154

    MMP Cardiovascular Disease
    MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively.
  • HY-12530S
    Velpatasvir-d7

    HCV SARS-CoV Cancer
    Velpatasvir-d7 (GS-5816-d7) is the deuterium labeled Velpatasvir. Velpatasvir (GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM.
  • HY-13768A
    Topotecan Hydrochloride

    SKF 104864A Hydrochloride; NSC 609669 Hydrochloride

    Topoisomerase Autophagy Apoptosis Cancer
    Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.
  • HY-101511
    TTT-28

    P-glycoprotein Cancer
    TTT-28 is a synthesized thiazole-valine peptidomimetic, a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated Multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1.
  • HY-14852A
    Tafamidis meglumine

    Fx-1006A

    Others Neurological Disease
    Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
  • HY-123824
    GNE-0439

    Sodium Channel Neurological Disease
    GNE-0439 is a novel Nav1.7-selective inhibitor with IC50 of 0.34 uM and inhibits Nav1.5 with an IC50 of 38.3 μM. GNE-0439 inhibits mutant N1742K channels (IC50=0.37 uM) in membrane potential assays. GNE-0439 possesses a carboxylic acid group, binds outside of the channel pore, and is unique compared with known selective VSD4 binders.
  • HY-14565
    Pozanicline

    ABT-089

    nAChR Neurological Disease
    Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a novel cholinergic agent that is a partial agonist at α4β2* nAChRs (Ki=16 nM) and shows high selectivity for α6β2* and α4α5β2 nAChR subtypes, the binding affinity (Ki, rat) for Pozanicline to [ 3H] cytisine sites is 16.7 nM. Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction.
  • HY-131973
    PDE10A-IN-2 hydrochloride

    Phosphodiesterase (PDE) Metabolic Disease Cardiovascular Disease
    PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research.
  • HY-B1071
    Lasalocid

    Lasalocid-A; Ionophore X-537A; Antibiotic X-537A

    Bacterial Autophagy Antibiotic Infection Cancer
    Lasalocid (Lasalocid-A; Ionophore X-537A; Antibiotic X-537A) is an antibacterial agent and a coccidiostat, used in the feed additives
  • HY-B1071A
    Lasalocid sodium

    Lasalocid-A sodium; Ionophore X-537A sodium; Antibiotic X-537A sodium

    Bacterial Autophagy Antibiotic Cancer Infection
    Lasalocid sodium (Lasalocid-A sodium) treatment led to an increase in cell wall thickness, whilst the quantity and sugar composition of the cell wall remained unchanged in BY-2 cells.
  • HY-100686
    U93631

    GABA Receptor Neurological Disease
    U93631 is a GABAA receptor ligand of novel chemical structure with IC50 of 100 nM,and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell Cl-currents in recombinant GABAA receptors.
  • HY-12462
    WS3

    Others Inflammation/Immunology
    WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes.
  • HY-135470
    Nifurpirinol

    P-7138

    Antibiotic Bacterial Infection
    Nifurpirinol (P-7138) is a nitroaromatic antibiotic and acts as a novel substrate for the bacterial nitroreductase (NTR) enzyme. Nifurpirinol is a more potent prodrug compared to Metronidazole to trigger cell-ablation in nitroreductase expressing transgenic models.
  • HY-122872
    MKK7-COV-9

    p38 MAPK Cancer
    MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
  • HY-15511
    Tyrphostin A9

    Tyrphostin 9; Malonoben

    VEGFR Influenza Virus Cancer Infection
    Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has anti-influenza virus activities.
  • HY-139031
    ALDH1A2-IN-1

    Aldehyde Dehydrogenase (ALDH) Endocrinology
    ALDH1A2-IN-1 is an active site-directed reversible ALDH1A2 inhibitor (IC50=0.91 μM; Kd=0.26 μM) with several hydrophobic interactions.
  • HY-100877
    GCN2-IN-1

    A-92

    Eukaryotic Initiation Factor (eIF) Cancer
    GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay.
  • HY-16146
    Combretastatin A-1 phosphate tetrasodium

    OXi-4503 tetrasodium

    Microtubule/Tubulin Cancer
    Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a prodrug of Combretastatin A-1, is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 phosphate tetrasodium inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 phosphate tetrasodium exhibits anti-tumor and anti-vascular effects.
  • HY-101496
    MT-DADMe-ImmA

    MTDIA; Methylthio-DADMe-Immucillin A

    Others Cancer
    MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a Ki of 90 pM.
  • HY-19824
    3PO

    Autophagy Cancer
    3PO is a novel small-molecule inhibitor of the PFKFB3 isozyme, 3PO markedly attenuates the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50, 1.4-24 μM) IC50 value Target: PFKFB3 isozyme in vitro: 3PO inhibits recombinant PFKFB3 activity, suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.
  • HY-108069
    Iptakalim hydrochloride

    Potassium Channel nAChR Neurological Disease
    Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist.
  • HY-14848
    Naluzotan

    PRX 00023

    5-HT Receptor Potassium Channel Neurological Disease
    Naluzotan is a novel, potent, and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM, used for the treatment of anxiety and depression; Also a weak hERG K + channel blocker, with IC50 of 3800 nM.
  • HY-N1373
    Sophoridine

    Apoptosis Cancer
    Sophoridine is a quinolizidine alkaloid isolated from leafs of Leguminous plant Sophora alopecuroides.L. Sophoridine induces apoptosis. Sophoridine has the potential to be a novel, potent and selective antitumor drug candidate for pancreatic cancer with well-tolerated toxicity.
  • HY-18649
    Galidesivir hydrochloride

    BCX4430 hydrochloride; Immucillin-A hydrochloride

    DNA/RNA Synthesis SARS-CoV Filovirus Infection
    Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM.
  • HY-18649A
    Galidesivir

    BCX4430; Immucillin-A

    DNA/RNA Synthesis SARS-CoV Filovirus Infection
    Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM.
  • HY-112363
    Aloisine A

    RP107

    CDK GSK-3 ERK JNK CFTR Cancer Inflammation/Immunology
    Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC50s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC50=0.5 µM) and GSK-3β (IC50=1.5 µM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research.
  • HY-N1724
    Concanamycin A

    Antibiotic X 4357B; Concanamycin; X 4357B

    Proton Pump Bacterial Antibiotic Cancer Infection
    Concanamycin A (Antibiotic X 4357B) is a macrolide antibiotic and a specific vacuolar type H +-ATPase (V-ATPase) inhibitor.
  • HY-N6682
    Cytochalasin D

    Zygosporin A; NSC 209835

    Arp2/3 Complex Bacterial Antibiotic YAP Infection
    Cytochalasin D (Zygosporin A; NSC 209835) is a potent and cell-permeable inhibitor of actin polymerization derived from fungus, inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D (Zygosporin A; NSC 209835) also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells.Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of YAP.
  • HY-117430
    Hymeglusin

    F-244; 1233A; L-659699

    Antibiotic Cancer Infection Metabolic Disease
    Hymeglusin, as a fungal β-lactone antibiotic, is a HMG-CoA synthase inhibitor (IC50 = 0.12 μM). Hymeglusin covalently modifies the active Cys 129 residue of the enzyme.
  • HY-14261
    Vilazodone Hydrochloride

    EMD 68843 Hydrochloride; SB659746A Hydrochloride

    5-HT Receptor Serotonin Transporter Neurological Disease
    Vilazodone Hydrochloride (EMD 68843 Hydrochloride) is a serotonin transporter (SER) inhibitor and 5-HT1A receptor partial agonist.
  • HY-12424
    Zotarolimus

    ABT-578; A 179578

    Others Cancer Cardiovascular Disease
    Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis.
  • HY-N1913
    Danshensu

    Dan shen suan A; Salvianic acid A

    Keap1-Nrf2 Autophagy Apoptosis Cardiovascular Disease Cancer
    Danshensu, an active ingredient of Salvia miltiorrhiza, shows wide cardiovascular benefit by activating Nrf2 signaling pathway.
  • HY-124596
    CD161

    NKR-P1A

    Epigenetic Reader Domain Cancer
    CD161 (NKR-P1A) is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity.
  • HY-106690
    Centhaquin

    Centhaquine; PMZ-2010

    Others Inflammation/Immunology Cardiovascular Disease
    Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of  haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.
  • HY-122190
    TAK-071

    mAChR Neurological Disease
    TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM.
  • HY-15445
    CTEP

    RO 4956371; mGluR5 inhibitor

    mGluR Neurological Disease
    CTEP (RO 4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, and shows > 1000-fold selectivity over other mGlu receptors.
  • HY-N0619A
    cis-Mulberroside A

    Mulberroside D

    TNF Receptor Interleukin Related Tyrosinase Inflammation/Immunology
    cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory and anti-apoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC50 of 53.6 μM.
  • HY-113986
    (R)-Fadrozole

    (R)-CGS 16949A free base; FAD286

    Others Cardiovascular Disease
    (R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats..
  • HY-10895
    SB-334867

    SB 334867A

    Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 (SB 334867A) is an excellent,selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively. SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo.
  • HY-100014
    KDM5A-IN-1

    Histone Demethylase Cancer
    KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B).
  • HY-N8154
    Tortoside A

    Others Others
    Tortoside A is a bioactive compound that could be found in the roots of Ilex pubescens.
  • HY-P1333
    Dynorphin A

    Opioid Receptor Neurological Disease
    Dynorphin A, an endogenous opioid peptide, is a highy potent kappa opioid receptor (KOR) activator. Dynorphin A also serve as an agonist for other opioid receptors,  such as mu (MOR) and delta (DOR).
  • HY-N2025
    Oroxin A

    PPAR Glucosidase Metabolic Disease
    Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.
  • HY-N2420
    Flavokawain A

    Apoptosis Cancer
    Flavokawain A, a proming anticarcinogenic agent, is a chalcone from kava extract with anti-tumor activity. Flavokawain A induces cell apoptosis by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway. Flavokawain A has the potential for the study of bladder cancer.
  • HY-N7496
    Odoroside A

    Apoptosis Cancer
    Odoroside A is an active ingredient extracted from the leaves of Nerium oleander Linn. Odoroside A has anti-cancer activity. Odoroside A could induce apoptosis and cell cycle arrest through ROS/p53 signaling pathway, leading to the tumor cell death.
  • HY-N0239
    Bulleyaconitine A

    Sodium Channel Neurological Disease
    Bulleyaconitine A is an analgesic and antiinflammatory drug isolated from Aconitum plants; has several potential targets, including voltage-gated Na+ channels.
  • HY-N3051
    Piperlotine A

    Others Cardiovascular Disease
    Piperlotine A is an alkaloid isolated from Piper lolot, with potent antiplatelet aggregation activity.
  • HY-50697
    A-740003

    P2X Receptor Neurological Disease
    A-740003 is a potent, selective and competitive P2X7 receptor antagonist with IC50 values are 18 and 40 nM for rat and human P2X7 receptors, respectively.
  • HY-130993
    Isatropolone A

    Parasite Infection
    Isatropolone A, a natural product containing a 1,5-diketone moiety, is reisolated from Streptomyces Gö66. Isatropolone A shows potent activity against Leishmania donovani with an IC50 of 0.5 μM.
  • HY-120295
    A-192621

    Endothelin Receptor Apoptosis Endocrinology Cardiovascular Disease
    A-192621 is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level.
  • HY-N3204
    Neoechinulin A

    Apoptosis Neurological Disease
    Neoechinulin A is an isoprenyl indole alkaloid that exhibits scavenging, neurotrophic factor-like, and anti-apoptotic activities. Neoechinulin A induces memory improvements and antidepressant-like effects in mice.
  • HY-N7621
    Bryonamide A

    Others Others
    Bryonamide A is a natural compound isolated from red algae Bostrychia radicans (Rhodomelaceae).
  • HY-N2416
    Taccalonolide A

    Microtubule/Tubulin Apoptosis Cancer
    Taccalonolide A is a microtubule stabilizer, which is a steroid isolated from Tacca chantrieri, with cytotoxic and antimalarial activities. Taccalonolide A causes G2-M accumulation, Bcl-2 phosphorylation and initiation of apoptosis. Taccalonolide A is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug resistance protein 7 (MRP7), with an IC50 of 622 nM for SK-OV-3 cells.
  • HY-103382
    Arcyriaflavin A

    Fungal Infection
    Arcyriaflavin A is a fungal metabolite obtained from the fungi, Nocardiopsis sp.
  • HY-100080
    A-887826

    Sodium Channel Neurological Disease
    A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo.
  • HY-N7680
    Neopuerarin A

    Others Metabolic Disease
    Neopuerarin A is an isoflavones isolated from the water extraction of the dried roots of Pueraria lobata (Willd.). Neopuerarin A shows significant hepatoprotective effect.
  • HY-120687
    A68930

    Dopamine Receptor Cancer
    A68930, as a dopamine D1 receptor agonist, can be used for the research of bronchiectasis.
  • HY-N6572
    Sutchuenmedin A

    Others Others
    Sutchuenmedin A is a prenylflavonoid. Sutchuenmedin A is isolated from the 70% EtOH extract of Epimedium sutchuenense.
  • HY-N2606
    Bernardioside A

    Others Metabolic Disease
    Bernardioside A is a triterpenoid saponin isolated from Bellis bernardii.
  • HY-N6065
    Praeruptorin A

    NF-κB Inflammation/Immunology
    Praeruptorin A is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin A exerts anti-inflammatory effects in vitro through inhibition of NF-κB activation.
  • HY-N8227
    Szechenyin A

    Others Others
    Szechenyin A is a constituent from Tibetan medicine Gentianae Szechenyii Spray.
  • HY-N7028
    Withanolide A

    Others Neurological Disease
    Withanolide A, isolated from the indian herbal drug Ashwagandha (root of Withania somnifera), could regenerate neurites and reconstruct synapses in severely damaged neurons.
  • HY-N0318
    Salvianolic acid A

    MMP Inflammation/Immunology
    Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.
  • HY-N0023
    Cistanoside A

    Others Inflammation/Immunology
    Cistanoside A is a phenylethanoid isolated from Cistanche deserticola, reduces NO accumulation, but shows no effect on iNOS mRNA, iNOS protein levels or iNOS activity. Anti-inflammatory effect.
  • HY-131098
    Enduracidin A

    Antibiotic Infection
    Enduracidin A is a major component of Enduracidin. Enduracidin is a polypeptide antibiotic produced by Streptomyces fungicides.
  • HY-N3201
    Neoprzewaquinone A

    Others Others
    Neoprzewaquinone A is isolated from the roots of Salvia miltiorrhiza.
  • HY-N6820
    Iristectorin A

    Others Cancer
    Iristectorin A, a natural product from Iris tectorum, has anti-cancer activities in breast cancer.
  • HY-N0581
    Qingyangshengenin A

    Others Neurological Disease
    Qingyangshengenin A, a C-21 steroidal glycoside isolated from the roots of Cynanchum otophyllum Schneid, has antiepileptic activity.
  • HY-N0257
    Epimedin A

    Others Others
    Epimedin A is a natural compound extracted from Herba Epimedii.
  • HY-11079
    A-803467

    Sodium Channel Inflammation/Immunology Neurological Disease
    A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter.
  • HY-P1539
    Cecropin A

    Bacterial Antibiotic Cancer Infection Inflammation/Immunology
    Cecropin A is a linear 37-residue antimicrobial polypeptide, with anticancer and anti-inflammatory activity.
  • HY-16941
    Damulin A

    Others Cancer
    Damulin A is a saponin found in G. pentaphyllum with anti-cancer activities.
  • HY-N7679
    Stachyanthuside A

    Others Inflammation/Immunology
    Stachyanthuside A is an ellagic acid glycoside isolated from the leaves of Diplopanax stachyanthus.
  • HY-N0659
    Jujuboside A

    GABA Receptor Neurological Disease
    Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.
  • HY-113673
    A-935142

    Potassium Channel Cardiovascular Disease
    A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization.
  • HY-N5104
    Clemaphenol A

    Others Others
    Clemaphenol A is a chemical constituent of the flower of Fritillaria pallidiflora.
  • HY-N8177
    Bletilloside A

    Others Others
    Bletilloside A is a natural glucoside that could be found in the tubers of Bletilla striata.
  • HY-B0767
    Spinosyn A

    Others Others
    Spinosyn A, a polyketide-derived macrolide produced by Saccharopolyspora spinosa, is a potent insecticide.
  • HY-125361
    Ganosporeric acid A

    Others Others
    Ganosporeric acid A, a natural product, is isolated from the ether-soluble fraction of the spores of Ganoderma lucidum (Curt.: Fr.) P. Karst. Ganosporeric acid A can be used for the research of liver injury.
  • HY-116941
    A-381393

    Dopamine Receptor Neurological Disease
    A-381393 is a potent, selective, brain penetrate dopamine D4 receptor antagonist, with Kis of 1.5, 1.9 and 1.6 nM for human dopamine D4.4, D4.2, and D4.7 receptor, respectively, >2700-fold selectivity over D1, D2, D3 and D5 dopamine receptors. A-381393 shows moderate affinity for 5-HT2A (Ki, 370 nM).
  • HY-N6992
    Dulcoside A

    Others Metabolic Disease
    Dulcoside A is isolated from Stevia rebaudiana, it often advertised as a sweetener.
  • HY-N1508
    Ecliptasaponin A

    Others Inflammation/Immunology
    Ecliptasaponin A , a pentacyclic triterpenoid saponin, is one of major compounds separated from Eclipta prostrate. Eclipta prostrate is considered as a nourishing herbal medicine with pleiotropic effects, including anti-inflammatory, hepatoprotective, antioxidant, and immunomodulatory.
  • HY-N2175
    Cixiophiopogon A

    Others Metabolic Disease
    Cixiophiopogon A, a steroidal glycoside, obtained from the tuberous roots of Ophiopogon japonicus (Liliaceae).
  • HY-N2440
    Gypenoside A

    Others Metabolic Disease
    Gypenoside A is a natural compound isolaated from Gynostemma pentaphyllum Makino.
  • HY-N0081
    (±)-Praeruptorin A

    Calcium Channel Infection
    (±)-Praeruptorin A is the di-esterified product of cis-khellactone (CKL) and the major active ingredient in Peucedani Radix which consists of the dried roots of Peucedanum praeruptorumDunn (Apiaceae). (±)-Praeruptorin A has been widely employed as one of the famous traditional Chinese medicines (TCMs) for the treatment of cough with thick sputum and dyspnea, nonproductive cough and upper respiratory infections for centuries in China. (±)-Praeruptorin A has dramatically therapeutic effects on hypertension mainly through acting as a Ca 2+-influx blocker.
  • HY-P2324
    Gramicidin A

    Bacterial HIF/HIF Prolyl-Hydroxylase Infection
    Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α).
  • HY-N1823
    Pygenic acid A

    Apoptosis Cancer Metabolic Disease Inflammation/Immunology
    Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces apoptosis in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers.
  • HY-P1096
    A71623

    Cholecystokinin Receptor Metabolic Disease
    A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.
  • HY-N2626
    Epimedoside A

    Others Infection
    Epimedoside A is a flavonoid isolated from the roots of Epimedium wushanense. Epimedoside A exhibits significant antioxidant activity in vitro.
  • HY-N2281
    Leachianone A

    Apoptosis Cancer Inflammation/Immunology
    Leachianone A, isolated from Radix Sophorae, has anti-malarial, anti-inflammatory, and cytotoxic potent. Leachianone A induces apoptosis involved both extrinsic and intrinsic pathways.
  • HY-N8034
    Glychionide A

    Apoptosis Autophagy Cancer
    Glychionide A is a flavonoside that can be found in the roots of Glychirriza glabra. Glychionide A promotes apoptosis and autophagy of PANC-1 pancreatic cancer cells. Glychionide A can be used for the research of cancer.
  • HY-N5057
    Przewalskinic acid A

    Others Cardiovascular Disease
    Przewalskinic acid A is a phenolic acid found in the Salvia przewalskii Maxim herb. Phenolic acids show potent antioxidant activities and potential effects in protecting against brain and heart damage caused by ischemia reperfusion.
  • HY-N0237
    Atractyloside A

    Others Others
    Atractyloside A is a natural TCM reference compound.
  • HY-N5146
    Ophiopogonside A

    Others Cancer
    Ophiopogonside A, a natural conpound that could be isolated from ophiopogon japonicas, possesses anti-cancer activity.
  • HY-N5087
    Nudicaucin A

    Others Others
    Nudicaucin A is a triterpenoid saponin isolated from Hedyotis nudicaulis.
  • HY-12455
    Duocarmycin A

    ADC Cytotoxin Apoptosis Caspase Cancer
    Duocarmycin A, which is one of well-known antitumor antibiotics, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results HLC-2 cells typically apoptotic changes, including chromatin condensation, sub-G1 accumulation in DNA histogram pattern, and decrease in procaspase-3 and 9 levels.
  • HY-103431
    A68930 hydrochloride

    Dopamine Receptor Others
    A68930 hydrochloride, as a dopamine D1 receptor agonist, can be used for the research of bronchiectasis.
  • HY-N1472
    Levistolide A

    Apoptosis Cancer
    Levistolide A (LA), a natural compound isolated from the traditional Chinese herb Ligusticum chuanxiong Hort, is used for treating cancer. Levistolide A can induce apoptosis via ROS-mediated ER stress pathway.
  • HY-N1371
    Clinodiside A

    Others Infection
    Clinodiside A is isolated from the Chinese medicinal herb Clinopodium chinensis.
  • HY-N6930
    Shikonofuran A

    Others Metabolic Disease
    Shikonofuran A is a natural product isolated from the root of Lithosperraum erythrorhizon Sieb.
  • HY-N0028
    Forsythiaside A

    Others Inflammation/Immunology
    Forsythiaside A, a phenylethanoside product isolated from air-dried fruits of Forsythia suspense, has anti-inflammatory and antioxidant effects.
  • HY-N8024
    Rubinaphthin A

    Others Infection
    Rubinaphthin A is a naphthohydroquinone that can be found in the roots of Rubia yunnanensis. Rubinaphthin A exhibits inhibitory activity against tobacco mosaic virus (TMV).
  • HY-N6059
    Ophiopogonanone A

    Others Others
    Ophiopogonanone A is a homoisoflavonoidal compound isolated as a constitutent of Ophiopogonis tuber.
  • HY-P1581
    Ceratotoxin A

    Bacterial Infection
    Ceratotoxin A, a 29-residue peptide isolated from the accessory gland secretion fluid, with strong anti-bacterial activity.
  • HY-N4210
    Yadanziolide A

    Others Cancer Infection
    Yadanziolide A, isolated from the cultivated dry seeds of Brucea javanica, has strong antiviral activities with IC50 of 5.5 μM against tobacco mosaic virus. Yadanziolide A shows significant antitumor effects.
  • HY-108463
    A-967079

    TRP Channel Inflammation/Immunology
    A-967079 is a selective TRPA1 receptor antagonist with IC50s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the CNS.
  • HY-N2155
    Tubuloside A

    Others Metabolic Disease
    Tubuloside A is a phenylethanoid glycoside with antioxidative effect and hepatoprotective activity.
  • HY-131058
    Muscotoxin A

    ADC Cytotoxin Cancer
    Muscotoxin A is an ADC cytotoxin. Muscotoxin A is a cytotoxic lipopeptide that permeabilizes mammalian cell membranes and induces necrotic cell death.
  • HY-N2331
    Proscillaridin A

    Topoisomerase Cancer
    Proscillaridin A is a potent poison of topoisomerase I/II activity with IC50 values of 30 nM and 100 nM, respectively.
  • HY-50662
    A-769662

    AMPK Cancer
    A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM.
  • HY-N5107
    Epimagnolin A

    Parasite Infection
    Epimagnolin A, a furfuran lignan, shows mild antiplasmodial activities (IC50=5.7 μg/mL) without noticeable toxicity on mammalian normal cells.
  • HY-N7991
    Rubiayannone A

    Others Cardiovascular Disease
    Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity.
  • HY-N6776
    Penitrem A

    Potassium Channel Cancer Neurological Disease
    Penitrem A is an indole diterpene neurotoxic alkaloid produced by Penicillium, acts as a selective BK channel antagonist with antiproliferative and anti-invasive activities against multiple malignancies. Penitrem A increases the spontaneous release of endogenous glutamate, gamma-aminobutyric acid (GABA) and aspartate from cerebrocortical synaptosomes, and induces tremorgenic syndromes in animals.
  • HY-N4084
    Thonningianin A

    Apoptosis Cancer
    Thonningianin A, an ellagitannin, is isolated from the methanolic extract of the African medicinal herb, Thonningia sanguinea. The antioxidant properties of Th A involve radical scavenging, anti-superoxide formation and metal chelation. Anti-cancer activities.
  • HY-N6255
    Ilexgenin A

    Others Cancer Inflammation/Immunology
    Ilexgenin A is a pentacyclic triterpenoid, which extracted from Ilex hainanensis Merr. Ilexgenin A can be used for the research of inflammation and cancer.
  • HY-15568A
    A-317491 sodium salt hydrate

    P2X Receptor Inflammation/Immunology Neurological Disease
    A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux.
  • HY-N2637
    Yibeinoside A

    Others Others
    Yibeinoside A is an alkaloid isolated from the bulb of Fritillaria pallidiflora Schreb [1].
  • HY-N3680
    Danshenxinkun A

    Others Cardiovascular Disease
    Danshenxinkun A is a natural compound that could be isolated from Tanshen and is used in the study for heart diseases.
  • HY-N2109
    Macranthoidin A

    Others Metabolic Disease
    Macranthoidin A is an orally active saponin from Flos Lonicerae. Macranthoidin A possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil.
  • HY-N8995
    Bruceoside A

    Others Cancer
    Bruceoside A, an abundant quassinoid glycoside in Fructus Bruceae, possesses anti-cancer activity.
  • HY-N4236
    Angelol A

    Others Others
    Angelol A is a coumarin isolated from the roots of Angelica pubescens f. biserrata, which is passive diffusion as the dominating process in Caco-2 cell monolayer model.
  • HY-N2249
    Hosenkoside A

    Others Inflammation/Immunology
    Hosenkoside A is a baccharane glycoside isolated from the seeds of impatiens balsamina.
  • HY-N2524
    Camelliaside A

    Others Inflammation/Immunology
    Camelliaside A is a flavonoid from the methanol extract of tea (Camellia oleifera) seed pomace.
  • HY-N8018
    Leucosceptoside A

    PKC Glucosidase Angiotensin-converting Enzyme (ACE) Metabolic Disease Neurological Disease
    Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against α-glucosidase and PKCα (IC50 of 19.0 μM).
  • HY-108421
    Xinjiachalcone A

    Bacterial Infection
    Xinjiachalcone A is an active principle of Glycyrrhiza inflata Batalin. Xinjiachalcone A shows both a low MIC and a strong bactericidal activity against H. pylori, with MIC values ranged from 12.5 to 50 µM for seventeen H. pylori strains.
  • HY-N9528
    Lyciumin A

    Angiotensin-converting Enzyme (ACE) Renin Cardiovascular Disease
    Lyciumin A, a cyclic octapeptide, exhibits inhibitory activity on proteases, renin and angiotensin-converting enzyme. Lyciumin A can be used for the research of hypertension.
  • HY-133168
    Englerin A

    TRP Channel Cancer
    Englerin A is a potent and selective activator of TRPC4 and TRPC5 channels, with EC50s of 11.2 and 7.6 nM, respectively. Englerin A can induce renal carcinoma cells death by elevated Ca 2+ influx and Ca 2+ cell overload.
  • HY-59201A
    A-582941 dihydrochloride

    nAChR 5-HT Receptor Neurological Disease
    A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with Kis of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT3 receptor with a Ki of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research.
  • HY-N0743
    Senkyunolide A

    Others Cancer
    Senkyunolide A, isolated from Ligusticum chuanxiong Hort, has cytoprotective and antiproliferative activities. Anti-tumor activity.
  • HY-N9402
    Prosaikogenin A

    Others Cardiovascular Disease
    Prosaikogenin A is a triterpene saponin isolated from Clinopodium chinense. Prosaikogenin A has significant promoting effects on platelet aggregation with an EC50 value of 12.2 μM.
  • HY-N3595
    Cleomiscosin A

    TNF Receptor Inflammation/Immunology
    Cleomiscosin A is a coumarino-lignoid from branch of Macaranga adenantha. Cleomiscosin A is active against TNF-alpha secretion of the mouse peritoneal macrophages.
  • HY-N7499
    Sibiricaxanthone A

    Others Others
    Sibiricaxanthone A, a xanthone C-glycoside, is isolated from the roots of Polygala sibirica.
  • HY-103416
    A-77636 hydrochloride

    Dopamine Receptor Neurological Disease
    A-77636 hydrochloride is a potent, orally active, selective and long acting dopamine D1 receptor agonist (pKi=7.40; Ki=39.8 nM) with antiparkinsonian activity. A-77636 hydrochloride is functionally inactive at dopamine D2 receptor.
  • HY-136293
    Mechercharmycin A

    Apoptosis Cancer
    Mechercharmycin A is a cytotoxic substance isolated from marine-derived Thermoactinomyces sp. YM3-251. Mechercharmycin A exhibits relatively strong antitumor activity.
  • HY-N6076
    Tenuifoliside A

    ERK Neurological Disease
    Tenuifoliside A is isolated from Polygala tenuifolia, has anti-apoptotic and antidepressant-like effects. Tenuifoliside A exhibits its neneurotrophic effects and promotes cell proliferation through the ERK/CREB/BDNF signal pathway in C6 cells.
  • HY-N4316
    Flemiphilippinin A

    Others Endocrinology
    Flemiphilippinin A is a prenylated isoflavone isolated from Flemingia philippinensis.
  • HY-N4257
    Yadanzioside A

    Others Cancer
    Yadanziolide A, a quassinoid glycoside from Brucea javanica, has antitumor activity.
  • HY-128973
    Pyropheophorbide-a

    Others Cancer
    Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT).
  • HY-108013
    Armillarisin A

    Interleukin Related Inflammation/Immunology
    Armillarisin A has the potential for the ulcerative colitis (UC) study. Armillarisin A increases IL-4 and lower IL-1β.
  • HY-N7980
    Rubipodanone A

    NF-κB Cancer
    Rubipodanone A, a naphthohydroquinone dimer, shows cytotoxicity against A549, BEL-7402, HeLa, HepG2, SGC-7901 and U251 cells. Rubipodanone A also shows obvious activating effect at 20 and 40 μM for NF-κB.
  • HY-N9379
    Fissistigine A

    Others Others
    Fissistigine A is an alkaloid separated of the basic fractions from Formosan Fissistigma glaucescens, F. oldhamii and Goniothalamus amuyon.
  • HY-125531
    Dactylorhin A

    Others Others
    Dactylorhin A, a succinate derivative ester, is isolated from rhizomes of Gymnadenia conopsea. Dactylorhin A exhibits moderate inhibitory effects on NO production effects in RAW 264.7 macrophage cells.
  • HY-N2441
    Methylophiopogonone A

    Others Inflammation/Immunology
    Methylophiopogonone A, a homoisoflavonoid isolated from the tuberous roots of Ophiopogon japonicas, shows anti-inflammatory activity.
  • HY-N2111
    Momordicoside A

    Phosphatase Metabolic Disease
    Momordicoside A is isolated from Momordica charantia L. Momordicoside A has the inhibitory effect on protein tyrosine phosphatase (PTP1B).
  • HY-N2505
    Iristectorigenin A

    Others Inflammation/Immunology
    Iristectorigenin A is a natural isoflavone isolated from B. chinensis rhizomes. Iristectorigenin A shows antioxidant activity.
  • HY-126252
    A-9758

    ROR Interleukin Related Inflammation/Immunology
    A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation.
  • HY-N0819
    Raddeanin A

    Apoptosis Cancer
    Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway.
  • HY-P2123
    Colistin A

    Bacterial Antibiotic Infection
    Colistin A is a major component of Colistin. Colistin is a polymyxin antibiotic and can be used to combat infections caused by problematic gram-negative bacteria.
  • HY-128851
    Coenzyme A

    Endogenous Metabolite Cancer Neurological Disease
    Coenzyme A is is an obligatory cofactor in all living cells synthesised from pantothenate (Vitamin B5), adenosine triphosphate (ATP) and cysteine. Covalent binding of Coenzyme A to Peroxiredoxin 5 (Prdx5) results in complete inhibition of its peroxidase activity, which is reversed by reduction with DTT.Coenzyme A and its thioester derivatives are key players in major catabolic and anabolic pathways and the regulation of gene expression. Many human pathologies, including cancer, diabetes and neurodegeneration, have been associated with abnormal biosynthesis and homeostasis of CoA and its derivatives.
  • HY-N8212
    Isofutoquinol A

    Others Others
    Isofutoquinol A is a neolignan that can be found in Piper futokadzura.
  • HY-12428
    A-1165442

    TRP Channel Neurological Disease
    A-1165442 is a potent, competitive and orally available TRPV1 antagonist with an IC50 of 9 nM for human TRPV1.
  • HY-N0632
    Esculentoside A

    COX NF-κB Inflammation/Immunology
    Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models, has selective inhibitory activity towards cyclooxygenase-2 (COX-2). Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways.
  • HY-12761
    A-836339

    Cannabinoid Receptor Neurological Disease
    A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.
  • HY-N8145
    Gingerglycolipid A

    Others Others
    Gingerglycolipid A is a monoacyldigalactosyl glycerol.
  • HY-N7644
    Comanthoside A

    Others Others
    Comanthoside A is a plant derived natural flavonoid glycoside isolated from the leaves of Comanthosphace japonica. Comanthoside A also serves as a key intermediate for the synthesis of Comanthoside B and Linaroside.
  • HY-N4278
    Huangjiangsu A

    Reactive Oxygen Species Inflammation/Immunology
    Huangjiangsu A, pseudoprotodioscin, methyl protobioside, protodioscin, and protodeltonin, isolated from D. villosa. Huangjiangsu A has hepatoprotective potential against H2O2-induced cytotoxicity and ROS generation and could be promising as potential therapeutic agents for liver diseases.
  • HY-131448
    A3334

    Others Metabolic Disease
    A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC50 of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH.
  • HY-U00225
    A7132

    Bacterial Infection
    A7132 is an antibacterial agent. A7132 possess broad and potent antibacterial activity.
  • HY-N1989
    Bacoside A

    Others Metabolic Disease
    Bacoside A exhibits hepatoprotective activity.
  • HY-126708
    Luisol A

    ADC Cytotoxin Infection
    Luisol A, an aromatic tetraol, is a major metabolite of an estuarine marine actinomycete of the genus Streptomyces. Luisol A, anthraquinone antibiotic analog, is an ADC Cytotoxin.
  • HY-N8136
    Volvalerenic acid A

    Others Others
    Volvalerenic acid A is a germacrane-type sesquiterpenoid that can be found in the roots of Valeriana officinalis var. latifolia.
  • HY-N8103
    Heishuixiecaoline A

    Others Neurological Disease
    Heishuixiecaoline A is a germacrane-type sesquiterpenoid. Heishuixiecaoline A shows protective effect on the neurotoxicity of PC12 cells induced by Aβ25-35.
  • HY-N4175
    Cucurbitacin A

    Others Cancer
    Cucurbitacin A, a triterpenoid that could be isolated from the Stems of Cucumis melo, shows anti-cancer activity.
  • HY-107313
    Macranthoside A

    Bacterial Infection
    Macranthoside A is a triterpene glycoside with anti-microbially activity.
  • HY-N8199
    Ardisicrenoside A

    Others Cancer
    Ardisicrenoside A exhibits anti-cancer activity.
  • HY-N4019
    Maohuoside A

    Others Metabolic Disease
    Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways.
  • HY-18260
    Bisphenol A

    Endogenous Metabolite Endocrinology
    Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.
  • HY-100483
    A-804598

    P2X Receptor Cancer
    A-804598 is a CNS penetrant, competitive and selective P2X7 receptor antagonist with IC50s of 9 nM, 10 nM and 11 nM for mouse, rat and human P2X7 receptors, respectively.
  • HY-15568
    A-317491

    P2X Receptor Inflammation/Immunology Neurological Disease
    A-317491 is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux.
  • HY-N8496
    Clinopodiside A

    Others Others
    Clinopodiside A, a triterpenoid saponin, is isolated from Clinopodium polycephalum which is a popular Chinese traditional medicinal herb.
  • HY-111009
    Swinholide A

    Fungal Infection
    Swinholide A is the actin-binding marine polyketide and dimerizes actin with the Kd of ~ 50 nM. Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments. Swinholide A disrupts the actin cytoskeleton of cells.Antifungal activity.
  • HY-N8257
    Dehydrobruceine A

    Parasite Infection Inflammation/Immunology
    Dehydrobruceine A is a low potent antitrypanosomal agent, with an IC50 of 88.5 nM for Plasmodium falciparum.
  • HY-N2017
    Maoecrystal A

    Others Others
    Maoecrystal A is a compound isolated from leaves of Isodon eriocalyx.
  • HY-N4318
    Graveobioside A

    Others Metabolic Disease
    Graveobioside A is an anthoxanthin glycoside.
  • HY-N6593
    Arillanin A

    Others Others
    Arillanin A is an oligosaccharide ester isolated from Polygala arillata.
  • HY-N4223
    Sibirioside A

    Others Metabolic Disease
    Sibirioside A is a phenylpropanoid glycoside isolated from Scrophulariae Radix. Sibirioside A has the potential for the treatment of diabetes.
  • HY-N4274
    Ophiopogonoside A

    Others Others
    Ophiopogonoside A is an eudesmane sesquiterpene glycoside isolated from Liriope muscari.
  • HY-U00142
    A-802715

    Others Cancer
    A802715 is a methylxanthine derivative. A802715 has a TD50 (toxic dose of 50%) of 0.9-1.1 mM.
  • HY-N6994
    Isoasatone A

    Others Infection
    Isoasatone A is a natural product isolated from the plant Heterotropa takaoi M., with anti-insect activity. Isoasatone A againsts S. litura by acting on cytochrome P450 monoxygenases and glutathione transferases.
  • HY-P1629
    Temporin A

    Bacterial Fungal Antibiotic Infection
    Temporin A is a short alpha-helical antimicrobial peptide isolated from the skin of the frog Rana temporaria. Temporin A is effective against a broad spectrum of Gram-positive bacteria. Temporin A interacts directly with the cell membrane of the microorganism and it is non-toxic to erythrocytes at concentrations that are antimicrobial. Temporin A also has antifungal activities (against yeast-like Candida albicans).
  • HY-N2437
    Methylophiopogonanone A

    Others Inflammation/Immunology
    Methylophiopogonanone A, a major homoisoflavonoid in Ophiopogon japonicas, has both anti-oxidative and anti-inflammatory properties.
  • HY-N0246
    Saikosaponin A

    LXR Bacterial Inflammation/Immunology Cancer
    Saikosaponin A is an active component of Bupleurum falcatum, up-regulates LXRα expression, with potent anti-inflammatory activity.
  • HY-14364
    A-987306

    Histamine Receptor Inflammation/Immunology
    A-987306 is a potent and oral bioavailable histamine H4 antagonist, with Kis of 3.4 nM and 5.8 nM for rat H4, and human H4. A-987306 shows anti-inflammatory activity in mice peritonitis model.
  • HY-N6917
    Siraitic Acid A

    Others Cancer
    Siraitic Acid A is a cucurbitane triterpenoid isolated from the root of S. grosvenori [1].
  • HY-N2326
    (±)-Anatoxin A fumarate

    nAChR Neurological Disease
    (±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits Ki values of 1.25 nM and 1.84 μM for binding to putative α4β2-type nAChR and α7-type nAChR in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ 3H]-dopamine release from rat striatal synaptosomes (EC50=134 nM).
  • HY-131103
    Phenylethanolamine A

    Adrenergic Receptor Metabolic Disease Inflammation/Immunology
    Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.
  • HY-N7692
    Polyporusterone A

    Others Others
    Polyporusterone A is a triterpene carboxylic acid isolated from Polyporus umbellatus Fries. Polyporusterone A has inhibitory effect on free radical-induced lysis of red blood cells (hemolysis).
  • HY-P2322
    Iturin A

    Fungal
    IturinA exhibits strong antifungal activity against pathogenic yeast and fungi. Iturin A interacts with the cytoplasmic membrane of the target cell forming ion conducting pores.
  • HY-N9377
    Platyconic acid A

    Others Metabolic Disease Inflammation/Immunology
    Platyconic Acid A is an active component of changkil saponins from platycodon grandiflorum and can be used for the research of reducing airway inflammation.
  • HY-12149
    A-867744

    nAChR Autophagy Neurological Disease
    A-867744 is a highly potent and selective type II positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptors (nAChR) with an EC50 of 1.0 μM.
  • HY-N0673
    Pseudolaric Acid A

    Fungal Infection
    Pseudolaric Acid A is a diterpene acid isolated from Pseudolarix kaempferi, has antifungal, cytotoxic and antifertile activities.
  • HY-N2475
    Lappaol A

    Others Metabolic Disease
    Lappaol A is a natural compound with antiaging activity.
  • HY-N1945
    Bonvalotidine A

    Others Others
    Bonvalotidine A is a lycoctonine-type C19-diterpenoid alkaloid isolated from the roots of Delphinium bonvalotii Franch.
  • HY-N6997
    Ceratamine A

    Microtubule/Tubulin Cancer
    Ceratamine A is an antimitotic heterocyclic alkaloid isolated from the marine sponge Pseudoceratina sp., acts as a microtubule-stabilizing agent. Ceratamine A exhibits cytotoxicity against human cancer cell lines.
  • HY-N8135
    Sterebin A

    Others Others
    Sterebin A is a bisnorditerpenoid that can be found in Blumea aromatic.
  • HY-N3510
    Peritassine A

    HIV Infection Inflammation/Immunology
    Peritassine A, an alkaloid that could be isolated from Tripterygium wilfordii Hook. f., possesses anti-HIV activity.
  • HY-N7931
    Regaloside A

    NO Synthase NF-κB Inflammation/Immunology
    Regaloside A, a phenylpropanoid, shows significant DPPH radical scavenging activity of 58.0% at 160 ppm. Regaloside A has anti-inflammatory activity.
  • HY-N3163
    Obtucarbamate A

    Others Inflammation/Immunology Cancer
    Obtucarbamate A isolated from Disporum cantoniense has antitussive activity.
  • HY-15556A
    GSK269962A hydrochloride

    GSK 269962 hydrochloride

    ROCK Inflammation/Immunology Cardiovascular Disease
    GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.
  • HY-15556
    GSK269962A

    GSK 269962

    ROCK Inflammation/Immunology Cardiovascular Disease
    GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities.
  • HY-15662
    Tulathromycin A

    Tulathromycin; CP 472295

    Antibiotic Bacterial Infection
    Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC50=0.26 µM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects.
  • HY-125836
    CCR4 antagonist 2

    CCR Cancer Endocrinology
    CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca 2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.
  • HY-111532B
    (3S,4S)-A2-32-01

    Others Infection
    (3S,4S)-A2-32-01 is a less active S-enantiomer of (3R,4R)-A2-32-01. (3R,4R)-A2-32-01 is an anti-virulence agent and a specific caseinolytic protein proteases (ClpP) inhibitor.
  • HY-12993B
    RSV604 (R enantiomer)

    A-60444 (R enantiomer)

    RSV Infection
    RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV.
  • HY-136297
    DGN549-C

    Drug-Linker Conjugates for ADC Cancer
    DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-128946
    CL2A-SN-38

    Drug-Linker Conjugates for ADC Cancer Inflammation/Immunology
    CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond.
  • HY-P3204A
    POT-4 TFA

    AL-78898A TFA

    Complement System Metabolic Disease
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research.
  • HY-14247A
    Fadrozole

    CGS 16949A free base; (Rac)-FAD286

    Aromatase Cancer
    Fadrozole (CGS 16949A free base) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
  • HY-N1372A
    Fangchinoline

    HIV FAK Apoptosis Autophagy Cancer Infection
    Fangchinoline is isolated from Stephania tetrandra with extensive biological activities, such as enhancing immunity, anti-inflammatory sterilization and anti-atherosclerosis. Fangchinoline, a novel HIV-1 inhibitor, inhibits HIV-1 replication by impairing gp160 proteolytic processing. Fangchinoline targets Focal adhesion kinase (FAK) and suppresses FAK-mediated signaling pathway in tumor cells which highly expressed FAK. Fangchinoline induces apoptosis and adaptive autophagy in bladder cancer.
  • HY-15295
    Vonoprazan Fumarate

    TAK-438

    Proton Pump Metabolic Disease
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
  • HY-N0692
    Schisandrol B

    Gomisin-A; TJN-101; Wuweizi alcohol-B

    Reactive Oxygen Species Cytochrome P450 Autophagy Cancer
    Schisandrol B (Gomisin-A) is a major active constituent of Schisandra sphenanthera with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and CYP3A and also has anti-inflammatory, anti-diabetic and antioxidant activities.
  • HY-N6707
    Triacsin C

    WS 1228A; FR 900190

    Others Infection
    Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C is found to be highly effective against rotavirus replication.
  • HY-P2265A
    SAH-SOS1A TFA

    Ras Cancer
    SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM) and directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.
  • HY-N9109
    Lipopolysaccharides, Escherichiacoli (11C)

    Others Inflammation/Immunology
    Lipopolysaccharides, Escherichiacoli (11C) consists of a hydrophobic lipid A, a core oligosaccharide (core OS), and a distal polysaccharide (O-PS). Lipopolysaccharides, Escherichiacoli (11C) can be used to induce inflammation.
  • HY-100007
    Vonoprazan

    TAK-438 free base

    Proton Pump Endocrinology
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
  • HY-N7614
    Anemarrhenasaponin A2

    Schidigerasaponin F2; Timosaponin AII

    Others Cardiovascular Disease
    Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation.
  • HY-13032
    Molibresib

    I-BET762; GSK525762; GSK525762A

    Epigenetic Reader Domain Cancer
    Molibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
  • HY-15308
    Avermectin B1a

    Abamectin B1a

    Parasite Antibiotic Infection
    Avermectin B1a is an antiparasitic agent that paralyzes nematodes without causing hypercontraction or flaccid paralysis.
  • HY-136310
    PIP4K-IN-a131

    Others Cancer
    PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC50s of 1.9 µM and 0.6 µM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways.
  • HY-19644
    GSK2256294A

    GSK 2256294

    Epoxide Hydrolase Cardiovascular Disease
    GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH.
  • HY-16994
    OICR-0547

    Others Cancer
    OICR-0547 is a closely related derivative of OICR-9429. OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction, while OICR-0547 is an inactive control compound that no longer binds to WDR5.
  • HY-N7497
    Protoescigenin

    Others Others
    Protoescigenin is the main aglycone of horse chestnut saponin mixture known as escin. Protoescigenin is selected as substrate for exploratory chemistry towards selective protection, followed by propargyl ether formation and subsequent condensation with azido-monosaccharides, to obtain novel triazole linked conjugates of the triterpene.
  • HY-14854A
    Tecarfarin sodium

    ATI-5923 sodium

    Others Metabolic Disease
    Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Tecarfarin sodium has the antithrombotic activity.
  • HY-16963
    GW627368

    Prostaglandin Receptor Inflammation/Immunology Endocrinology Cancer
    GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.
  • HY-10252
    NVP-ADW742

    ADW742; GSK 552602A; ADW

    IGF-1R Insulin Receptor Apoptosis Cancer Endocrinology
    NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells.
  • HY-43913
    (R)-eIF4A3-IN-2

    Others Others
    (R)-eIF4A3-IN-2 is a less active enantiomer of eIF4A3-IN-2. eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM.
  • HY-130665
    TL12-186

    PROTACs CDK Cancer
    TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC50=73 nM) and CDK9/cyclin T1 (IC50=55 nM).
  • HY-101513
    eIF4A3-IN-1

    Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC50=0.26 μM; Kd=0.043 μM), which binds to a non-ATP binding site of eIF4A3 and shows significant cellular nonsense-mediated RNA decay (NMD) inhibition at 10 and 3 μM and can be as a probe for further study of eIF4A3, the exon junction complex (EJC), and NMD.
  • HY-14649
    Retinoic acid

    Vitamin A acid; all-trans-Retinoic acid; ATRA

    RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
  • HY-12838
    Mirk-IN-1

    Dyrk1B/A-IN-1

    DYRK Cancer
    Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively.
  • HY-14763A
    Cariprazine hydrochloride

    RGH188 hydrochloride

    Dopamine Receptor 5-HT Receptor Neurological Disease
    Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
  • HY-P1192
    GR-73632

    Neurokinin Receptor Neurological Disease Endocrinology
    GR-73632 is a novel tachykinin neurokinin 1 (NK-1) receptor agonist. GR-73632 acts directly on the peripheral terminals of primary sensory neurons through NK1 receptor which convey itch signals.
  • HY-14763
    Cariprazine

    RGH-188

    Dopamine Receptor 5-HT Receptor Neurological Disease
    Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
  • HY-101724
    ReN-1869 hydrochloride

    NNC-05-1869 hydrochloride

    Histamine Receptor Inflammation/Immunology Endocrinology
    ReN 1869 hydrochloride is a novel, selective histamine H1 receptor antagonist, which demonstrates affinity to the histamine H1 receptor (guinea pig brain) with Ki of 0.19±0.04 μM and the non-selective σ site (guinea pig brain) with Ki of 0.45 μM.
  • HY-125990
    SLC13A5-IN-1

    Sodium Channel Metabolic Disease Cardiovascular Disease
    SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of  14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.
  • HY-136093
    HL271

    IM156 hydrochloride; HL156A hydrochloride

    AMPK Cancer Neurological Disease
    HL271 (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. HL271 attenuates aging-associated cognitive impairment in animal model. HL271 is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors.
  • HY-111532
    (3R,4R)-A2-32-01

    Bacterial Infection
    (3R,4R)-A2-32-01 (compound 2), an anti-virulence drug, is a specific caseinolytic protein proteases (ClpP) inhibitor with an EC50 of 4.5 μM, and shows a tolerable cytotoxicity.
  • HY-136093A
    IM156

    HL156A; HL271 acetate

    AMPK Cancer Neurological Disease
    IM156 (HL156A; HL271 acetate), a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. IM156 attenuates aging-associated cognitive impairment in animal model. IM156 is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors.
  • HY-B0422S
    Nateglinide D5

    A4166 D5; Senaglinide D5

    Potassium Channel Dipeptidyl Peptidase Metabolic Disease
    Nateglinide D5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K + channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.
  • HY-P9805
    Anti-MERS-3A1 mAb

    MERS-3A1; MERS Antibody-3A1

    SARS-CoV Infection
    Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor.
  • HY-N2236
    Dipsanoside B

    Others Infection
    Dipsanoside B is a novel tetrairidoid glucoside from Dipsacus asper. Dipsacus asper Wall., a perennial plant widespread in China, has been used in traditional Chinese medicine for hundreds of years as a tonic for refreshment, as a fissiparism promoter of the osseous cells, and as an embryo security agent, etc.
  • HY-136219
    Protein kinase affinity probe 1

    Others Others
    Protein kinase affinity probe 1 is a novel protein kinase affinity probe for the functional identification of protein kinases (PKs). Protein kinase affinity probe 1 is a modified Purvalanol B (HY-18299) probe with 50% beads loading (Compound S3).
  • HY-12650
    Mirogabalin

    DS5565

    Calcium Channel Neurological Disease
    Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium channel complexes in the CNS.
  • HY-101947
    SMI-16a

    PIM1/2 Kinase Inhibitor VI

    Pim Cancer
    SMI-16a is a selective Pim kinase inhibitor with IC50 values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.
  • HY-138298
    Trastuzumab deruxtecan

    DS-8201; DS-8201a

    Antibody-Drug Conjugate (ADC) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
  • HY-136569
    DSR-141562

    Phosphodiesterase (PDE) Neurological Disease
    DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9 nM, and the IC50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia.
  • HY-119706
    Barbadin

    Others Others
    Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors.
  • HY-12473
    Vps34-IN-2

    PI3K SARS-CoV Cancer
    Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively. Vps34-IN-2 shows antiviral activity against SARS-CoV-2 (IC50 of 3.1 μM), HCoV-229E (IC50 of 0.7 μM) and HCoV-OC43.
  • HY-N2348
    Tubulysin D

    Microtubule/Tubulin Apoptosis Cancer
    Tubulysin D is one of the most potent derivatives among the tubulysins isolated from the myxobacterial species Archangium geophyra and Angiococcus disciformis. Tubulysin D is a novel tetrapeptide that displays potent antitumor activity and leads to cell cycle arrest and apoptosis by inhibiting tubulin polymerization with an IC50 of 1.7 μM. Tubulysin displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the lower nanomolar range.
  • HY-16668
    Tyrphostin A1

    Tyrphostin 1; AG9

    Interleukin Related Inflammation/Immunology
    Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
  • HY-N9536
    Cinnamtannin A2

    Others Metabolic Disease
    Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect.
  • HY-112398
    GSK1379725A

    Epigenetic Reader Domain Others
    GSK1379725A is a selective BPTF ligand with a Kd of 2.8 uM, showing no binding activity for Brd4.
  • HY-111098
    GSK1702934A

    TRP Channel Cardiovascular Disease
    GSK1702934A is a selective TRPC3 agonist. GSK1702934A modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3.
  • HY-N4146
    Proanthocyanidin A4

    Others Inflammation/Immunology
    Proanthocyanidin A4 is a polyphenol found in a variety of plants. Proanthocyanidin A4 possesses anti-inflammatory effects.
  • HY-19608
    GSK1016790A

    TRP Channel Calcium Channel Metabolic Disease Cardiovascular Disease
    GSK1016790A is a potent and selective transient receptor potential vanilloid 4 (TRPV4) channel agonist. GSK1016790A can elicit Ca 2+ influx and elevate intracellular Ca 2+ in HEK cells.
  • HY-N6982
    Licoricesaponin A3

    Others Metabolic Disease
    Licoricesaponin A3 is a terpenoid saponin identified from licorice.
  • HY-133777
    Ciprofibrate impurity A

    PPAR Cancer
    Ciprofibrate impurity A is an impurity of Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha.
  • HY-N7597
    Epimedoside

    Korepimedoside A

    Others Others
    Epimedoside is a flavonol glycoside, isolated from the aerial parts of Epimedium koreanum Nakai (Berberidaceae).
  • HY-N0873A
    Iso-Sagittatoside A

    Drug Metabolite Others
    Iso-Sagittatoside A is the metabolite of effective Erxian Decoction (EXD, a Chinese medicine prescription for menopausal syndromes) in rat plasma.
  • HY-122815
    Fusicoccin

    Fusicoccin A

    Apoptosis Cancer
    Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H +-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity.
  • HY-75041
    Calcitriol Impurities A

    VD/VDR Metabolic Disease
    Calcitriol Impurities A is the impurity of Calcitriol, Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
  • HY-N2012
    7-Hydroxyaristolochic acid A

    Others Inflammation/Immunology
    7-Hydroxyaristolochic acid A is an aristolochic acid analogue found in Aristolochia plants. Aristolochic acid can be used as an anti-inflammatory agent.
  • HY-N4133
    Ciwujianoside A1

    Others Others
    Ciwujianoside A1 is isolated from the Eleutherococcus senticosus leaf.
  • HY-N5045
    Jionoside A1

    Others Inflammation/Immunology
    Jionoside A1 isolated from Radix Rehmanniae Praeparata displays dose dependent immune-enhancement activity and possesses moderate protective activities on H2O2-treated SH-SY5Y cells.
  • HY-N0568
    Madecassoside

    Asiaticoside A

    Apoptosis Endogenous Metabolite Others
    Madecassoside is a pentacyclic triterpene isolated from Centella asitica (L.
  • HY-13032A
    GSK 525768A

    Others Cancer
    GSK 525768A is the inactive enantiomer of GSK525762A. GSK 525768A has no activity towards BET.
  • HY-105237
    Eesperamicin A1

    Antibiotic DNA/RNA Synthesis Cancer
    Esperamicin A1, as an extremely potent antitumor antibiotic, is isolated from cultures of Actinomadura verrucosospora. Esperamicin A1 can be used for the research of antitumor.
  • HY-B0343A
    Sarafloxacin hydrochloride

    A-56620 hydrochloride

    Bacterial Antibiotic Infection
    Sarafloxacin (hydrochloride) (A-56620 (hydrochloride)) is a quinolone antibiotic drug.
  • HY-N6950
    Hederacolchiside A1

    PI3K Akt mTOR Parasite Apoptosis Cancer Infection
    Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro.
  • HY-N9373
    Bacoside A2

    Others Neurological Disease
    Bacoside A2 is a triterpenoid saponin.
  • HY-138161
    JR14a

    Complement System Inflammation/Immunology
    JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation.
  • HY-N2264
    Wulignan A1

    Influenza Virus Infection
    Wulignan A1 is isolated from the stems of Schisandra henryi. Wulignan A1 exhibits anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities.
  • HY-P1539A
    Cecropin A TFA

    Bacterial Antibiotic Cancer Infection Inflammation/Immunology
    Cecropin A TFA is a linear 37-residue antimicrobial polypeptide isolated from Hyalaphora cecropia pupae. Cecropin A TFA exhibits anti-bacterial, anti-inflammatory and anti-cancer activity.
  • HY-12361
    PF 1022A

    Parasite Infection
    PF 1022A is a cyclooctadepsipeptide with broadspectrum anthelmintic properties produced by fermentation of the fungus Mycelia sterilia. PF 1022A is a channel-forming ionophore. PF 1022A showes strong anthelmintic activities against Ascaridia galli in chickens. PF 1022A also can be used for angiostrongyliasis research.
  • HY-107676
    SIB-1553A

    nAChR Neurological Disease
    SIB-1553A is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand. SIB-1553A is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders.
  • HY-B1802A
    Tosufloxacin tosylate hydrate

    A-61827 tosylate hydrate

    Bacterial Antibiotic Infection
    Tosufloxacin (tosylate hydrate) is a fluoroquinolone antibacterial agent.
  • HY-P2123A
    Colistin A sulfate hydrate

    Bacterial Antibiotic Infection
    Colistin A sulfate hydrate is a major component of Colistin. Colistin is a polymyxin antibiotic and can be used to combat infections caused by problematic gram-negative bacteria.
  • HY-107273
    Delavinone

    Sinpeinine A

    Others Inflammation/Immunology
    Delavinone (Sinpeinine A) is an alkaloid. Delavinone is suitable for electrospray ionization (ESI) positive electrode detection.
  • HY-N5064
    Bacoside A3

    Others Neurological Disease
    Bacoside A3, a triterpenoid saponin, is one of the major active constituents in Bacopa monnieri. Bacoside A3 has neuroprotective activity.
  • HY-P1333A
    Dynorphin A TFA

    Opioid Receptor Neurological Disease
    Dynorphin A TFA, an endogenous opioid peptide, is a highy potent kappa opioid receptor (KOR) activator. Dynorphin A TFA also serve as an agonist for other opioid receptors,  such as mu (MOR) and delta (DOR).
  • HY-15442
    Biphenylindanone A

    BINA

    mGluR Neurological Disease
    Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders.
  • HY-111616
    GSK1820795A

    Others Others
    GSK1820795A, as a telmisartan analog, is a selective hGPR132a antagonist. GSK1820795A blocks activation of yeast cells expressing hGPR132a by N-acylamides.
  • HY-N7438
    Mogroside VI A

    Others Others
    Mogroside VI A, an isomer of Mogroside VI isolated from Luo Han Guo, exerts sweetness property. Mogroside VI A can be used for sweetener and/or taste modifier research.
  • HY-112091
    GSK2200150A

    Bacterial Infection
    GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.
  • HY-N5106
    (E)-Flavokawain A

    Apoptosis Cancer
    (E)-Flavokawain A, a chalcone extracted from Kava, has anticarcinogenic effect. (E)-Flavokawain A induces apoptosis in bladder cancer cells by involvement of bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.
  • HY-N2343
    Procyanidin A2

    Bacterial Cancer Infection Inflammation/Immunology
    Procyanidin A2 is a flavonoid found in cranberries and lingonberries, with anti-cancer, antioxidant, antimicrobial and anti-inflammation activity.
  • HY-113573
    Protosappanin A

    PTA

    JAK STAT Inflammation/Immunology
    Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.
  • HY-103200
    SR59230A hydrochloride

    Adrenergic Receptor Metabolic Disease Cardiovascular Disease
    SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.
  • HY-136151
    UNC10217938A

    Others Others
    UNC10217938A is a 3-deazapteridine analog with strong oligonucleotide enhancing effects. UNC10217938A enhances oligonucleotides effects by modulating their intracellular trafficking and release from endosomes. UNC10217938A also enhances the effects of antisense and siRNA oligonucleotides.
  • HY-N2172
    Sibiricose A6

    Others Neurological Disease
    Sibiricose A6 is an oligosaccharide ester isolated from Polygalae Radix with potent antioxidant activity.
  • HY-111828
    TTA-A2

    Calcium Channel Neurological Disease
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.
  • HY-N0495
    Aloenin

    Aloenin A

    Beta-secretase Neurological Disease
    Aloenin (Aloenin A) is a natural compound, which has potent peroxyl radical-scavenging activities and moderate inhibitory active on β-secretase (BACE).
  • HY-15995
    Tubulysin A

    TubA

    Microtubule/Tubulin ADC Cytotoxin Apoptosis Cancer
    Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.
  • HY-N0150
    Monensin sodium salt

    Monensin A sodium salt

    Bacterial Sodium Channel Antibiotic Infection Cancer
    Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Monensin sodium salt is an ionophore that mediates Na +/H + exchange. Monensin sodium salt causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion.
  • HY-103129
    SB-200646A

    5-HT Receptor Neurological Disease
    SB-200646A is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A is orally active and has electrophysiological and anxiolytic properties in vivo.
  • HY-101582
    ZT 52656A hydrochloride

    Opioid Receptor Neurological Disease
    ZT 52656A is a selective kappa opioid agonist, used for the prevention or alleviation of pain in the eye.
  • HY-101746
    GSK376501A

    PPAR Metabolic Disease
    GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus.
  • HY-19243
    GV-196771A

    iGluR Neurological Disease
    GV-196771A is the sodium salt form of GV196771, is an NMDA receptor antagonist.
  • HY-19477
    SB-616234-A

    5-HT Receptor Neurological Disease
    SB-616234-A is a selective and orally bioavailable 5-HT1B receptor antagonist, with anxiolytic and antidepressant activity.
  • HY-101192
    GSK682753A

    EBI2/GPR183 Inflammation/Immunology
    GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (EBI2) with an IC50 of 53.6 nM.
  • HY-108434
    Ceapin-A7

    Others Metabolic Disease Neurological Disease
    Ceapin-A7 is a selective blocker of ATF6α signaling in response to ER stress, with an IC50 of 0.59 μM. Ceapin-A7 can be used to explore both the mechanism of activation of ATF6α and its role in pathological settings.
  • HY-111398
    ALB-127158(a)

    MCHR1 (GPR24) Metabolic Disease Endocrinology
    ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (MCH1) receptor antagonist.
  • HY-113263
    17a-Hydroxypregnenolone

    Endogenous Metabolite Endocrinology
    17a-Hydroxypregnenolone is a pregnane steroid. 17a-Hydroxypregnenolone is a prohormone in the formation of dehydroepiandrosterone (DHEA).
  • HY-102064
    SR 57227A

    5-HT Receptor Neurological Disease
    SR 57227A is a potent, orally active and selective 5-HT3 receptor agonist, with ability to cross the blood brain barrier. SR 57227A has affinities (IC50) varying between 2.8 and 250 nM for 5-HT3 receptor binding sites in rat cortical membranes and on whole NG 108-15 cells or their membranes. Anti-depressant effects.
  • HY-N6915
    Mogroside II-​A

    Others Inflammation/Immunology Metabolic Disease
    Mogroside II-​A is a natural product isolated from Siraitia grosvenorii.
  • HY-N6079
    Timosaponin A1

    Others Others
    Timosaponin A1 is a coprostane type steroidal saponin isolated from Rhizoma Anemarrhenae.
  • HY-N6942
    Mogroside IV-A

    Others Cancer Metabolic Disease
    Mogroside IV-A, a triterpenoid glycoside isolated from the extracts of Luo Han Guo, is a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
  • HY-N8117
    Bisabolol oxide A

    Others Inflammation/Immunology
    Bisabolol oxide A possesses antihyperalgesic and antiedematous effects with oral activity.
  • HY-N2167
    Sibiricose A5

    Others Neurological Disease Metabolic Disease
    Sibiricose A5 is an oligosaccharide ester isolated from Polygalae Radix with potent antioxidant activity.
  • HY-124906
    JAMI1001A

    iGluR Neurological Disease
    JAMI1001A is a positive allosteric modulator of AMPA receptor. JAMI1001A efficaciously modulates AMPA receptor deactivation and desensitization of both flip and flop receptor isoforms.
  • HY-B0519A
    Tylosin

    Tylosin A

    Bacterial Antibiotic Infection
    Tylosin (Tylosin A) is a macrolide antibiotic found naturally as a fermentation product of Streptomyces fradiae. Tylosin exerts potent antimicrobial activity against Gram-positive bacteria. Tylosin is widely used as a feed additive for promoting animal growth. Tylosin is used for veterinary purposes against bacterial dysentery and respiratory diseases in poultry, pigs and cattle.
  • HY-128945
    CL2A

    ADC Linker Cancer Inflammation/Immunology
    CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker.
  • HY-14467
    GSK-269984A

    Prostaglandin Receptor Neurological Disease Endocrinology
    GSK-269984A is a Prostaglandin E2 Receptor 1 (EP1) antagonist with a pIC50 of 7.9.
  • HY-100672
    SR59230A

    Adrenergic Receptor Metabolic Disease Cardiovascular Disease
    SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.
  • HY-N8208
    Sibiricose A1

    Others Others
    Sibiricose A1is an oligosaccharide ester that can be found in Polygala tenuifolia.
  • HY-112486
    TA-316

    Megakaryocytes/platelets inducing agent

    Others Cardiovascular Disease
    TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells.
  • HY-14262
    Vilazodone

    EMD 68843; SB659746A

    5-HT Receptor Serotonin Transporter Neurological Disease
    Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders.
  • HY-108359
    Alsterpaullone

    9-Nitropaullone; NSC 705701

    CDK GSK-3 Apoptosis Cancer
    Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC50s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders. Alsterpaullone induces apoptosis in leukemia cell line.
  • HY-105129
    Pimonidazole hydrochloride

    Others Cancer
    Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
  • HY-105129A
    Pimonidazole

    Others Cancer
    Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
  • HY-W015764
    T-1105

    Influenza Virus Infection
    T-1105, a novel broad-spectrum viral polymerase inhibitor, structural analogue of T-705, inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses, including Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV). T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase.
  • HY-13768
    Topotecan

    SKF 104864A; NSC 609669

    Topoisomerase Autophagy Cancer
    Topotecan (SKF 104864A; NSC 609669) is a Topoisomerase I inhibitor. The IC50 values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87.
  • HY-P1505
    C3a (70-77)

    Complement 3a (70-77)

    Complement System Inflammation/Immunology
    C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
  • HY-P1788
    Influenza A NP(366-374) Strain A/PR/8/35

    Influenza Virus Infection
    Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein.
  • HY-19231
    DPI-3290

    Org 41793

    Opioid Receptor Neurological Disease
    DPI-3290 (Org 41793) is a potent and specific opioid receptors agonist with Ki values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively。DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity.
  • HY-100260
    beta-L-D4A

    2'3'-didehydro-2'3'-dideoxyadenosine

    HIV Infection
    beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor.
  • HY-126810
    NP213

    Fungal Infection
    NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections.
  • HY-131349
    CCR4 antagonist 3

    CCR Cancer
    CCR4 antagonist 3 is an orally active, potent and selective CCR4 antagonist. CCR4 antagonist 3, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4 antagonist 3 has antitumor activity.
  • HY-131349A
    CCR4 antagonist 3 hydrochloride

    CCR Cancer Metabolic Disease
    CCR4 antagonist 3 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4 antagonist 3, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4 antagonist 3 has antitumor activity.
  • HY-B0075
    Melatonin

    N-Acetyl-5-methoxytryptamine

    Melatonin Receptor Autophagy Mitophagy Endogenous Metabolite Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.
  • HY-19469
    Roluperidone

    CYR-101; MIN-101; MT-210

    5-HT Receptor Sigma Receptor Neurological Disease
    Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively).
  • HY-133869
    cGMP-HTL

    cGMP-HaloTag-ligand

    Autophagy Cancer
    cGMP-HTL contains a HT-ligand, a linker and the Cys-S-cGMP (autophagy tag). cGMP-HTL increases the K63-linked ubiquitination of mitochondria. AUTAC (autophagy-targeting chimera) is a novel targeted-clearance strategy that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity.
  • HY-111793
    NUCC-390

    CXCR Neurological Disease
    NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo.
  • HY-103076
    EZ-482

    Others Neurological Disease
    EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas.
  • HY-111793A
    NUCC-390 dihydrochloride

    CXCR Neurological Disease
    NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo.
  • HY-138247
    β-Lactamase-IN-2

    EX-A4764; UUN51204

    Bacterial Antibiotic Infection
    β-Lactamase-IN-2 is a beta-lactamase inhibitor, extracted from patent WO 2019075084 A1, compound 1. β-Lactamase-IN-2 has anti-microbial and anti-bacterial effects.
  • HY-102024
    A2A receptor antagonist 1

    CPI-444 analog

    Adenosine Receptor Cancer Neurological Disease
    A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A2A receptor and A1 receptor with Ki values of 4 and 264 nM, respectively.
  • HY-12692
    DO3A tert-Butyl ester

    DO3A tert-butyl; DO3A-t-Bu-ester

    Others Others
    DOTA tert-Butyl ester is a benxyl derivative of the cyclic tosamide; can be nitrated directly; is more convenient to incorporate the nitro group after deprotection lithium aluminum hydride.
  • HY-P0088
    Porcine dynorphin A(1-13)

    Dynorphin A Porcine Fragment 1-13

    Opioid Receptor Others
    Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations.
  • HY-114495
    Caerulomycin A

    Cerulomycin; Caerulomycin

    Fungal Antibiotic Infection Inflammation/Immunology
    Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases.
  • HY-126937
    Ivermectin B1a

    Parasite SARS-CoV Infection
    Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310). Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19.
  • HY-18260S1
    Bisphenol A-d6

  • HY-112667
    CU-CPT-9a

    Toll-like Receptor (TLR) Inflammation/Immunology
    CU-CPT-9a is a specific TLR8 antagonist, with an IC50 of 0.5 nM.
  • HY-19555
    Seco Rapamycin

    Secorapamycin A

    Others Others
    Seco Rapamycin (Secorapamycin A) is the ring-opened product of Rapamycin. Seco-rapamycin is reported not to affect the mTOR function.
  • HY-100080S
    A-887826-d8

  • HY-12993A
    RSV604 racemate

    A-60444 racemate

    RSV Others
    RSV604 (A-60444) racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.
  • HY-B0355
    Ginkgolide A

    BN-52020

    GABA Receptor Endogenous Metabolite Inflammation/Immunology
    Ginkgolide A (BN-52020) is an extract from in Ginkgo biloba and a g-aminobutyric acid (GABA) antagonist.
  • HY-110155
    LM11A-31 dihydrochloride

    Others Neurological Disease
    LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. M11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.
  • HY-101437
    Ralfinamide

    FCE-26742A

    Sodium Channel Neurological Disease
    Ralfinamide (FCE-26742A) is an orally available Na + blocker derived from α-aminoamide, with function of suppressing pain.
  • HY-P9904
    Atezolizumab

    MPDL3280A

    PD-1/PD-L1 Apoptosis Autophagy Cancer
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-108272
    Mogroside II-A2

    Others Cancer Metabolic Disease
    Mogroside II-A2 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
  • HY-101437A
    Ralfinamide mesylate

    FCE-26742A mesylate

    Sodium Channel Neurological Disease
    Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na + channel blocker derived from α-aminoamide, with function of suppressing pain.
  • HY-100638
    RPR132595A

    NPC

    Others Cancer
    RPR132595A (NPC) is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine.
  • HY-100673
    LM22A-4

    Trk Receptor Neurological Disease
    LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.
  • HY-N3502
    20(21)-Dehydrolucidenic acid A

    HIV Protease Infection
    20(21)-Dehydrolucidenic acid A is a triterpenoid isolated from the fruiting body of the fungus Ganoderma sinense. 20(21)-Dehydrolucidenic acid A has weak anti-HIV-1 protease activity.
  • HY-B0395C
    Sitafloxacin hydrate

    DU6859a hydrate

    Bacterial Antibiotic Infection
    Sitafloxacin (DU6859a) hydrate is a potent, orally active fluoroquinolone antibiotic with in vitro activity against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin can be used for the research of respiratory tract infection and urinary tract infection.
  • HY-N0679
    Retinyl acetate

    Retinol acetate; Vitamin A acetate

    Others Cancer
    Retinyl acetate is a synthetic acetate ester form derived from retinol and has potential antineoplastic and chemo preventive activities.
  • HY-B0197A
    Naratriptan hydrochloride

    GR-85548A hydrochloride

    5-HT Receptor Neurological Disease
    Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
  • HY-135283
    ABT-546

    A-216546

    Endothelin Receptor Endocrinology Cardiovascular Disease
    ABT-546 (A-216546) is a potent, highly selective and active endothelin ETA receptor antagonist with a Ki of 0.46 nM for [ 125I]endothelin-1 binding to cloned human endothelin ETA. ABT-546 is >25,000-fold more selective for the ETA receptor than for the ETB receptor. ABT-546 blocks endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis with IC50 of 0.59 nM and 3 nM, respectively.
  • HY-N6940
    Prosapogenin A

    Progenin III

    Apoptosis Cancer
    Prosapogenin A, a natural product from Veratrum, induces apoptosis in human cancer cells in vitro via inhibition of the STAT3 signaling pathway and glycolysis.
  • HY-B0284
    Nifedipine

    BAY-a-1040

    Calcium Channel Autophagy Cardiovascular Disease Cancer
    Nifedipine (BAY-a-1040) is a potent calcium channel blocker and drug of choice for cardiac insufficiencies.
  • HY-N2214
    7-O-Methylaloeresin A

    Bacterial Inflammation/Immunology
    7-O-Methylaloeresin A is 5-methylchromone glycoside isolated from Commiphora socotrana (Burseraceae). 7-O-Methylaloeresin A exhibits good activity against multiple drug resistant Staphylococcus aureus (NCTC 11994) and Salmonella typhimurium (ATCC 1255) with MIC values of 0.72 and 0.18 mM, respectively. 7-O-Methylaloeresin A has antioxidant activities, gives IC50 values of 0.026  mM and 0.021  mM for DPPH and 2-deoxyribose degradation assay, respectively.
  • HY-B0523A
    Anagrelide hydrochloride

    BL4162A

    Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
  • HY-P2159
    Dynorphin A (1-8)

    Opioid Receptor Neurological Disease
    Dynorphin A (<